

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables.

- AB blood group typing 715–17, 1102, 1103
 abdominal artery aneurysms 691
 ABO blood group typing 1101
 AC133 66
 acanthocytes 146
 acetaminophen (paracetamol), oxidative injury 240–1, 242
 acetylcholinesterase 1148, 1154
 α_1 -acid glycoprotein 266
 acid phosphatase (ACP) 1148, **1150**, 1153
 acid-citrate-dextrose (ACD) 765, 766
 acrodermatitis, lethal in bull terriers 404
 actin 565
 cytoskeletal of neutrophils 1119
 actin-related protein (Arp) 2/3 complex 565
 activated clotting time (ACT) 1091
 acquired coagulopathies 657
 avian 705
 activated partial thromboplastin time (aPTT) 92, 93, 597, 1091
 acquired coagulopathies 657
 assay 1086–7
 coagulation factor assays 1088
 compound-related increases 93–4
 elephants 946
 fish 998
 normal range 1086
 prolongation 1086–7
 reagents 1086, 1087
 shortening 1087
 activated protein C (APC) 637, 645
 FVa proteolysis 643
 inflammation 652
 activated protein C resistance (APCR) 1090–1
 acute erythroleukemia **479**, 481
 acute intermittent porphyria (AIP) 176
 acute lymphoblastic leukemia (ALL) 462, 463
 B cell 493–5
 T cell 494, 526–7
 acute megakaryoblastic leukemia (AML) **479**, 481
 acute monoblastic leukemia (AML) **479**, 481
 acute monocytic leukemia (AML) **479**, 480–1
 acute myeloblastic leukemia (AML) 478, **479**, 480
 acute myelogenous leukemia (AML) 462, 463
 cytochemical staining 1144
 acute myeloid leukemia (AML) 475–82
 classification 476–7
 clinical findings 476
 definition 475
 diagnosis 477–8, **479**, 480–2
 laboratory findings 476
 leukocyte alkaline phosphatase activity 1151
 nomenclature 478, **479**
 organ involvement 476
 subtypes 478, **479**, 480–2
 terminology 478, **479**
 acute myelomonocytic leukemia (AML) **479**, 480, 481
 acute phase proteins
 detection 1160
 electrophoresis 1159
 marine mammal infections 954
 measurements 1160–1
 acute promyelocytic leukemia (AML) **479**, 480
 acute respiratory distress syndrome (ARDS), neutrophils 273–4
 acute undifferentiated leukemia (AUL) 477, 478, **479**
 ADAMTS13
 deficiency 598
 inherited macrothrombocytopenia 620
 von Willebrand disease 612, 1128
 Addison's disease *see* hypoadrenocorticism
 additive solutions (AS) 733
 adducin 565
 adenosine diphosphate/adenosine triphosphate (ADP/ATP) receptors 569–71
 adenosine triphosphate (ATP), production in RBCs 132
 adenovirus
 conditionally replicative (CRAd) 553, 556
 equine 407
 serotype 5 (Ad5) 551, 552
 structure 551
 adipose tissue, bone marrow 9
 adverse drug reactions (ADRs) 98, 100
 acquired susceptibility 99
 cats 103–4
 dogs 100–3
 evaluation 100
 genetic susceptibility 99
 horses 104
 mechanism of action 93, 93
 oxidative injury 99–100
 site of action 99
 type A 99
 type B 99
 dogs 101, 102
 ADVIA 120/2120[®] analyzer 1056–7, 1058, 1059, 1060, 1061–2, 1064, 1065
 reticulocyte evaluation 1068, 1069, 1070, 1071
 afibrinogenemia 664
 agammaglobulinemia, equine 401
 agarose gel electrophoresis 1158, 1159
 agglutination tests 718
 manual 1085
 α -globin chain 125
 agranulocytosis, drug-induced 87, 89, 90
 Akt activation 59
 albendazole adverse reactions, cats 103
 albumin 744–5
 Alcian blue stain 1146
 Alder-Reilly bodies 328
 alkaline phosphatase 266, 267
 see also leukocyte alkaline phosphatase
 alkaloids 306
 allergic disease
 basophil role 291, 294, 295
 eosinophil role 286
 mast cells 294, 295
 parasitic diseases 310
 allergic reactions, transfusion therapy 771
 alloantibodies 725–6
 blood screens 759
 disorders 727
 platelet GP binding 728
 alpaca, blood groups 720
 alpha granules, platelet 566–7, 643
 alpha naphthyl acetate esterase (ANAE) 1146, 1152
 alpha naphthyl butyrate esterase (ANBE) 1146, 1152–3
 alpha-1-acid glycoprotein (AGP) 1160–1
 alpha-globins 5
 alpharetroviruses 441
 AMD3100 786
 American College of Rheumatology
 diagnostic criteria for systemic lupus erythematosus 389, **390**
 amino acid transport deficiency 193
 amino acids, transport in RBCs 132
 e-aminocaproic acid (EACA) 697
 aminolevulinic synthase 129
 α -amino-levulinic acid dehydratase (ALA-D) 177
 α -amino-levulinic acid dehydratase (ALA-D) porphyria 176
 amiodarone, adverse reactions in dogs 103
 amphibians, MHC 780
 amyloid, vascular 690–1
 amyloid A 1160
 amyloidosis
 spleen 371, 379
 systemic 655–6, 665
 analytical bias 1023
 analytical quality specifications 1022–3
 analytical variation 1035
 anaphase 425–6
 anaphylaxis
 basophils 294
 IgA deficiency 772
 mast cells 294
 anaplasmosis 200–1
 leukocyte changes 309
 neutropenia 310
 neutrophils 315, 315, 327
 thrombocytopenia 600
 androgens, erythropoiesis stimulation 163
 anemia
 anaplasmosis 200–1
 avian 763
 chronic 764
 babesiosis 204, 205–7
 bleeding time 740
 blood loss 157, 159
 blood smear morphology 157, **158**
 camelid RBC response 911
 classification systems 153–7
 clinical manifestations 152
 cytauxzoonosis 207

- decreased erythropoiesis 249
 diabetes mellitus 249
 diagnosis 157, 159
 drug-induced 88–9
 embryos 5
 endocrine disease 249
 equine infectious anemia 119, 213–14, 237–8, 601
 erythrocyte volume 155–7
 erythropoietin treatment 791
 estrogen-induced in dogs 100
 etiology 157, 158, 160
 ferrets 765–6
Haemoproteus 208, 209
 hemoglobin concentration 155–7
 hemorrhagic 88
 HgbC 126
 hydration status 153
 hyperthyroidism 249
 hypoadrenocorticism 249
 hypoproliferative 88
 immune-mediated thrombocytopenia 589
 induced suicidal erythrocyte death 88
 infections 211–14
 inflammation 246–7
 laboratory diagnosis 152
 laboratory parameters 152–3
 lymphadenopathy 414
 macrocytic hypochromic 155
 macrocytic normochromic 155–6
 marine mammals 951
 microcytic hypochromic 155
 copper deficiency 170
 microcytic in iron deficiency 168
 multiple myeloma 513
 mycoplasmas 201–4
 neonatal isoerythrolysis 236, 237
 neonates 5
 neoplasia 247–8
 non-regenerative 153, 159–60
 hypothyroidism 249
 normocytic normochromic 155, 978
 oxidative injury 239–44
 phosphofructokinase deficiency 181
Plasmodium 208–9
 protozoal infections 204–9
 pyruvate kinase deficiency 184, 185
 rabbits 766
 refractory 468, 469, 470, 472
 with excess blasts 468–9, 469, 470–1, 473
 with excess blasts in transition 468
 with ringed sideroblasts 468, 469, 470, 472
 regenerative 153, 157
 renal disease 248–9
 reticulocytes 138
 rickettsial infection 199–201
 rodents 766
 sarcocystis 208
 secondary myelofibrosis 114
 severity 152–3
 sideroblastic 169–70, 471–2
 systemic lupus erythematosus 387
 trypanosomiasis 207–8
 waterfowl 978
 see also aplastic anemia; autoimmune hemolytic anemia (AIHA); Heinz body anemia; hemolytic anemia; immune-mediated hemolytic anemia (IMHA)
- anaerobic glycolysis see Embden–Meyerhof pathway
 anesthesia
 blood collection 74
 feline 732, 734
 fish 994–5
 laboratory primates 869, 870
 aneurysms 691
 angiogenesis, sustained 435–6
 angio-immunoblastic T cell lymphoma 533
 angiopoiesis 65–6
 angiopoietin-1 17
 Animal Leukemia Study Group, AML classification adaptations 477
 animal studies
 hemotoxicological 86
 routine laboratory studies 92–3
 see also laboratory animals
 anion exchange protein 124, 140
 see also band 3
 anisocytosis 144–5, 155
 phosphofructokinase deficiency 181
 ankyrin 124
 deficiency 190
 antibacterial drugs
 adverse drug reactions
 dogs 101–2
 horses 104
 aplastic anemia in cattle 259
 antibodies
 against coagulation factors 656
 drug-dependent 87
 drug-independent 87
 drug-induced 87
 flow cytometry 1077
 see also autoantibodies
 antibody detection, feline
 immunodeficiency virus 396–7
 antibody-dependent cell-mediated cytotoxicity (ADCC) 364
 antibody-dependent enhancement (ADE) 693
 anticoagulant(s)
 fish 998
 monitoring tests 1091
 anticoagulant deficiency, DIC 683
 anticoagulant preservative solutions (APS) 733
 anticoagulant rodenticides 658–9
 toxicity 598
 anticoagulant therapies
 biomarker development 95–7
 DIC 685, 686
 pharmacologic 656
 thrombotic disorders 699–700
 anticonvulsant drugs, adverse reactions in dogs 102–3
 anti-DEA 1.1 713, 1102
 antifibrinolytic drugs 697
 antigen presenting cells (APCs) 360, 361, 362
 enhanced antigen presentation 554
 signaling 363
 T cell interactions 387
 defective 541
 antigen processing, dendritic cells/
 macrophages 302
 antigen–antibody complexes, immune-mediated vasculitis 693–4
 antigen–antibody interactions 726
 antigenic stimulation
 chronic 342
 lymphocytosis 353
 antiglobulin test 1107
 anti-inflammatory drugs
 adverse effects in dogs 100
 DIC 685, 686–7
 platelet hypofunction 628
 see also non-steroidal anti-inflammatory drugs (NSAIDs)
 anti-inflammatory proteins, neutrophil granules 266
 anti-inflammatory response, lymphocytes/
 monocytes 304
 antimalarial drugs, systemic lupus erythematosus 392
 anti-neoplastic therapies, myelosuppression 248
 antineutrophil antibodies 87, 726
 antineutrophil antibody tests 1107–8
 antinuclear antibodies (ANAs) 386, 389, 390
 autoimmune disease 1111
 canine 1111–12
 testing 1109–12
 antioxidants, RBCs 141
 antiparasitic drugs, adverse reactions in dogs 103
 antiphospholipid syndrome inhibitors 659–60
 antiphospholipid-protein antibodies (APLAs) 656, 659, 660
 α_2 -antiplasmin 651
 assay 1092
 antiplasmin deficiency 667
 antiplatelet antibodies 627
 detection 728, 1078
 tests 1108–9
 antiplatelet drugs 698–9
 antiretroviral drugs 397
 antithrombin 94, 638, 644, 646
 activity assay 597, 1090
 deficiency 669
 inherited 1090
 thromboembolism risk 673
 aortic rupture 691
 aortic thromboembolism 676
 apheresis 733–4
 platelets 752, 754
 aplastic anemia 256–60
 antibacterial drug-induced in dogs 102
 anti-inflammatory induced in dogs 101
 bovine 263
 canine 103, 104, 258, 260
 chlorinated hydrocarbons 110
 chronic 256
 diagnosis 257
 drug-induced 87, 258
 equine 259
 estrogen-induced in dogs 100
 feline 257–8, 343
 FeLV-associated 254
 idiopathic 258
 immune-mediated 257
 infections 257–8
 models 257
 mycotoxins 110, 259
 pathogenesis 256–7
 ruminants 259–60
 apoferritin 128
 apolipoprotein AI-derived amyloid 691
 apoptosis 386
 evasion in neoplasia 435
 feline immunodeficiency virus 395
 neutrophils 1120–1
 arachidonic acid 572
 lipid body storage 283
 platelet agonist 1126
 arsenic
 hematopoietic cell injury 109
 poisoning in dogs 471
 arterial degeneration 690–1
 arterial hypertrophy 691–2
 arterial mineralization 691
 arterial rupture 691
 arteriovenous fistula 690
 arteritis, verminous 693
 ascorbate 135
 aspirin
 platelet hypofunction 628
 thrombotic disorders 698
 asplenia 381
 asthma
 eosinophil role 286
 platelet hyperfunction 629
 atherosclerosis 690
 thromboembolism risk 673
Atoxoplasma, avian leukocytes 348
 Aurora kinases 425

- autoagglutination of whole blood, immune-mediated hemolytic anemia 228
 autoantibodies 385–6, 389, 726
 disorders 727
 drug-induced 1112
 platelet GP binding 728
 autoimmune disease, antinuclear antibodies 1111
 autoimmune hemolytic anemia (AIHA) 218
 canine 216–19
 drug-induced 87
 immunopathogenesis 218–19
 predisposing factors 218
 see also immune-mediated hemolytic anemia (IMHA)
 autoimmune thrombocytopenia, drug-induced 87
 autoimmunity induction 385
 automated hematology systems 1054–65
 centrifugal analysis 1056
 electronic impedance 1055
 in-house instruments 1063, 1064, 1065
 light scatter 1055–6
 automated latex enhanced turbidimetric assay 1085
 avian leukosis and sarcoma viruses (ALSVs) 443
 azathioprine
 adverse drug reactions
 cats 103
 dogs 101
 systemic lupus erythematosus 391
 azidothymidine 397
 adverse reactions in cats 104
 azurophils
 cytochemical staining 1146–7
 reptile 1006, 1008, 1011
- B cell(s)** 12, 61, 359, 364–6
 activation 365
 class switching 62–3
 development 62–3
 differentiation 365
 immune system diseases 401–3
 lymph node migration 371
 memory 365–6
 programmed hypermutation 62
 proliferation 365
 self-reactivity 385
 spleen 370
 systemic lupus erythematosus 386, 387
B cell immune system diseases 401–3
B cell lymphoma 423, 491–2
 diffuse large-cell 504–7
 large 504–7, 523–4
 small lymphocytic 495–7
B cell progenitors 5
B cell receptor (BCR) 360, 365
B cell tumors 491–509
 mature 495–509
 precursor 493–5
babesiosis 204, 205–7
 immune-mediated thrombocytopenia 594
 large canine 205–6
 small canine 206
bacillary hemoglobinuria 212–13
bacteria permeability-enhancing factor (BPE) 271
bacterial infections
 anemia 211–13
 elasmobranch 1016
 endotoxin release 579
 fish 1002, 1016
 lymphadenitis 416
 marine mammals 954
 RBCs 1167, 1168
 thrombocytopenia 600
 transfusion-associated sepsis 773
 see also named organisms and diseases
 bacterial lymphadenitis 416
 bacterial sepsis, acute inflammation 108–9
 bactericidal assays 401
 bactericidal/permeability-increasing protein (BPI) 266
 Bactrian camel *see* camelids
 band 3 124, 140–1
 autoantibodies against 218, 219
 clustering 141
 functions 189
 hereditary deficiency 188–9, 190
 see also anion exchange protein
 band cells, psittacine 975
 band granulocytes 46
 Bartonella 379
 basic fibroblast growth factor (bFGF) 16
 basket cells 336
 basopenia 296
 avian 355
 canine 329–30
 causes 330
 equine 318
 feline 342
 ruminants 310
 basophil progenitors (BaPs) 48
 basophilia 296
 avian 354–5
 canine 329–30
 causes 329, 330
 diffuse cytoplasmic 337
 feline 342
 ruminants 310
 basophilic rubricytes 37, 38
 basophilic stippling 149, 155
 basophil/mast cell progenitors (BMCPs) 44, 48
 basophils 48
 activation 294–5
 allergic disease 294, 295
 anaphylaxis 294
 avian 354–5
 biologic functions 291
 bovine 831
 canine 804
 caprine 840
 cervids 921, 925
 chickens 963
 cytochemical staining 1146
 cytogram 1061
 development 12
 elephant 944, 945, 946
 eosinophil interactions 295
 equine 824
 Fc receptors for IgG1 294
 feline 342, 814–15
 ferret 890, 891
 fish 1003
 gerbil 901, 902
 stippling 903
 guinea pig 894, 896
 hamster 905–6, 907
 histamine release assays 296
 host defense 295–6
 hypersensitivity reactions 295
 IgE binding 293
 inflammation 295–6
 laboratory animals
 primates 872–81, 884–5
 rabbits 864, 866, 867
 rodents 857
 laboratory evaluation 296
 mediators 293–5
 microscopic appearance 296
 migration 291
 ovine 840
 parasitic diseases 296
 production 290–1
 products 295
 properties 292
 psittacine 970, 973
 raptors 984–5, 982
 ratite 991–2
 reindeer 937, 937, 939, 939–40
 reptile 1006, 1007, 1010
 tissue distribution 291
 turkeys 963
 water buffalo 928, 929
 batroxobin test 1087
 Bcl-x_i 40
 BCR-Abl translocation 447
 Bence Jones proteins
 multiple myeloma 513
 Waldenström's macroglobulinemia 517
 benzene, hematopoietic cell injury 109–10
 benzocaine, oxidative injury 242, 243
 Bernard-Soulier syndrome 728
 PFA-100 use 1128
 beta-globin chain 125
 beta-globins 5
 betaretroviruses 441
 bias 1028–9
 reference intervals 1038
 bicytopenia, aplastic anemia 256
 bilirubin 142
 formation 126
 biliverdin 126, 142
 Binet staging for chronic lymphocytic leukemia 497
 biological variation 1023, 1035
 Birbeck granules 374
 birds
 anemia 763
 avian leukosis and sarcoma viruses 443
 basophils 354–5
 blood collection 704, 765
 blood donor selection 764–5
 blood group antigens 764
 blood smears 346, 347, 348
 blood storage 765
 coagulation factors 703–6
 coagulation testing 704–5
 defensins 963
 DIC 706
 eosinophils 355
 erythropoietin 980
 fibrinolysis 704
 granulopoiesis 349
 growth factors 961
 hematopoiesis 349
 hemoglobin 962
 hemorrhagic disorders 705–6
 hemostasis 703–6
 hepatotoxins 705–6
 heteropenia 351–2, 356
 heterophilia 351, 356
 heterophil:lymphocyte ratio 355–6
 heterophils 962–3
 ineffective erythropoiesis 763
 infections 706
 leukocytes 345–56
 leukocytosis 350
 leukograms 349–50
 leukopenia 350, 352
 liver disease 705–6
 lymphocytes 349–53
 lymphocytosis 352–3
 lymphopenia 352, 353
 monocytes 353–4
 RBCs 961–2
 reference intervals 349
 thrombocytes 704
 transfusion reactions 765
 transfusion therapy 706, 763–5
 venipuncture technique 704
 viral infections 352
 vitamin K deficiency 705
 white blood cell count 346
 see also chickens; psittacines; raptors; ratites; turkeys; waterfowl
 Birman cat neutrophil granulation anomaly 276, 277

- bison, American
 - normal hematology 931–2, 933–4
 - RBCs 931, 932, 933
 - reference intervals 931–2, 933–4
- blast cells
 - acid phosphatase 1153
 - acute myeloid leukemia 477
 - leukemia 493
- blast crisis, chronic myeloid leukemia 464
- blastogenesis test 401
- bleeding disorders 656–7
 - hereditary 746–7
- bleeding time
 - anemia 740
 - measurement 95
 - normal 1124
- blood banking 731–7
 - collection 73–5, 731–5
 - component separation 734–6
 - donors 731–2
 - quality control 737
 - storage 736–7
- blood collection 73–5, 731–4
 - additive solutions 733
 - anticoagulant preservative solutions 733
 - apheresis 733–4
 - avian 704, 765
 - poultry 958–9
 - psittacines 971–3
 - raptors 982
 - ratites 987–8
 - waterfowl 979–80
 - bison 931
 - bovine 761
 - canine 731–2, 733
 - chickens 958–9
 - contamination 760
 - elephants 942–3
 - equine techniques 759–60
 - feline 732, 733
 - ferret 888
 - fish 995
 - gerbil 899
 - guinea pig 893
 - hamster 904
 - health of animal 731–2
 - laboratory animals
 - primates 869
 - rabbits 862
 - rodents 853
 - marine mammals 950–1
 - principles 732–3
 - psittacines 971–3
 - raptors 982
 - ratites 987–8
 - reindeer 940
 - reptiles 1004
 - screening 732
 - supplies 733–4
 - systems 732, 733
 - turkeys 958–9
 - waterfowl 979–80
 - whole blood 732, 734
- blood crossmatching *see* crossmatching
- blood donors 767
 - canine 731–2
 - feline 732
 - preoperative autologous 759
 - selection
 - avian 764–5
 - equine 758–9
 - ruminants 761
- blood dyscrasias, drug-induced 99–105
- blood films, manual slide evaluation 1025–6
- blood filters 741
- blood group(s) 711–21
 - AB typing 715–17, 1102, 1103
 - ABO typing 1101
 - applications 720–1
 - avian 764
 - bovine 717–18, 719
 - typing 1103
 - canine 712–15
 - typing 1102, 1103
 - feline 231, 715–17, 811
 - typing 1102, 1103
 - livestock 717–20
- blood group antigens 711
 - avian 764
 - canine 712–15
 - feline 715–17, 811
 - livestock 717–20
 - nomenclature 712, 713
- blood islands 4, 6
- blood products
 - stored whole blood 738
 - transfusion therapy 695–6
 - see also* fresh whole blood (FWB); fresh-frozen plasma (FFP); plasma products; whole blood
- blood smears 75
 - avian 346, 347, 348
 - canine 799–800
 - chickens 959
 - fish 995
 - immune-mediated hemolytic anemia 221
 - morphology in anemia classification 157, 158
 - platelet estimation 607
 - thrombocytopenia 582
 - turkeys 959
- blood storage 736–7
 - avian 765
- blood transfusion *see* transfusion reactions; transfusion therapy
- blood typing 759, 1101–3
 - clinical methods 1102–3
 - laboratory testing 1101–2
- blood vessel anatomy 689, 690
- blood viscosity, marine mammal 955
- blood volume
 - guinea pig 893
 - psittacines 972
- blood-borne disease, transmission 760
- bone marrow
 - acute inflammatory response 108–9
 - adipose tissue 9
 - aspiration 1039–40, 1041
 - B cell ALL 493
 - biopsy 1040–1
 - bovine 834
 - collection 1041
 - camelids 914–15
 - collection 1042
 - canine 806–9
 - collection 1039–41, 1043
 - caprine 841
 - cellular organization 11–12
 - cellularity evaluation 1045–6
 - chemotherapeutic agent susceptibility 99
 - chickens 960
 - clonogenic assays 76
 - coagulation necrosis 107
 - collagen 9
 - collection 1039–45
 - cytology 75–6
 - cytospin slides 1045
 - elephants, collection 942–3
 - embryonic 5
 - equine 827–8
 - collection 1041
 - estrogen-induced suppression 100, 257
 - evaluation 582–3, 1039–46
 - failure in hematopoietic neoplasms 492
 - feline 816–19
 - collection 1039–40, 1041
 - ferret 891–2
 - fibrosis 310
 - flow cytometry 1079–80
 - gerbil 903
 - guinea pig 897
 - hamster 907–8
 - hematopoietic function 33
 - hematopoietic stem cells 783, 785
 - histopathology 75
 - immunophenotyping sample preparation 1134
 - infections 118–20
 - innervation 10–11
 - iron levels 168
 - ischemia 107
 - laboratory animals
 - collection/processing 1042–5
 - cytology preparations 1044–5
 - primates 883, 885–6
 - rabbits 867–8
 - rodents 860–1
 - staining 1045
 - llama 1042
 - long-term culture 1049
 - lymphadenopathy 415
 - lymphocytosis 112
 - lymphoid aggregates 113
 - macrophage proliferation 113
 - mastocytosis 297
 - mesenchymal stem cells 785
 - microenvironment 30–2
 - microvascular injury 106–9
 - monkey 1043
 - multiple myeloma infiltration 514
 - necrosis 310
 - neoplasia 248
 - neutrophil transit time 47
 - non-regenerative anemia 159–60
 - ovine 841
 - collection 1042
 - particle-squash preparations 1045
 - plasmacytosis 113
 - porcine 845
 - processing in laboratory animals 1042–5
 - proliferative activity 1080
 - psittacines 973–6
 - pure red cell aplasia 220
 - push smear preparation 1044–5
 - RBC clearance 142
 - regeneration 154
 - reptile 1008–9
 - reticulocytes 137
 - rodents
 - collection 1043
 - flow cytometry staining 1044
 - laboratory 860–1
 - ruminants, collection 1041–2
 - secondary myelofibrosis 114–15
 - serous atrophy of fat/gelatinous transformation 116
 - sinus architecture 9–10
 - sinusoidal system innervation 10–11
 - slide preparation 1045
 - smears
 - evaluation 1045–6
 - preparation 1045
 - staining 1045
 - stromal cells 8–9
 - structure 8–12
 - suppression
 - drug-induced 88
 - neutropenia 310
 - thrombocytopenia assays 598
 - transdifferentiation 788
 - turkeys 960
 - vasculature 9–10
 - venous sinuses 10
 - waterfowl 980–1
 - wedge-type smears 1045
 - see also* myeloid : erythroid (M : E) ratio
- bone marrow endothelial cells (BMECs) 57
- bone marrow stromal cells (BMSC)
 - feline immunodeficiency virus 119
 - multiple myeloma 512

- bone marrow transplantation 783
 after lethal irradiation 33–4
 canine lymphoma 459
 G-CSF therapy 792
 purified hematopoietic stem cells 785
 SCID
 Arabian foals 408
 X-linked recessive 410
 whole marrow 785
 bone marrow-derived stem cells 16
 bone marrow-derived tumors 436–7
 sarcomas 447–9
 bovine congenital erythropoietic porphyria 174–5
 bovine herpesvirus-1 infection 379
 bovine leukemia virus 119–20, 444
 lymphocytosis 310–11
 bovine leukocyte adhesion deficiency (BLAD) 275–6, 310
 bovine spongiform encephalopathy (BSE) 379
 bovine viral diarrhea virus (BVDV) 119, 279, 310
 platelet hypofunction 627
 bovine viral diarrhea-mucosal disease (BVD-MD) 379
 bracken fern
 aplastic anemia 259
 hematopoietic cell injury 109
 brassicas, oxidative injury 244
 bromodeoxyuridine 1080
 buccal mucosal bleeding time 1123–4
 buffalo *see* water buffalo
 see also Bison, American
 Burkitt's lymphoma 507–9
 Burkitt-type lymphoma 495, 509
 large B cell lymphoma differential diagnosis 507
 treatment 509
 burst-forming units–erythroid (BFU-Es) 37
 time to maturation 41
 burst-forming units–megakaryocyte (BFU-MK) 56
- C1-inhibitor 644
 C3 deficiency 404
 Cabot's rings, camelid RBCs 911
 calcium
 fibrin clot formation 650
 metastatic mineralization 691
 platelet 566, 570
 plateletpheresis 752
 RBCs 132
 thrombin amplification 648
 see also hypercalcemia; hypocalcemia
 calcium diacylglycerol guanine nucleotide exchange factor I (CalDAG-GEFI) disorder 621, 622–3
 calves
 failure of transfer of passive immunity 720
 leukocyte counts 308
 neutrophil dysfunction 278–9
 thymic hyperplasia 368
 camelids
 aging 914–15
 anemia 911–12
 blood groups 720
 bone marrow 916–17
 collection 1042
 environmental factors 915–16
 eosinophils 311–12
 gender 914
 genetic relationships 910
 hemotropic mycoplasmas 204
 leukocytes 914–15, 916, 917
 responses 311–12
 leukocytosis 312
 leukogram 311, 312
 neutrophilia 312
 normal hematology 910–18
 platelets 914–15
 RBCs 910–14, 914–15
 oxygen affinity 911
 reference intervals 914–16
 transfusion therapy 720, 761
 see also llama
 camels, bone marrow collection 1042
 cancer
 cell cycle 426
 heritable syndromes 433–4
 see also neoplasia
 cancer procoagulant (CP) 672
 cancer stem cells 17, 19, 438
Candidatus Mycoplasma haemominutum 202–3
Candidatus Mycoplasma haematoparvum 202
Candidatus Mycoplasma haemolamae 204
Candidatus Mycoplasma turicensis 203
 canine adenovirus (CAV) 553
 canine cutaneous histiocytoma 540, 541, 542–3
 canine distemper virus 326, 327
 thrombocytopenia 601
 canine granulocytic ehrlichiosis 200
 canine hemophagocytic histiocytic sarcoma 248
 canine herpesvirus 1 (CHV-1) 692
 canine histiocytic sarcoma complex 430, 541, 543–5
 canine histiocytosis 541–7
 canine juvenile polyarteritis syndrome (CJPS) 694
 canine leukocyte adhesion deficiency (CLAD) 276
 canine monocytic ehrlichiosis (CME) 199–200
 canine parvovirus (CPV) 119
 canine reactive histiocytoses 541, 545–7
 hCAP-18 266
 capillary electrophoresis 1158–9, 1160
 capillary zone electrophoresis 1158–9, 1160
 CAR (coxsackie adenovirus receptor) 551, 552
 carbohydrate metabolism in RBCs 132
 carcinogenesis
 molecular events 437
 see also neoplasia
 carcinogenicity studies 72–3
 cardiac disease
 erythrocytosis 163, 165
 infective endocarditis 673
 platelet hyperfunction 629
 thromboembolism risk 673
 cardiomyopathy 673
 cardiovascular drugs, adverse reactions in dogs 103
 carprofen, adverse reactions in dogs 101
 catalase 134
 cathelicidins 267
 cathepsin G 271
 cats
 AB blood group typing 715–17, 1102, 1103
 adverse drug reactions 104–5
 aortic thromboembolism 676
 aplastic anemia 258–9, 343
 B cell prolymphocytic leukemia 497–8
 babesiosis 206–7
 basophils 342, 814–15
 blood collection 732, 733
 blood donation 732
 blood groups 231, 715–17, 811
 AB system 715–17, 1102, 1103
 Mik 717
 typing 1102, 1103
 bone marrow 816–19
 collection 1039–40, 1041
 erythroid series 816–17
 granulocytic series 817–18
 megakaryocytic series 818, 819
 cancer
 epidemiology 428–9
 risk assessment 431
 Chediak-Higashi syndrome 622
 cytauxzoonosis 207
 drug-induced oxidative injury 99–100
 enteropathy-type T cell lymphoma 530
 eosinophils 342, 814
 extranodal NK/T cell lymphoma 533
 Heinz bodies 126
 Heinz body anemia 99
 hemangiosarcoma 431
 hematocrit 812–13
 hemoglobin 126, 240, 812–13
 hemolytic anemia with increased erythrocyte osmotic fragility 193
 hemolytic transfusion reactions 770
 hemotropic mycoplasmas 202–3
 hereditary stomatocytosis 193
 histiocytic proliferative diseases 547–9
 Hodgkin's lymphoma 520
 immune response to rhEPO 254
 immune-mediated hemolytic anemia 226–31
 immune-mediated thrombocytopenia 591
 infectious thrombocytopenia 601
 large B cell lymphoma 506
 leukemia 341, 342–3, 429, 462–5
 B cell prolymphocytic 497–8
 risk 431
 T cell large granular lymphocytic 528–9
 leukocytes 335–43, 813–15
 leukogram 336, 337
 lymphadenopathy 415–17
 classification 413
 lymphocytes 341–2, 815, 819
 lymphocytosis 342
 lymphoma 428–9, 456–7, 458
 enteropathy-type T cell 530
 extranodal NK/T cell 533
 large B cell 506
 lymphoplasmacytic 498
 mantle cell 500, 501
 T cell 243
 T cell-rich large B cell 523–4
 lymphopenia 342
 lymphoplasmacytic lymphoma 498
 mantle cell lymphoma 500, 501
 mast cell tumors 431, 488–9
 MHC 779
 monocytes 341, 815, 819
 monocytopenia 341
 monocytosis 341
 mucopolysaccharidosis 338, 339
 multiple myeloma 514
 mycoplasmas 202–3
 mycosis fungoides 531
 mycotoxin sensitivity 259
 myelodysplastic syndrome 343, 472–3
 classification 468, 469
 myelonecrosis 107
 neonatal isoerythrolysis 717
 neutropenia 340–1
 neutrophilia 340
 neutrophils 337–41, 814
 normal hematology 811–19
 nude kittens 403
 oxidative injury
 causes 240–2
 drug-induced 99–100
 platelets 581, 815–16
 porphyria 176
 pulmonary artery medial hypertrophy 692
 pure red cell aplasia 253–4
 pyruvate kinase deficiency 184–5
 RBCs 811–13
 lifespan 138
 morphology 811, 812
 quantitative parameters 812–13

- red cell antigens 715–17
 reticulocytes
 count 138
 release 137
 types 153, 154–5
 secondary dysmyelopoiesis 473
 splenic infections 379
 systemic lupus erythematosus 388
 T cell large granular lymphocytic leukemia 528–9
 T cell lymphoma 243
 T cell-rich large B cell lymphoma 523–4
 taurine deficiency 629
 thrombocytopenia
 immune-mediated 591
 infectious 601
 thrombosis 670, 671
 transfusion reactions 716–17, 770
 von Willebrand disease 613, 614
 whole blood
 collection 734
 separation into components 736
 see also feline entries
 cattle
 acute inflammation 108–9
 anaplasmosis 309
 aplastic anemia 259
 B cell prolymphocytic leukemia 497–8
 babesiosis 206
 bacillary hemoglobinuria 212–13
 basophils 831
 blood collection 761
 blood groups 717–18, 719
 typing 1103
 bone marrow 834
 collection 1041
 CalDAG–GEFI disorder 621, 622–3
 cancer risk 432
 eosinophils 831
 granulocytic anaplasmosis 200–1
 hemotropic mycoplasmas 204
 hereditary band 3 deficiency 188–9, 190
 immune-mediated hemolytic anemia 233–8
 infectious thrombocytopenia 601
 inherited macrothrombocytopenia 620
 leptospirosis 213
 leukocytes 830–3
 lymphocytes 831–2
 lymphoma 432
 malignant catarrhal fever 692
 MHC 779–80
 monocytes 832–3
 mycotoxin toxicity 259–60
 neoplasia 429
 neutrophils 830–1
 dysfunction in periparturient dairy cattle 278
 granules 266
 oxidative metabolic burst activity 943–4
 normal hematology 829–34
 environmental/physiological variables 833–4
 oxidative injury 243–4
 parturition 309
 plasma proteins 834
 platelets 833
 RBCs 829–30
 lifespan 138
 metabolism 830
 theileriosis 204–5
 transfusion therapy 761
 trypanosomiasis 207
 von Willebrand disease 613, 614
 see also calves
 CC chemokines 270, 272
 CD1 541
 feline progressive histiocytic proliferations 548, 549
 feline progressive histiocytosis 548
 histiocytic sarcoma 544–5
 CD3 494, 1135
 lymphoblastic T cell lymphoma 527
 T cell acute lymphoblastic leukemia 526
 CD3e 1135
 CD4 63, 359, 1135
 CD5 1135
 CD8 63, 359, 1135
 CD11a 270, 726
 antibodies 726
 CD11b 269, 726
 antibodies 726
 CD11c 54, 270
 CD11/CD18 269–70, 273
 canine cutaneous histiocytoma 542
 canine leukocyte adhesion deficiency 276
 canine leukocyte differentiation 541
 deficiency 727
 granulocyte antigens 726
 histiocytic sarcoma 544, 545
 CD11d 270
 CD14 54, 448, 1135
 CD14+ cells 66
 CD18 269–70
 canine cutaneous histiocytoma 542
 feline progressive histiocytosis 548
 granulocyte antigens 726
 leukocyte adhesion deficiency 275, 276
 CD20 459, 493, 495
 B cell prolymphocytic leukemia 498
 Burkitt's lymphoma 508
 follicular lymphoma 504
 large B cell lymphoma 506
 lymphoplasmacytic lymphoma 498
 mantle cell lymphoma 501–2
 marginal zone lymphoma 499
 CD21 1135
 CD30, enteropathy-type T cell lymphoma 530
 CD34 15, 448, 577, 1135
 bone marrow transplantation 785
 expression in leukemia 463
 mast cells 291
 CD36 31, 567, 577
 CD41 576
 CD42 576, 577
 CD44 31
 CD45 448, 1042–4, 1080, 1135
 CD61 576
 CD63 264
 CD68 264
 CD71 1042, 1080
 CD79 365
 CD79a 493, 495, 1135
 B cell prolymphocytic leukemia 498
 Burkitt's lymphoma 508
 follicular lymphoma 503, 504
 large B cell lymphoma 506
 lymphoplasmacytic lymphoma 498
 mantle cell lymphoma 501–2, 502
 marginal zone lymphoma 499, 500
 CD117 448
 CD133 66
 CD142 *see* thromboplastin; tissue factor (TF)
 CDK1 422, 425
 CDK2 422, 423, 424
 CDK3 422
 CDK4 422, 423, 424
 CDK5 422
 CDK6 422, 423
 CDK-activating kinase (CAK) 422, 423
 CDR3 1136–7
 cell cycle
 cancer 426
 negative regulation of entry 423
 phases 421, 422
 cell cycle engine 421–3
 cell hemoglobin of reticulocytes (CHr) 1069
 cell sorters 1074–5, 1076
 cell surface antigens 725
 detection by flow cytometry 1134
 CELL-DYN® 3500 Hematology Analyzer (Abbott) 987, 988, 992, 1062
 cellular transformation, acquired
 characteristics 435
 cellular typing 777
 cellulitis, puppy strangles 416
 cellulose acetate electrophoresis 1158
 centrifugal analysis 1056
 cephalosporins, adverse reactions in dogs 102
 cerebral amyloid angiopathy 690–1
 ceruloplasmin 170, 1161
 cervids
 aging 923
 disease response 923, 926
 gender 923
 leukocytes 919, 920–2, 925, 926
 normal hematology 918–19, 920–2, 923, 923–5, 927
 platelets 919, 923
 RBCs 918, 919, 923, 927
 sickling phenomenon 918, 919
 reference intervals 923, 923–4
 reproductive status 923
 see also reindeer
 Chagas' disease 207
 Charcot–Leyden crystal protein (CLCP) 283
 Chédiak–Higashi syndrome 276, 277, 307–8, 621, 622
 feline 338–9
 platelet aggregation 1126
 chemicals, hematopoietic cell injury 107–8
 chemiluminescence alteration in Weimeraners 277
 chemokines
 eosinophil recruitment 284
 eosinophil trafficking 285
 modulation 554
 neutrophil receptors 270
 chemotactic factors, eosinophil recruitment 284
 chemotaxis, neutrophils 270, 1116–17
 chemotherapeutic agents
 adverse drug reactions
 cats 100
 dogs 100–1
 bone marrow susceptibility 99
 lymphoma 455, 456, 457–8, 459
 mast cell tumors 487, 488
 multiple myeloma 515
 neutropenia 341
 dogs 324
 thrombocytopenia induction 602
 chickens
 blood collection 958–9
 blood smears 959
 bone marrow 960
 defensins 963
 endothelium 961
 granulocytes 962–3
 granulopoiesis 960–1
 growth factors 961
 hematopoiesis 960–1
 leukocyte count 959, 960
 lymphocytes 963, 964
 medullary sinuses 961
 MHC 780
 monocytes 963, 964
 normal hematology 958–66
 RBCs 961–2, 965
 count 959–60
 reference intervals 965
 spleen 960, 961
 thrombocytes 962, 963, 965
 thymus 960
 Chinese chive, oxidative injury 242

- Chlamydomytila psittaci* 349
 avian leukocytes 348
 chlorambucil, systemic lupus erythematosus 391
 chloramphenicol, adverse reactions in dogs 102
 chloride–bicarbonate exchange, defective 189
 chlorinated hydrocarbons, hematopoietic cell injury 110
 chloroacetate esterase (CAE) 1143, 1145, 1146, 1147, 1148, 1149, 1150, 1151
 chromatin condensation 425
 chromogenic substrates, coagulation tests 1085
 chronic granulomatous disease, Doberman Pinschers 277
 chronic lymphocytic leukemia (CLL) 112, 463–4
 angiogenesis 436
 B cell 463, 464, 495–7
 B cell prolymphocytic leukemia differential diagnosis 498
 canine 463–4
 clinical features 497
 diagnosis 464
 hyperglobulinemia 415
 lymphocytosis 331
 staging 497
 T cell 463, 529
 treatment 463, 464
 chronic myelogenous leukemia (CML) 460
 chronic myeloid leukemia (CML) 464–5
 essential thrombocythemia differential diagnosis 608, 609–10
 treatment 464–5
 chronic myelomonocytic leukemia 468, 1146
 chronic myeloproliferative diseases 608
 essential thrombocythemia differential diagnosis 609–10
 chronic renal failure
 anemia 248
 aplastic anemia in cats 258
 circulating endothelial cells (CECs) 66
 circulating endothelial progenitors (CEPs) 66
 circulating immune complexes (CIC) 386, 389
 circulating neutrophil pool (CNP) 336
 citrate toxicity 773
 citrate–phosphate–dextrose (CPD) 735, 739, 765, 766
 c-kit 16, 448
 mast cells 291
 c-kit ligand *see* stem cell factor (SCF)
 classical swine fever virus (CSFV) 119–20
 Clinical and Laboratory Standards Institute (CLSI), reference interval guidelines 1034–5
 clinical decision limits 1034
 clonal evolution theory 438
 clonality 1136–9
 leukemia assays 1139
 lymphoma 1139
 quality control 1138
 results interpretation 1138
 samples 1137–8
 sensitivity/specificity 1138
 testing 1136–7
 clopidogrel 699
Clostridium haemolyticum 212–13
Clostridium perfringens type A 211–12
 clot detection methods 1083–4
 clotting cascade 636
 clotting time 1084
 prolonged 93–4
 cluster of differentiation (CD) antigens 20, 21–3, 24–5
 integration 24
 structure 24
 tissue distribution 24–5
see also individual CDs
 CMAH gene 716
 coagulation 636
 elephants 946
 excessive activation 669
 feedback regulation by thrombin 649
 ferret 892
 fish 998
 guinea pig 897
 hamster 908
 laboratory animals
 primates 882, 885
 rabbits 868
 rodents 859–60
 porcine 846
 rate 638–9
 screening tests 1085–7
 coagulation assays 1084
 chromogenic/fluorogenic substrates 1085
 coagulation defects, transfusion therapy 696
 coagulation disorders, laboratory testing 1082–97
 coagulation enzymes 636–8
 coagulation factors
 activators 1084
 assays 1088–9
 thromboelastography 1094–7
 avian 703–4
 chromogenic assays 1089
 consumption 655–6
 deficiencies 654–6
 autosomal 664–7
 hereditary 662, 746–7
 X-linked 661–4
 elephants 946
 inhibitor assays 1088–9
 laboratory rodents 859–60
 recombinant 746–7, 748–9
see also individual named factors
 coagulation inhibitors 644–5, 656, 659–60
 coagulation panel screen 582
 acquired coagulopathies 657, 658
 hemophilia diagnosis 662
 hypercoagulability 673
 coagulation pathway
 cell surface membranes 647
 common 637, 639–40, 643–4
 contact 640–1
 extrinsic 637, 639–40, 641–2
 intrinsic 93, 637, 639–40, 642–3
 systemic lupus erythematosus 388
 coagulation pathway inhibitors 95
 coagulation proteins 93–4, 636, 637
 enzymatic activation 636, 638
 thrombin generation 639–45
 coagulometers 1083–4
 coagulopathies
 acquired 654–60
 classification 654–6
 clinical evaluation 656–7
 disorders 657–60
 pathogenesis 654–6
 physical examination 657
 plasma therapy 747
 point-of-care tests 657
 dilutional 655–6
 hereditary 661–7
 plasma therapy 747
 X-linked 661–4
 plasma therapy 747
 volumes 760
 vitamin K antagonists in birds 705
 cobalamin, inherited selective malabsorption 196–7, 198
 codocytes 146
 marine mammals 955–6
 coefficient of variation (CV), imprecision 1028
 cofactors 636
 inhibition 638
 phospholipid interactions 639
 Coggins test 238
 cold agglutinin disease 231
 cold agglutinins, immune-mediated hemolytic anemia 221–2
 cold stress 279
 collagen
 binding 561
 bone marrow 9
 platelet agonist 1126
 collagen gel technique for chemotaxis 1117
 collagen receptors 571–2
 colony stimulating factors (CSFs)
 granulopoiesis regulation 44
see also granulocyte colony-stimulating factor (G-CSF); granulocyte–macrophage colony-stimulating factor (GM-CSF)
 colony-forming unit–erythroid (CFU-E) 37
 erythropoietin role 790
 time to maturation 41
 colony-forming units–megakaryocyte (CFU-MK) 56
 colony-forming unit–spleen (CFU-S) assay 1047
 colony-stimulating factor 1 receptor (CSF-1R) 448
 combinatorial diversity 61–2
 common lymphocyte progenitors (CLPs) 30, 44, 50–1
 common myeloid progenitors (CMPs) 37, 44, 47, 50–1
 comparative genomic hybridization 1173, 1175
 complement
 MHC encoding 776
 RBC clearance 141
 complement system deficiencies 404
 complementarity determining region *see* CDR3
 complementary DNA (cDNA) generation 1166
 computed tomography (CT), pulmonary thromboembolism 675–6
 congenital anemia, dyskeratosis, and progressive alopecia in polled Hereford calves 198
 congenital dyserythropoiesis 196–8
 polymyopathy and cardiac disease 198
 congenital erythropoietic porphyria
 bovine 174–5
 carrier state detection 175
 congenital heart disease, erythrocytosis 163, 165
 contact activation 640
 contact factor
 deficiency 666
 pathway 704
 contagious streptococcal lymphadenitis 416
 Coombs' test 1106–7
 immune-mediated hemolytic anemia 221–2, 228, 235, 1106–7
 systemic lupus erythematosus 387
 copper deficiency 170
 neutrophil function 280
 oxidative injury 243–4
 copper toxicity
 elasmobranchs 1016–17
 oxidative injury 244
 COPRO I 174, 176
 coproporphyrin, hereditary 177
 coproporphyrin 174, 175, 176
 core binding factors (CBFs) 57
 corpuscular Hgb concentration mean (CHCM) 1056
 corrected reticulocyte percentage (CRP) 154

- corticosteroid therapy, thromboembolism risk 672
- cortisol, erythropoiesis stimulation 163
- corynebacteriosis 213
- coulometry 1162
- coumadin 658–9
- coxsackie adenovirus receptor (CAR) 551, 552
- cranial mediastinal lymphoma 527–8
- C-reactive protein
marine mammals 955
measurement 1160
porcine 846
- crossmatching 759, 1101, 1103–5
avian 764
gel microtubes 1105
indications 1103, 1104
large animals 1104
limitations 1103–4
rabbits/rodents 767
saline replacement technique 1104–5
standard procedure 1104–5
- cryoprecipitate 735, 745–6
fibrinogen defect treatment 664
hemophilia A response 749
storage 736
see also transfusion therapy
- cryosupernatant 735, 746
storage 736
see also transfusion therapy
- Cushing's disease *see* hyperadrenocorticism
- cutaneous histiocytoma 540, 541, 542–3
- cutaneous histiocytosis 540, 541, 545–6
immunophenotypic studies 546
morphological features 546
pathogenesis 546–7
treatment 547
- cutaneous T cell lymphoma (CTCL) 531
- CXC chemokine ligand 12 (CXCL12) 44
- CXC chemokine receptor 4 (CXCR4) 30, 31, 44
thrombopoiesis 59
- CXC chemokines 270, 272
- CXCL12 30, 31
- cyclic hematopoiesis in gray collies 277, 311, 621, 622
G-CSF therapy 792
GM-CSF therapy 793
- cyclin(s) 421–2
G0 phase maintenance 423
- cyclin B 425–6
- cyclin–CDK complexes 422, 424, 425
- cyclin-dependent kinase inhibitors (CDKIs) 422–3, 426
- cyclin-dependent kinases (CDKs) 422
see also individual named CDKs
- cyclo-oxygenase (COX) 628, 698
- cyclophosphamide 391
- cytauxzoonosis, feline 207
- cytochemical staining 1141–54
applications 1149, 1150, 1151–4
azurophils 1146–7
basophils 1146
erythroid cells 1149
hematopoietic cells 1142–3, 1144, 1144–5, 1146–9
lymphocytes 1147–8
mast cells 1149
megakaryocytes 1148–9
monocytes 1146–7
pattern 1142
peroxidase (PEROX) activity 1142–3, 1144–5, 1146–9
platelets 1148–9
principles 1149, 1150, 1151–4
reactions 1144
Sudan black B staining 1142–3, 1144–5, 1146–9
- cytochemistry
principles 1141
species differences 1142
- cytochrome *c* reduction assay 1118
- cytogenetics 1173, 1174, 1175
- cytopathicity, direct 442
- cytopenias
chemotherapeutic agent-induced 99
compound-related 85–91
preclinical studies 85–6
drug-induced 86–90
immune 86–8
investigations 90–1
idiosyncratic reactions 87
myelodysplastic syndromes 467
refractory with multilineage dysplasia 468–9, 469, 470, 472–3
- cytoplasm, dysplastic changes 106
- cytospin slides, bone marrow 1045
- cytotoxic T lymphocytes (CTLs) 553
feline immunodeficiency virus 396
- dacryocytes 147
camelid 911
- dalteparin 1096
- darbepoetin alfa 791
- Darier's sign 484
- D-dimer, fibrinolysis 650
- D-dimer assays 583, 597, 1093
DIC 94, 684
hypercoagulability 673
pulmonary thromboembolism 675
- DEA *see* dog erythrocyte antigens (DEA)
- deer *see* cervids
- defensins 266, 267
antimicrobial properties 271
avian 963
- dehydrated hereditary stomatocytosis 191
- deltaretroviruses 442
- demarcation membrane system (DMS) 58, 577
- dendritic cells
antigen processing 302
B cell proliferation 365
canine 541
circulation 53
cytokine regulation 51
differentiation from macrophages and monocytes 54
expansion 52
function 53–4
generation 52
histiocytic disorders 541
histiocytic sarcoma 544–5
innate immunity 359
interstitial 541
intraepithelial 541
lymph nodes 372
microenvironment 53
production 50–1
recruitment by neutrophils 272
skin 374
- T cells
activation 360–1
development 360
tissue distribution 53
transcriptional regulation 51
- dense granule defect 622
- dense granules 565–6
- dense tubular system (DTS) 564–5
- desmopressin 697
inherited intrinsic platelet disorders 624
von Willebrand disease treatment 617
- diabetes mellitus
anemia 249
Heinz body formation in cats 249
oxidative injury 241, 242–3
platelet hyperfunction 629
thromboembolism risk 673
- diagnostic test validation 1027–33
analytical performance 1027, 1031
clinical performance 1031
control material 1029
detection limit 1030
- imprecision 1028
linearity checks 1029
method comparison 1029–30
overlap performance 1031
predictive values 1032
receiver-operating-characteristic curves 1032
sensitivity/specificity 1031–2
spiking recovery 1029
- Diamond–Blackfan syndrome 253
- diffuse large B cell lymphoma 504–7
clinical features 507
pathologic features 505–7
- dilutional coagulopathy 659
- dimethylsulfoxide (DMSO), adverse reactions in horses 104
- dioxins, chlorinated 110
- diphosphoglycerate 6, 181
- diphosphoglycerate pathway, RBCs 132–3
- direct antiglobulin test (DAT) 1106, 1107
drug-induced autoantibodies 1112
- Dirofilaria* (heartworm) 330, 673
vasculitis 693
- disseminated intravascular coagulation (DIC) 93, 599, 659, 679–87
antithrombin testing 583
avian 706
chronic 685
compound-related 94
D-dimer testing 583
definition 679
diagnosis 683–5
diagnostic assays 597–8, 599
endothelial cell dysfunction 683
fulminant 684
hemorrhage due to neoplasia 248
hemorrhagic 684
coagulation factor deficiency 696
immune-mediated hemolytic anemia 220
inflammatory response 683
initiation 680–1
laboratory criteria 684, 685
neoplasia association 602
non-overt 679, 680, 681
diagnosis 683, 684–5
overt 679, 680, 683
coagulation factor deficiency 696
diagnosis 683–4
pathogenesis 599, 680–1, 682, 683
perpetuation 683
phosphatidylserine role 681
plasma therapy 747
platelet consumption 579, 598
platelet hypofunction 627
primary disease conditions 679, 681
progression 681, 682
thrombocytopenia 599, 602
treatment 685–7
- distemper vaccine, modified live virus (MLV) 594
- divalent metal iron transporter-1 (DMT-1) 127–8
- DNA
abnormalities 437
amplification 1167
isolation for molecular diagnosis 1166
replication 437
sequencing 1167
- DNA-dependent protein kinase (DNA-PK) 62
- DNA-dependent protein kinase (DNA-PK_{cs}), SCID in Arabian foals 407, 408
- dog erythrocyte antigens (DEA) 712–14
DEA 1.1, 1.2, 1.3 712–13
typing 1102, 1103
DEA 3 713–14
DEA 4,5,6,7,8 714
transfusion reactions 712–13

- dogs
 adverse drug reactions 100–3
 anticoagulant rodenticide toxicity 598
 antinuclear antibodies 1111–12
 aortic thromboembolism 676
 aplastic anemia 257–8
 autoimmune hemolytic anemia 216–19
 B cell prolymphocytic leukemia 497–8
 babesiosis 205–6
 basopenia 329–30
 basophilia 329–30
 basophils 804
 blood collection 731–2, 733
 blood donation 731–2
 blood groups 712–15
 C system 715
 D system 714–15
 Dal type 715
 DEA system 712–14
 NeuAc/NeuGc 714
 typing 1102, 1103
 bone marrow 806–9
 collection 1039–41, 1043
 erythroid series 806–7
 granulocytic series 807–8
 megakaryocytic series 808–9
 myeloid:erythroid ratio 809
 buccal mucosal bleeding time 1124
 Burkitt's lymphoma 508–9
 CalDAG–GEFI disorder 621, 622–3
 Döhle bodies 106, 307
 canine 326
 feline 337–8
 dolphins *see* marine mammals
 drepanocytes 144
 dromedary camel *see* camelids
 drug eruptions, cutaneous 747
 drug toxicity mechanisms 99–100
 drug-associated conditions
 agranulocytosis 87, 89
 aplastic anemia 258, 259
 blood dyscrasias 98–104
 immune-mediated hemolytic anemia
 trigger 87, 220, 230–1, 233–4
 immune-mediated thrombocytopenia 87,
 594
 myelofibrosis 115
 platelet hyperfunction 630
 platelet hypofunction 628
 secondary dysmyelopoiesis in dogs 471
 sideroblastic anemia 170
 systemic lupus erythematosus 384
 thrombocytopenia 600, 601, 602
 thrombocytosis 607
 drug-induced autoantibodies 1112
 ductus arteriosus, persistent 690
 ductus venosus, persistent 690
 dyserythropoiesis, congenital 196–8
 dysfibrinogenemia 664
 plasma therapy 747
 dysmegakaryopoiesis, selective 471
 dysmyelopoiesis, secondary
 cats 473
 dogs 471–2
 E selectin 268–9
 E2F transcription factors 424
 ε-aminocaproic acid (EACA) 697
 E-cadherin 541, 542
 eccentrocytes 147, 239, 240
 echinocytes 146, 147
 canine 799
 echocardiography, pulmonary
 thromboembolism 675
 ehrlichiosis 118, 199–201
 aplastic anemia 257–8
 feline 339–40, 341
 immune-mediated thrombocytopenia 593
 lymphocytosis 331
 neutropenia 310, 324, 341
 neutrophils 327, 328
 elasmobranchs
 heterophils 1013, 1014, 1014–15
 infections 1016
 leukocytes 1013, 1014
 movement between fresh and saltwater
 1016
 normal hematology 1013–14, 1015,
 1016–17
 RBCs 1013, 1014
 thrombocytes 1013, 1014, 1016
 elastase 267, 271
 electronic impedance 1055
 electrophoresis 1157–61
 detection 1157
 monoclonal peak detection 1160
 patterns in different species 1159
 protein fraction correlation 1159–60
 separation 1157
 types 1158–9
 elephants
 aging 947
 bone marrow collection 942–3
 coagulation 946
 endotheliotropic herpesviruses 947, 948
 gender 947
 infections 947–8
 leukocytes 943–5, 946, 947
 monocytes 944, 945, 946, 946–7, 948
 myoglobin 943, 947
 normal hematology 942–8
 parasitic diseases 948
 platelets 946
 RBCs 943, 947
 reference intervals 946–7
 elk, RBCs 918, 919
 elliptocytes 147, 148
 elliptocytosis *see* hereditary elliptocytosis
 Embden–Meyerhof pathway 132, 179–81
 embryonic stem cells (ESCs) 14
 emus *see* ratites
 endocrine disease, anemia 249
 endogenous thrombin potential (ETP) 674
 endomitosis 58
 endosteal blood vessels 8
 endothelial cells
 atherosclerosis 690
 blood vessel 689
 bone marrow 57
 dysfunction in DIC 683
 hemostasis 645–6
 NO synthesis 646
 von Willebrand factor synthesis 612,
 613
 endothelial precursor cells 16
 endothelial progenitor cells (EPCs) 65–6
 endothelial protein C receptor (EPCR) 645
 endothelium
 antithrombotic properties 646
 chickens 961
 prothrombotic properties 646
 turkeys 961
 endotoxemia
 canine 324, 325
 DIC 679, 681
 neutropenia 340
 thrombocytopenia 600
 endotoxins 579
 platelet hypofunction 627
 water buffalo response 930
 enteric system, MALT 374
 enteropathy-type T cell lymphoma (ETTCL)
 530
 enterotoxemic jaundice 211–12
 enzootic nasal tumor virus (ENT) 445
 enzyme-linked immunosorbent assay
 (ELISA) 1085
 serum ferritin measurement 1163
 eosinopenia 288
 avian 355
 camelids 311–12
 canine 328–9
 causes 328–9
 equine 318
 feline 342
 mechanisms 328–9
 ruminants 310
 stress 329
 eosinophil(s) 47–8, 281–8
 activation 284
 allergic disease 286
 antitumor effect 286
 asthma 286
 avian 355
 basophil interactions 295
 bison 931, 932, 934
 bovine 831
 camelids 311–12, 914, 916
 canine 803–4
 caprine 839–40
 cell surface receptors 283–4
 cervids 921, 924
 chickens 963
 cytochemical staining 1143, 1144–5,
 1146–9
 cytokine release 287
 development 12
 effector functions 285–7
 mechanisms 287
 elasmobranchs 1013, 1014, 1015
 elephant 944, 945, 946
 equine 315, 316, 823–24, 823
 feline 342, 814
 ferret 890, 891
 fish 1002, 1013, 1014, 1015
 gerbil 901, 902
 granule protein release 287
 granules 282–3
 guinea pig 894, 896
 hamster 905–6, 907
 helminthic parasite defense 285–6
 homeostasis involvement 284–5
 immune system involvement 284–5
 inflammation 285
 laboratory animals
 primates 872–82, 883–4
 rabbits 864, 866, 867
 rodents 857
 lipid bodies 283
 lipid mediators 287
 mast cell interactions 295
 membrane-bound primary granules
 283
 metabolism 282
 morphology 282–3
 ovine 839–40
 phagocytosis 286
 plasma membrane 282–3
 porcine 844
 production 281
 psittacines 970, 972–3
 raptors 982, 984
 ratite 991
 regulation 281
 reindeer 937, 937–938, 939–40
 release 281
 reptile 1006, 1007, 1010
 structure 282–3
 surface molecules 283–4
 tissue distribution 282
 trafficking 285
 turkeys 963
 water buffalo 928, 929
 eosinophil cationic protein 284
 eosinophil peroxidase 282, 284
 eosinophil sombrero vesicles (EoSVs) 284,
 287
 eosinophil-derived neurotoxin 282, 284
 eosinophilia
 avian 355
 canine 328–9
 causes 328
 equine 317–18

- feline 342
 hypersensitivity reactions 342
 inflammatory reactions 342
 laboratory primates 883–4
 mechanisms 287–8, 328
 parasitic diseases 310, 839–40
 ruminants 310
 seasonal parasitism 839–40
 eosinophilic syndrome, spleen 380
 eotaxin-1 282
 epigenetics 1172–3
 epinephrine, platelet agonist 1126
 epsilonretroviruses 442
 Epstein–Barr virus (EBV)
 Burkitt's lymphoma 507–8
 T cell lymphoma 243
 equine adenovirus, SCID in Arabian foals 407
 equine herpesvirus 1 (EHV-1) 692
 equine infectious anemia 213–14, 237–8
 thrombocytopenia 601
 equine infectious anemia virus (EIAV) 119, 213–14
 equine purpura hemorrhagica 694
 equine viral arteritis 692
 thrombocytopenia 601
 equinins 267
 eryptosis 88, 132
 erythroblast(s), primitive 4
 erythroblast macrophage protein (EMP) 41
 erythroblastic islands 11, 12, 41
 erythrocyte(s)
 polychromatophilic 977, 989
 see also red blood cell(s) (RBCs)
 erythrocyte antigen (EA) 717, 718–21
 erythrocyte sedimentation rate (ESR)
 elephant 943
 ferret 892
 guinea pig 897
 hamster 908
 marine mammals 954
 species variations 955
 water buffalo 929
 erythrocyte-bound immunoglobulins, flow cytometry 1078
 erythrocytosis 81
 absolute 162–4
 clinical signs 164
 diagnosis 164–5
 endocrinopathy-associated 163–4
 hemoglobin variants 165
 primary 162–3
 treatment 165
 relative 162, 164
 treatment 165
 secondary 163
 treatment 165
 tissue oxygenation 164–5
 treatment 165
 erythroid burst forming units (BFU-Es) 31
 erythroid cells 4
 cell surface molecules 38, 39
 cytochemical staining 1149
 differentiation 39
 proliferation 39
 erythroid hypoplasia 159
 erythroid Kruppel-like transcription factor (EKLF) 40
 erythroid precursors 6, 37–8, 136
 nomenclature 38
 erythroid progenitor cells 790
 erythrokinetics 41
 erythroleukemia, acute 479, 481
 erythrophages, reptile 1006
 erythropoiesis 12, 36–41
 adhesion molecules 41
 anemia with decrease 249
 cytokine regulation 39–40
 definition 36
 equine 828
 failure 251
 growth factor regulation 39–40
 humoral inhibitors 40
 ineffective 159, 229
 avian 763
 ferrets 766
 microenvironment 41
 molecular control 39–41
 negative regulators 41
 primitive 6
 process 36–8
 psittacines 974–5
 pure red cell aplasia 251
 strength 153–5
 transcription factors 40
 waterfowl 980
 erythropoiesis-stimulating agents (ESAs) 248–9
 erythropoietic niche 31–2
 erythropoietic protoporphyria, bovine 174–5
 erythropoietin (EPO) 6, 32, 39, 790–1
 adverse reactions 103, 791
 avian 980
 erythrocytosis 163, 164, 165
 excessive production 163
 platelet hyperfunction 630
 psittacine 974
 RBC effects 82
 veterinary uses 791
 waterfowl 980
 erythropoietin, recombinant (rEPO) 248–9
 erythropoietin, recombinant canine (rcEPO) 791
 erythropoietin, recombinant feline (rfEPO) 791
 erythropoietin, recombinant human (rhEPO) 249, 398, 791
 pure red cell aplasia 253, 254
 erythropoietin receptor (EPOR) 39
 essential thrombocythemia 608–10
 JAK2 gene mutation 608–9
 megakaryocytes 608
 reactive thrombocytosis differential diagnosis 608, 609, 610
 estimates of random error (CV) 1029–30
 estrogen
 adverse drug reactions 101
 bone marrow suppression in dogs 101, 258
 toxicosis in dogs 324
 ethylenediaminetetraacetic acid (EDTA) fish blood preservation 995
 neutrophil artifacts 326
 pseudothrombocytopenia 580, 603
 raptor blood collection 982
 reptile blood samples 1004–5
 European–American classification of lymphoid neoplasms 453
 revised 454, 460, 492
 excitement
 camelids 914
 cervids 923
 leukocyte changes 858
 leukogram changes 308
 exercise
 neutrophil effects 273
 stress 279
 exocytosis 265
 exosomes 137, 193
 external quality assessment (EQA) 1023
 extracellular signal related kinases (ERK) 16
 extramedullary plasmacytoma 516–18
 clinical manifestations 517
 diagnosis 517
 prognosis 517–18
 treatment 517
 extranodal NK/T cell lymphoma, nasal type 533
 FACSria 1075
 FACSCalibur 1075
 factor II
 deficiency 665
 vitamin K-dependent 94
 factor V 566, 643
 acquired inhibitors 656
 activated (FVa) 637
 deficiency 667
 factor VII 640, 641–2
 activated (FVIIa) 641, 642, 665
 activated recombinant (rhFVIIa) 697, 746
 deficiency 665
 tissue factor binding 642
 vitamin K-dependent 94
 factor VIII 612, 642–3
 acquired inhibitor 1089
 concentrate 746
 deficiency 656, 661
 gene mutation 661, 663–4
 inhibitory antibodies 656, 659, 1089
 recombinant human 746
 factor IX 642
 acquired inhibitor 1089
 activated (FIXa) 642, 648
 concentrate 746
 deficiency 661
 gene mutation 663
 recombinant human 746
 vitamin K-dependent 94
 factor X 643
 acquired inhibitor 1089
 deficiency 665–6
 FIXa substrate 642
 gene mutations 666
 vitamin K-dependent 94
 factor X, activated (FXa) 95, 640, 643, 644, 648
 inhibition 95–7
 synthetic inhibitors 700
 factor X clotting (FX:C) assay 95–7
 factor X coagulant activity (FX:C) 665, 666
 factor Xa-FVa complex 640
 factor XI 640, 642
 activated (FXIa) 648
 contact factor pathway 704
 factor XI deficiency 666
 insertion 1173
 factor XII 579, 640
 activated (FXIIa) 640, 651
 contact factor pathway 704
 contact pathway 640–1
 deficiency 666
 factor XIII
 activation 649
 deficiency 667
 familial stomatocytosis–hypertrophic gastritis 192–3
 Fas 41
 Fas ligand (FasL) 41
 fatty liver hemorrhagic syndrome 706
 Fc receptors, monocytes/macrophages 300
 FcεRI 293
 febrile, non-hemolytic transfusion reactions (FNHTRs) 771
 febrile reactions, transfusion 771
 feline enteric coronavirus (FECV) 693
 feline histiocytic sarcoma complex 549
 feline immunodeficiency virus (FIV) 119, 393–8
 antibody detection 396–7
 clinical disease 395
 diagnosis 396–7
 direct detection 396
 epidemiology 393–4
 genes 393
 global distribution 394
 hematological disorders 395–6
 immune reaction 396
 immune-mediated thrombocytopenia 593

- feline immunodeficiency virus (FIV)—*Continued*
 incidence 393–4
 latent infection 394–5
 maternal antibodies 397
 pathogenesis 394–5
 PCR 396
 prevalence **394**
 prognosis 398
 progression of disease 395
 thrombocytopenia 601
 transmission 393–4
 treatment 397–8
 vaccination 397
 virus isolation 396
- feline infectious peritonitis (FIP) 693
 thrombocytopenia 601
- feline leukemia virus (FeLV) 119, 444
 aplastic anemia 258
 genotypes 444
 immune-mediated hemolytic anemia
 trigger 230
 immune-mediated thrombocytopenia 593
 neutropenia 341
 neutrophil dysfunction 279
 peripheral lymph node hyperplasia 342
 platelet hypofunction 627
 pure red cell aplasia 254
 thrombocytopenia 601
 transmission 444
- feline panleukopenia virus (FPV) 119
 feline progressive histiocytosis 547–8
 feline pulmonary Langerhans cell
 histiocytosis 548–9
- Fell pony syndrome 408–9
- ferrets
 anemia 765–6
 bone marrow 891–2
 estrogen-induced suppression 100
 coagulation 892
 leukocytes **890**, 891
 normal hematology 888–92
 peripheral blood cells 888, **889–90**, 891
 platelets 888, 891
 RBCs 888, **889**
 transfusion therapy 765–6
- ferrereductase duodenal cytochrome b 128
- ferritin 125, 129
 serum levels 168, 1163
- ferroportin 127, 128
- ferrous iron 127
- fetal hemoglobin (HgbF) 126
- fibrin 744
 cascade model of formation 639
 clot
 dissolution 650
 structure 649–50
 deposits in bone marrow acute
 inflammatory response 108
 formation 639, 648, 649
 inflammation 651, 652
 monomers 1093–4
 soluble 1093–4
 thrombin in formation 649
- fibrin degradation products (FDPs) 94, 597
 assay 1093
 coagulation inhibitor actions 656
 fibrinolysis 650
 platelet hypofunction 627–8
- fibrinogen 566, 744
 assays 1087–8
 avian 704, 705
 bovine 834
 DIC 684
 elephants 946
 hemostasis 649–50
 hereditary defects 664
 liver disease 655
 marine mammal infections 954
 plasma levels 93, 597, 928
 porcine 846
 water buffalo 928
- fibrinogen deficiency 664
 plasma therapy 747
- fibrinolysis 700–1
 avian 704
 complications 700
 defects 656
 DIC 683
 enzymes 636–8
 functional tests 1091–3
 hemostasis 650–1
 neoplasia 672
- fibrinolysis inhibitors 651
- fibrinolytic drugs 700–1
- fibrinopeptide A 1093
- fibrinopeptides 649, 650
- fibroblast growth factor (FGF) 17
- fibroblasts 689, 690
- fibromuscular dysplasia 692
- fibronectin 566
- fibronectin-1 449
- fibrosis
 bone marrow 310
 macrophage induction 303
 secondary myelofibrosis 114
- filariasis, elephants 948
- fish
 anesthesia 994–5
 anticoagulants 998
 blood cell formation 996
 blood collection 995
 coagulation 998
 granulocytes 995, 996, 998, 999
 hematocrit 1000, **1001**
 hematologic techniques 994–5
 hematopoiesis 996
 hemoglobin 995, 996, 1000, **1001**
 infections 1002
 leukocytes 994, 995, 1002
 lymphocytes 995, 996, 997, 1002
 MHC 780
 monocytes 995, 998, 1000, 1002
 neutrophils 998, 1002
 normal hematology 994–1002
 RBCs 994, 1000, **1001**
 reticulocytes 996
 rostral blood island 996
 thrombocytes 995, 996, 997
see also elasmobranchs
- flavine adenine dinucleotide deficiency 147
- flow cytometers, analytical 1074–6
- flow cytometry 76, 1074–80
 antibodies 1077
 applications 1078–80
 bone marrow 1079–80
 staining in laboratory animals 1042–4
 cell surface antigen detection 1134
 chickens 959
 erythrocyte-bound immunoglobulins 1078
 fluorescence 1075–6
 fluorochrome 1077
 indications 1133–4
 instrumentation 1074–6
 maintenance 1077–8
 leukocytes 1076, 1079
 light scatter 1075–6
 neutrophils 1079, 1119–20
 phenotyping 726
 platelet-rich plasma 1128–9
 platelets 1078–9
 activation 1109, 1129, 1130
 function **1124**, 1128–30
 results reporting 1135
 reticulocytes 1078
 samples
 analysis 1077
 preparation 1076
 processing 1076–7
 turkeys 959
- Flt3 expression 30, 52
- fluorescent *in situ* hybridization (FISH)
 1173, 1174, 1175
- fluorine-18-fluoro-2-deoxy-d-glucose
 (¹⁸F-FDG) 1052–3
- fluorogenic substrates, coagulation tests 1085
- Foa–Kurloff cells 897
- foals
 age-related changes 825–6
 failure of transfer of passive immunity 758
 neonatal isoerythrolysis 236–7, 721–2, 759
 transfusion 760
 neutrophil dysfunction 278
 normal hematology 825–6
 SCID in Arabian foals 406–8
- foamy viruses 442
- FOG-1 41
- follicular lymphoma 372, 502–4
 clinical features 503, 504
 clinical presentation 503
 pathology 503–4
 treatment 504
- fondaparinux 700
- Food and Drug Administration (FDA) 71, 72
 database for drug toxicity 100
- ForCyte[®] analyzer, reticulocyte evaluation 1068
- fox squirrel porphyria 176
- French–American–British (FAB) leukemia
 classification system 460, 462
 acute myeloid leukemia 476
 B cell leukemia 492
 myelodysplastic syndromes 467–8
 T cell leukemia 492
- fresh whole blood (FWB) 734, 735–6
 indications 739
 transfusion 738, 754
- fresh-frozen plasma (FFP) 735, 739, 745
 acquired coagulation factor deficiencies 747
 massive transfusions 742
 storage 736
see also transfusion therapy
- friend leukemia integration 1 (FLI1) 57
- friend of GATA1 (FOG1) 57
- frozen plasma 745
- fungal infections 120
 deep 113
 granulomas 114
 macrophage proliferation 113
 thrombocytopenia 601
see also mycotoxins; *named diseases*
- G protein-coupled receptors 570
- G protein-gated inwardly rectifying
 potassium channels (GIRKs) 571
- G1 phase 421, 422
 progression 423–4
 restriction point 423–4
 transition to S phase regulation 424
- G2 phase 421, 422
 DNA damage checkpoint 425
 progression 425
- GA-binding protein 57
- gallinacin-3 963
- gallopavin-1 963
- gammacarboxyglutamic acid (Gla) residues 639
- gammaretroviruses 441
- Gap (G0) phase 421
 maintenance 423
 transition to G1 423–4
- garlic, oxidative injury 242, 243, 244
- gastric dilatation and volvulus (GDV) 378
- gastric ulceration 374

- GATA1 57
 GATA2 57
 GATA-binding proteins 6, 40, 41
 G-banded chromosomes 1173
 gel microtube crossmatching 1105
 gelatinase 266
 gelatinous transformation, serous atrophy 116
 gelsolin 565
 gene(s)
 expression profiling 1173
 mutations 433, 434, 435, 438
 neoplasia risk 433–4
 silencing 17, 437
 gene therapy 550–7
 cell-specific targeting 551–2
 clinical trials 556–7
 expression targeting 552–3
 future directions 556–7
 immune modulation 553–5
 leukemia 555–6
 lymphoma 555–6
 neoplastic outcomes 555
 novel vectors 556
 osteosarcoma 556
 promoters 552–3
 strategies 550–1
 suicide 553
 tumor cell killing 553
 tumor targeting 551–3
 tumor vaccines 553
 vector detargeting 551
 vector structures 550–1
 viral vectors 552
 X-linked SCID 410, 555
 genetic diseases 1171–2
 autosomal dominant 1171
 autosomal recessive 1171–2
 carriers 1172
 cytogenetics 1173, 1174, 1175
 deletions 1173
 expression profiling 1173
 insertions 1173
 mutation detection 1173
 tests 1174
 X-chromosomal recessive 1172
 genetic screening, SCID in Arabian foals 408
 genome-wide association analysis (GWAA) 1172
 genomic imprinting 437
 genomics 1171, 1173
 gerbil, Mongolian
 bone marrow 903
 leukocytes 901, 902–3
 normal hematology 899, 900–1, 902–3
 platelets 902
 RBCs 899, 900, 902
 Gla proteins 639, 643, 644
 Glanzmann's thrombasthenia 620–2, 728, 729
 PFA-100 use 1128
 platelet aggregation 1126
 glucocorticoids
 eosinopenia 329
 eosinophilic inflammation 285
 equine leukogram 317
 erythropoiesis 40
 heterophilia induction in birds 351
 immune-mediated hemolytic anemia 222, 223, 228
 leukocytosis in dogs 322
 lymphopenia 353
 stress response 311, 336
 systemic lupus erythematosus 391
 glucose, movement into RBCs 132
 glucose-6-phosphate dehydrogenase 134
 deficiency 147
 glucuronic acid 126
 β -glucuronidase 1150, 1153
 glutaredoxin 134
 glutathione 134
 high potassium RBCs 194
 oxidized 134
 RBC deficiency 193
 RBC levels 138
 reduced 134, 240
 glutathione peroxidase 134, 240
 RBC levels 138
 glutathione reductase 240
 glycoporphins 124, 218, 219
 glycosaminoglycans (GAGs) 9, 646
 goats
 anaplasmosis 309
 babesiosis 206
 basophils 840
 blood groups 719–20
 bone marrow 841
 corynebacteriosis 213
 eosinophils 839–40
 hemoglobin 126, 836
 hemotropic mycoplasmas 204
 leukocytes 838–41
 counts 308
 lymphocytes 840–1
 MHC 780
 monocytes 841
 neutrophils 838–9
 parturition 309
 platelets 841
 RBCs 836, 837, 838
 lifespan 138
 good laboratory practice (GLP) 79
 GP130 signaling 46
 GP $\alpha_2\beta_1$ complex 728
 GP $\alpha_{IIIb}\beta_3$ 728, 729
 Gpi transmembrane protein (IV) 24, 25
 GPIb α 573
 GPIb-IX-V complex 561, 565, 571, 728
 GPIIb-IIIa 561, 597
 antibodies against 627
 Glanzmann thrombasthenia 620–2
 GPIIb-IIIa inhibitors 87, 628
 GPVI 561, 570, 571
 graft *versus* host disease
 hematopoietic stem cell transplantation 786, 787
 prevention 785
 transfusion-related 772–3
 graft *versus* leukemia, hematopoietic stem cell transplantation 786
 granulocyte concentrate 754–5
 granule membrane proteins 565, 566
 granulocyte antigens 726
 granulocyte(s) 12, 47–8, 725–7
 antimicrobial properties 271
 band 46
 cell surface antigens 725
 chickens 962–3
 differentiation 44
 elasmobranch 1013, 1016
 equine 316
 fish 995, 996, 998, 999
 maturation 962
 Pelger-Huët anomaly 278
 psittacine 975
 raptors 983–4, 985
 ratite 991–2
 transfusion 754–5
 turkeys 962–3
 waterfowl 980, 981
 granulocyte colony-stimulating factor (G-CSF) 791–2
 granulocyte transfusion 755
 granulopoiesis 45–6
 hematopoietic stem cell mobilization 786
 neutrophil mobilization 47
 recombinant canine (rcG-CSF) 792
 recombinant human (rhG-CSF) 397–8
 uses 792
 granulocyte-macrophage colony-stimulating factor (GM-CSF) 32, 40, 792–3
 basophil development 48
 dendritic cell production 51
 granulopoiesis 45
 hematopoietic stem cell mobilization 786
 recombinant canine (rcGM-CSF) 793
 recombinant human (rhGM-CSF) 397
 uses 793
 granulocyte-monocyte progenitors (GMPs) 44, 47
 granulocytic anaplasmosis 200–1
 granulocytopenia, drug-induced immune 1112
 granulomas 113–14
 lipid 114
 granulomatous disease
 idiopathic systemic granulomatous inflammation 305
 metastatic mineralization 691
 granulomatous enteritis 331
 granulopoiesis 43–8
 avian 349
 chickens 960–1
 developmental stages 46
 endosteal niche 43–4
 microenvironment 43–4
 psittacine 975
 regulation 43
 transcription factor regulation 44, 45
 turkeys 960–1
 waterfowl 980, 981
 granzyme B 266
 green fluorescent protein (GFP) 553
 griseofulvin, adverse reactions in cats 103
 growth factors
 avian 961
 B cell development 62
 clinical use 790–4
 erythropoiesis 39–40
 hematopoietic cell culture 1049–50
 T cell 63
 growth hormone
 deficiency in T cell deficiency in dogs 403–4
 erythropoiesis stimulation 163
 guanaco *see* camelids
 guinea pig
 bone marrow 897
 coagulation 897
 Foa-Kurloff cells 897
 heterophils 894
 leukocytes 894, 896, 897
 MHC 779
 normal hematology 893–4, 895–6, 897
 peripheral blood cells 893–4, 895–6, 897
 platelets 893, 894
 RBCs 893, 894, 895
 gut-associated lymphoid tissue (GALT) 374–5
 H1 antagonists, mast cell tumors 487–8, 489
 H2 antagonists, mast cell tumors 487, 489
Haemoproteus 208, 209
 Hageman factor *see* factor XII
 hairy vetch poisoning 380
 hamster, Syrian (golden)
 bone marrow 907–8
 coagulation 908
 leukocytes 905–6, 906–7
 normal hematology 904, 905–6, 906–8
 platelets 904, 906
 RBCs 904, 905–6, 906
 sedimentation rate 908
 haplotype 1171
 haptoglobin 1160
 bovine 834
 porcine 846
 harderoporphyria 177

- Hassall's corpuscles 367, 368
Haversian canals 10
Hayflick limit 435
hCAP-18 266
heart disease *see* cardiac disease
heartworm (*Dirofilaria*) 330
 thromboembolism risk 673
 vasculitis 693
heavy metals
 elasmobranch toxicity 1016–17
 hematopoietic cell injury 109
 see also lead poisoning
Heinz bodies 89, 134, 150–1, 239, 240
 artifacts 1072
 camelids 911
 cat 126
 counting 1070–2
 diabetes mellitus 249
 evaluation 1067
 laboratory primates 870–1
 lymphoma 248
 oxidative toxins 1072
 size 1067
 species variations 1072
 staining 1070–2
Heinz body anemia 135, 141
 cats 99
 etiology 157
Helicobacter 374
helminthic parasites
 basophils in defense 291
 eosinophils in defense 285–6
hemangioblasts 4, 65
hemangiosarcoma 448–9
 canine 428, 430–1
 diagnosis 448
 equine 431
 feline 431
 genes 449
 thrombocytopenia 602
hematological parameters 75
hematopoiesis
 accelerated 34
 animal models 33–4
 avian 349
 bone marrow venous sinuses 10
 chickens 960–1
 compound-related effects 86
 cytokine effects 88
 cytokine signaling 32–3
 definitive 4–5
 fish 996
 function evaluation 33–4
 genetically altered mice 34
 model 18
 plasticity concept 30
 primitive 4
 regulation 11
 reptiles 1008–9
 species specificity 30
 spleen function 369
 turkeys 960–1
 see also cyclic hematopoiesis in gray collies
hematopoietic cells 367
 cell cycle control 421–6
 culture 1047–50
 growth factors 1049–50
 types 1048–9
 cytochemical staining 1142–3, 1144, 1144–5, 1146–9
 injury 106, 109–10
 long-term bone marrow culture 1049
 long-term culture initiating cell assay 1049
 neoplastic 1141–2
 progenitor assays 1048, 1049
 protective conditioning for transplantation 778
hematopoietic growth factors *see* growth factors
hematopoietic neoplasia *see* neoplasia
hematopoietic progenitor cells 5, 29–30
 nomenclature 28–9
hematopoietic stem cells (HSCs) 4–5, 14, 27–9
 amplification to mature RBCs 41
 blood cell development 18
 bone marrow-derived 783, 785
 CD34 15
 conditioning complications 787
 differentiation 37
 drug-induced destruction 99
 dye efflux 15
 failure 17
 G-CSF induced release 46
 granulocyte differentiation 44
 homing on endosteal niche 43–4
 life-span 28
 lineage commitment 28
 markers 785
 migration 6
 multipotent 28, 36–7
 nomenclature 28–9
 oligopotent 28
 pluripotent 27–8, 43
 precursors 29–30
 purification 785–6
 regulation 783
 sources 785–6
 stem cell niches 12, 30, 31
 transdifferentiation 788
 transplantation 783–8 (*see also* bone marrow transplantation)
 allogeneic 784
 applications 787–8
 autologous 784
 bone marrow 785
 complications 787
 donor selection 786
 donors 784–5
 methodology 786–7
 outcomes 787
 post-transplantation immune suppression 787
 procedure 787
 recipient conditioning 786–7
 space theory 786
 syngeneic 784
 types 784–5
 xenogeneic 784–5
hematopoietic system 3–6, 27–34
 cell cycle control 421–6
 development 3–4
 molecular mechanisms 6
 functional anatomy 367–74
 organs 367–74
hematopoietic transcription factors 28, 29
hematotoxicity studies *see* toxicological studies
heme 142
 biosynthesis 125
 catabolism 126
 synthesis 172–3
 disorders 169–70
 lead toxicity 177
heme enzymes 172, 173
heme iron 127
heme oxygenase 126, 142
heme pocket 125
heme proteins 172
hemochromatosis 170
hemoglobin
 ADVIA 120/2120[®] analyzer 1056
 avian 962
 bison 931, 932, 933
 camelids 910, 911, 912–13
 canine 799–800, 801
 caprine 836
 cervids 919, 923, 924, 940
 chickens 965
 clearance time 126
 crystals 149, 911
 denaturation 140, 141
 dissociation 142
 elephant 943, 947
 equine 822
 feline 126, 240, 812–13
 fetal 126
 fish 995, 996, 1000, 1001
 free plasma 126
 glycated 140
 hamster 904, 905–6
 heme synthesis 172–3
 laboratory animals
 primates 870, 871, 872–8
 rodents 856
 measurement 1056
 ovine 836
 oxygen affinity 133
 psittacines 968, 969, 971, 972
 raptors 982
 reindeer 940
 reptile 1005, 1009
 structure 124–5
 switching 5–6
 synthesis 125
 transfusion threshold 738, 739
 turnover 126
 types in animals 126
 waterfowl 979
hemoglobin C (HgbC) 126
hemoglobinopathies, erythrocytosis 165
hemoglobin-spectrin cross-linking 141
hemolysis
 non-immune 774
 in vitro testing 76
hemolytic anemia 88–9
 cold 231
 diagnosis 157
 drug-induced immune-mediated 87
 horses 104
 hereditary red cell membrane defects 187–91
 immune-mediated 107
 increased erythrocyte osmotic fragility in cats 193
 RBC infections 1167–8
 spleen 371
 zinc intoxication in dogs 141, 242
 see also autoimmune hemolytic anemia (AIHA)
hemolytic transfusion reactions 769–71, 774
 acute 770
 delayed 770–1
hemolytic uremic syndrome (HUS)
 platelet consumption 579, 598
 thrombotic thrombocytopenic purpura differential diagnosis 598
hemophagocytic histiocytic sarcoma, canine 248
hemophagocytic syndrome 305
hemophilia A 656, 661–4
 cryoprecipitate response 749
 diagnosis 661–2, 663
 genetics 663–4
 inheritance 661–2, 663
 plasma therapy 747
 treatment 663
hemophilia B 661–4
 diagnosis 661–2, 663
 genetics 663–4
 inheritance 661–2, 663
 plasma therapy 747
 treatment 663
hemoplasmas 201–4
hemorrhagic disorders
 avian 705–6
 drug therapy 696–8
 plasma therapy 746–7
 topical agents 697–8
 treatment 695–8, 706
hemosiderin 128

- hemosiderin granules, neutrophils 327, 328
 hemosiderosis 170
 splenic 380
 hemostasis 92, 635–52
 activation tests 1093–4
 avian 703–6
 blood sample processing/storage 1083
 blood sampling 1083
 buccal mucosal bleeding time 1123–4
 cells 645–7
 chromogenic substrates 1085
 coagulometers 1083–4
 compound-related alterations 92–7
 clinical signs 94–5
 definition 636
 dilutional defects 656
 endothelial cells 645–6
 enhanced with RBC transfusion 740
 fibrinogen 649–50
 fibrinolysis 650–1
 fluorogenic substrates 1085
 hereditary defects 656
 immunochemical methods 1085
 inflammation 651–2
 laboratory rodent parameters 859
 plasma-based testing 1083–5
 platelets 646
 RBC transfusions 740
 thrombin 644, 645, 646, 648–9
 thromboelastography 1094
 vascular-bed-specific 670
 hemostatic defects, treatment 695–701
 Hep-2 substrate, antinuclear antibody testing 1111
 heparan sulfate proteoglycans (HSPG) 646
 heparin
 adverse reactions in horses 104
 assays 1091
 low molecular weight 699, 1091
 thromboelastography 1096
 neoplastic cell production 1089
 overdose 660
 thrombocytopenia 1112
 unfractionated 660, 699
 heparin cofactor II 645
 hepatitis, infectious, thrombocytopenia 601
 hepatosplenic gamma-delta T cell lymphoma (HSTCL) 534
 hepatotoxins, avian 705–6
Hepatozoon infection 326, 327
 hepcidin 128, 246–7
 hephaestin 128, 170
 hereditary coproporphyrria (HCP) 177
 hereditary elliptocytosis 191
 hereditary gangliosidosis, emus 991
 hereditary spherocytosis 188–91
 hereditary stomatocytosis 149, 191–3
 heritable cancer syndromes 433–4
 heritable traits, cancer phenotypes 434
 herpesviruses
 bovine 379
 canine 692
 endotheliotropic in elephants 946, 948
 equine 692
 macrophages 304
 thrombocytopenia 601
 vasculitis 692
 heteropenia, avian 351–2, 356
 heterophil(s)
 avian 350–2, 962–3
 chickens 962–3
 cytochemical staining 1142–3, 1144, 1144–5
 deficient production 352
 elasmobranch 1013, 1014, 1014–15
 elephants 943–4, 946, 947
 guinea pig 894
 marine mammals 955, 956
 psittacines 969–70, 972
 raptors 984, 985
 ratites 987, 991, 992
 reptile 1007, 1010
 shift from circulating to marginal pool 352
 turkeys 962–3
 waterfowl 978, 979, 979
 heterophilia, avian 351, 356
 heterophilic granulocyte, marine mammals 955, 956
 heterophil:lymphocyte ratio, avian 355–6
 hexose-monophosphate shunt 180
 high molecular weight kininogen (HMWK) 666
 high-altitude adaptations, camelids 914
 RBCs 911
 high-altitude disease 691
 hirudin 656
 histamine 294
 histiocytic differentiation 541–2
 histiocytic proliferative diseases 540–9
 canine 540–7
 feline 547–9
 histiocytic sarcoma 381
 canine 430, 541, 543–5
 disseminated 543, 545
 hemophagocytic 544
 immunophenotypic studies 544–5
 localized 543
 morphology 543–4
 prognosis 545
 treatment 545
 histiocytic sarcoma complex, feline 549
 histiocytoma
 canine cutaneous 540, 541, 542–3
 metastatic 542–3
 regression 542
 solitary 542, 543
 histiocytosis
 canine 541–7
 feline progressive 547–8
 splenic 380
 histone deacetylases (HDACs) 424
Histoplasma capsulatum (histoplasmosis) 120
 canine 326, 327
 feline 339, 340
 immune-mediated thrombocytopenia 594
 Hodgkin's lymphoma 520–4
 animals 523–4
 classification 520
 lymphocyte depletion 522
 lymphocyte-predominant 521
 lymphocyte-rich classic 521
 mixed cellularity 522
 nodular 521
 pathologic features 521–2
 Reed–Sternberg cells 520, 521, 522
 horses
 acute inflammation 108–9
 adverse drug reactions 104
 agammaglobulinemia 401
 aplastic anemia 259
 babesiosis 206
 basopenia 318
 basophils 824
 blood collection techniques 759–60
 blood donor selection 758–9
 blood groups 718–19
 typing 1103
 bone marrow 827–8
 collection 1041
 cancer
 epidemiology 429
 risk 431
 colic 273
 corticosteroid leukogram 317
 crossmatching 1104
 eosinopenia 318
 eosinophilia 317–18
 eosinophils 315, 316, 822, 824
 erythropoiesis 828
 exercise stress 279
 Fell pony syndrome 408–9
 granulocytes 316
 granulocytic anaplasmosis 200
 hemangiosarcoma 431
 hemoglobin crystals 823
 hepatosplenic gamma-delta T cell lymphoma 534
 Howell–Jolly bodies 822, 822
 hypereosinophilic syndrome 318
 immune-mediated hemolytic anemia 233–8
 immune-mediated thrombocytopenia 592
 infections 317
 infectious thrombocytopenia 601
 inflammation 317
 inherited macrothrombocytopenia 620
 laminitis 273
 large B cell lymphoma 506
 leukemia 318
 leukocytes 822, 822, 823–4
 cell morphology 315, 316
 response 314–19
 leukocytosis 317
 leukogram 314–15
 changes 315–16
 endotoxemia 319
 response patterns 317–19
 septicemia 319
 serial 319
 leukopenia 315
 lymphocytes 822, 823
 lymphocytosis 318
 lymphoma 431
 hepatosplenic gamma-delta T cell 534
 large B cell 506
 lymphoplasmacytic 498
 lymphopenia 318
 lymphoplasmacytic lymphoma 498
 mast cell tumors 489
 megakaryocytes 828
 MHC 780
 monocytes 824
 monocytopenia 318
 myelodysplastic syndrome 473
 neoplasia 429
 neutropenia 315, 318–19
 neutrophils 316, 824
 age-related changes 825, 826
 hyper/hyposegmentation 314–15
 normal hematology 821–8
 age-related changes 825–6
 breed-related differences 825
 gender-related differences 826
 training influence 827
 oxidative injury 243
 parasitic diseases 318
 platelets 823, 824–5
 age-related changes 826
 RBCs 821, 822, 822, 824
 age-related changes 825, 826
 agglutination 822, 824
 Howell–Jolly bodies 822, 823
 lifespan 138
 rouleaux 821
 transfusion 759
 red maple toxicity 243
 reticulocyte release 137
 SCID 406–9
 selective IgM deficiency
 equine 403
 SCID in Arabian foals 407
 splenic atrophy 380
 stress 317
 systemic lupus erythematosus 388
 theileriosis 205
 thrombocytopenia
 immune-mediated 592
 infectious 601

- horses—*Continued*
 thrombosis 671–2
 transfusion reactions 760–1
 transfusions 721, 757–61
 von Willebrand disease 613, 614
see also equine entries; foals
- host cell proliferation, stimulation 442
 host defense, basophils 295–6
 host *versus* graft (HVG) response 786
see also graft *versus* host disease
- Howell–Jolly bodies 150, 155, 1071–2
 canine 196, 197, 799
 equine 822, 823
 marine mammals 956
 poodle macrocytosis 196, 197
- HOX genes 555–6
 human genome project 1167
 human leukocyte antigens (HLA) 726, 778
 genes 778
see also major histocompatibility complex (MHC)
- human neutrophil antigens (HNA) 726
 human platelet antigen (HPA) system 727–8
 human T cell lymphotropic virus (HTLV) 444
 T cell lymphoma 243
- hydroxyurea, polycythemia treatment 165
 hyperadrenocorticism 329
 thromboembolism risk 672
- hypercalcemia
 lymphadenopathy 414–15
 multiple myeloma 512, 513, 516
- hypercoagulability 669
 laboratory tests 673–4
- hypercoagulable syndromes 672–3
 hypercortisolism 672–3
- hypereosinophilic syndrome (HES) 288–9
 canine 328
 equine 318
- hyperfibrinogenemia 673
 avian 705
 bovine 834
- hyperfibrinolysis 656
- hyperglobulinemia
 lymphadenopathy 414–15
 platelet hypofunction 627
 pyruvate kinase deficiency 185
- hypersensitivity reactions
 basophils 295
 eosinophilia 342
 mast cells 295
 spleen toxic injury 380
 type 1 293, 295
- hypersplenism 380
 thrombocytopenia 580
- hypertension
 systemic 691
see also pulmonary hypertension
- hyperthyroidism
 anemia 249
 oxidative injury 241
- hyperviscosity syndrome 512, 513
 Waldenström’s macroglobulinemia 517
- hypoadrenocorticism
 anemia 249
 lymphocytosis 331
- hypocalcemia
 citrate toxicity 760
 plateletpheresis 752
- hypcholesterolemia, multiple myeloma 512, 513
- hypochromasia 145
 copper deficiency 170
 iron deficiency 169
 waterfowl 977
- hypofibrinogenemia 664, 1088
 avian 705
- hypofibrinolysis 669–70
- hypogammaglobulinemia of infancy in dogs, transient 403
- hypoproteinemia, plasma therapy 747
 volumes 760
- hyposplenism 381
- hypothermia, platelet morphology 580
- hypothyroidism, nonregenerative anemia 249
- hypotrichosis with thymic aplasia 403
- IDEXX VetAutoRead™ 1063
- idiopathic systemic granulomatous inflammation 305
- idraparinux 700
- IgA deficiency
 anaphylaxis 772
 canine 402–3
 diagnosis 402–3
 Fell pony syndrome 408
 human 402
 treatment 403
- IgM deficiency
 Fell pony syndrome 408
 SCID in Arabian foals 407
 selective equine 403, 407
- immune disorders
 juvenile llama immunodeficiency syndrome 311
 plasma therapy 747
 spleen 379–80
 vasculitis 693–4
see also feline immunodeficiency virus (FIV)
- immune modulation 553–5
 transplantation therapy 554–5
- immune modulators 397–8
- immune response
 adaptive 272, 359
 innate 358–9
 macrophage function 301
- immune stimulation, non-specific 555
- immune system, eosinophil involvement 284–5
- immune-mediated hematologic disease
 antineutrophil antibody tests 1107–8
 antinuclear antibody testing 1109–12
 antiplatelet antibody tests 1108–9
 drug-induced autoantibodies 1112
 testing 1106–12
see also Coombs’ test
- immune-mediated hemolytic anemia (IMHA) 107
 acute inflammation 108
 acute onset 220
 antiglobulin test 1107
 aspirin therapy 698
 autoagglutination of whole blood 228
 autoantibody persistence 223
 cats 226–31
 clinical signs 228
 diagnosis 228
 outcome 228
 primary 228–30
 secondary 229–31
 treatment 228
 cattle 233–8
 chronic onset 220
 clinical features 234
 cats 228
 dogs 220–1
 Coombs’ test 221–2, 228, 235, 1106–7
 definition 216–17
 diagnosis 234–5
 cats 228
 dogs 221–2
 DIC 679, 681
 differential diagnosis 235
 dogs 216–24
 clinical presentation 220–1
 diagnosis 221–2
 nonregenerative 220, 251–2
 outcome 223–4
 primary 216–19
 prognosis 223–4
 secondary 219–20
 spleen 379–80
 treatment 222–3
 venous thromboembolism 672
 equine 233–8
 equine infectious anemia 237–8
 IgG-mediated 226
 IVIG therapy 747, 749
 lymphocytosis 112
 monitoring 223–4
 neonatal isoerythrolysis 237
 nonregenerative 217, 226, 229
 dogs 220, 251–2
 pathogenesis 226–8, 234
 primary 233
 cats 228–30
 dogs 216–19
 prognosis 235
 cats 228
 dogs 223–4
 regenerative 229
 secondary 233
 cats 229–31
 dogs 219–20
 spherocytes 148
 spleen 379–80
 treatment 235, 698
 cats 228
 dogs 222–3
 triggers 219–20
 vaccine-associated 220, 223–4
 venous thromboembolism 672
see also autoimmune hemolytic anemia (AIHA)
- immune-mediated neutropenia (IMN) 725, 727
- immune-mediated thrombocytopenia (IMT) 586–94, 729
 antiplatelet antibody tests 1108–9
 assays 589–90
 canine 586–91, 729
 causes 588
 diagnosis 588–90, 591
 equine 592
 feline 591
 history 586, 591
 infections 593–4
 IVIG therapy 747, 749
 neoplasias 592
 outcome 590–1
 pathogenesis 587–8
 physical exam 586–7, 591
 platelet concentrations 588–9
 platelet transfusion 753
 primary 586–92
 secondary 592–4, 602
 splenectomy 590
 systemic autoimmune diseases 592
 treatment 590, 591
- Immuno Polymorphism Database 780
- immunoassays, serum ferritin measurement 1163
- immunocytochemistry 1133
- immunodeficiency diseases 400–1
 B cell 401–3
 diagnosis 401
 immunologic testing 401
 retrovirus-induced 442
 T cell 403–4
 viral infections 404
see also feline immunodeficiency virus (FIV)
- immunodeficiency syndrome in Shar-pei dogs 403
- immunofixation electrophoresis 1159
- immunofluorescence testing, indirect 1108
- immunoglobulin(s) 744–5
 erythrocyte-bound 1078

- immunoglobulin A (IgA) 375
see also IgA deficiency
- immunoglobulin E (IgE)
 cytokine synthesis/secretion 294
 excessive production 295
 surface Fc receptor 293
- immunoglobulin G (IgG), binding to RBCs 140–1
- immunoglobulin (Ig) genes 1136, 1137
- immunoglobulin M (IgM)
 B cell development 62
 Waldenström's macroglobulinemia 517
see also IgM deficiency
- immunoglobulin M (IgM)
 macroglobulinemia 516, 517
- immunohistochemistry 1133
- immunologic diversity 61–2
- immunophenotyping 1133–6
 antibody panels 1134–5
 flow cytometry results reporting 1135
 indications 1133–4
 leukemia 461, 1139
 leukocytes 1079
 lineage determination 1136
 lymphoma 456, 1139
 malignant cells 1135–6
 preparation of samples 1134
- immunosuppression, feline
 immunodeficiency virus 395
- immunosuppressive therapy
 immune-mediated thrombocytopenia 590, 591
 pure red cell aplasia 252–3, 253–4
 systemic lupus erythematosus 391–2
- immunotherapy, selective for systemic
 lupus erythematosus 392
- imprecision 1028
- indirect antiglobulin test (IAT) 1106
- indirect immunofluorescence (IIF) assay 1109, 1110
- infectious bovine rhinotracheitis virus (IBRV) 279
- infective endocarditis, thromboembolism risk 673
- inflammation
 anemia 246–7
 basophils 291, 295–6
 chronic 112–14
 eosinophilia 342
 eosinophilic 285
 treatment 289
 equine 317
 granulomatous 113–14
 hemostasis 651–2
 heterophilia induction in birds 351
 labeling of sites 1052–3
 leukocyte changes 858
 leukocytosis in dogs 322–3
 leukogram 337
 changes 309
 marine mammals 951, 954, 955
 modulation by eosinophils 286
 neutrophilia 323
 neutrophil-mediated amplification 271–2
 neutrophil-mediated tissue injury 272
 platelets
 hyperfunction 628–9
 hypofunction 627
 tissue factor–FVIIa complex 651
- inflammatory disorders
 hyperfibrinogenemia 93
 neutrophils 273
 spleen 379–80
- inflammatory mediators 652
- inflammatory response
 acute in bone marrow 108–9
 DIC 683
 eosinophilic 109
- inhibitor replacement, DIC 685, 686–7
- inositol pentaphosphate (IP5) 962
- insulin-like growth factor 1 (IGF-1) 40
- insulin-like growth factor 1, recombinant human (rhIGF-1) 398
- insulin-like growth factor 2 (IGF-2) 17
- integral membrane proteins 24, 124
- integrin(s) 6, 30, 269–70
- integrin receptors 291
 erythropoiesis 41
- β_1 -integrin 6
- β_4 -integrin 6
- integrin $\alpha 2\beta 1$ 571
- integrin $\alpha_{IIb}\beta_3$ *see* GPIIb-IIIa
- integrin receptors 300–1
- intercellular adhesion molecule 1 (ICAM-1) 269
- intercellular adhesion molecule 2 (ICAM-2) 270, 573
- intercellular adhesion molecule 3 (ICAM-3) 270
- intercellular adhesion molecule 4 (ICAM-4) 31, 41
- interferon α (IFN α) 398
- interferon γ (IFN γ) 40, 554
- interleukin 1 (IL-1), erythropoiesis humoral inhibitor 40
- interleukin 1 β (IL-1 β), neutrophil release 272
- interleukin 2 receptor (IL-2R) 554
 X-linked recessive SCID 409
- interleukin 3 (IL-3) 39, 45, 793–4
 basophils
 development 48
 function 291
 mast cell development 48
 uses 794
- interleukin 5 (IL-5) 281
- interleukin 6 (IL-6) 33
 canine tumor regression 554
 granulopoiesis 46
 marine mammals 955
 multiple myeloma 512
 neutrophil release 272
 platelet hyperfunction 629
- interleukin 7 (IL-7), B cell development 62
- interleukin 10 (IL-10) 17, 301, 363
- interleukin 12 (IL-12) 88
- interleukin 13 (IL-13) 281
- intermediate cell mass, fish 996
- international normalized ratio (INR) 1085
- International Prognostic Scoring System, myelodysplastic syndromes 469
- International Society of Thrombosis and Hemostasis (ISTH), disseminated intravascular coagulation
 definition 679
 diagnostic scoring systems 684, 685, 686
- International Working Formulation for hematologic malignancies 453
- intestinal T cell lymphoma 530
- intravenous immunoglobulin (IVIg) 747, 749
- iron
 absorption in intestine 127
 bone marrow levels 168
 cellular uptake 127
 marine mammal infections 954
 non-heme 127
 overload 170
 RBC transfusions 740
 serum levels 168
 measurement 1162–3
 storage 128
 total iron binding capacity 168, 1163
 toxicity 170
 transport 128, 170
- iron deficiency 168–9
 anemia 145
 causes 168
 clinical features 168–9
- functional 169
- hemoglobin content of RBCs 145
- hypochromasia 145
 waterfowl 977
- indices 167
- laboratory features 169
- portosystemic shunts 169
- RBCs 169
 reticulocytes 1069, 1071
 secondary dysmyelopoiesis in dogs 471
- iron disorder evaluation 167–8
- iron metabolism 126–8
 macrophages 303
 molecules involved 127–8
- iron regulatory proteins, genetic control 128–9
- iron-responsive elements (IREs) 128–9
- ischemia/reperfusion injury, neutrophils 272–3
- isoerythrolysis *see* neonatal isoerythrolysis
- Jaagsiekte sheep retrovirus (JRSV) 444–5
- Jack Russell terriers, SCID 410
- JAK2 gene 40–1, 59
 genetic testing 610
 mutation in essential thrombocythemia 608–9
- Janus kinase/signal transducers and activators of transcription (JAK/STAT) 16
 negative regulation of signal transduction 32–3
- Janus tyrosine kinases (JAKs) 32, 362
- jaundice, enterotoxemic 211–12
- Johne's disease 302
 metastatic mineralization 691
- junctional complexes 124
- junctional diversity 62
- juvenile llama immunodeficiency syndrome (JLIDS) 311
- kallikrein 651
- kallikrein–kinin pathway 640–1
- kaolin, thromboelastography 1095, 1096
- keratinocytes 374
- keratocytes 148
- Ki-67 486
- Kiel hematological malignancy
 classification 452, 453
- killer inhibitory receptors (KIRs) 364
- kininogens 641
- Kit
 expression 45
 mutations in mast cell tumors 483–4, 486
- Kit inhibitors, mast cell tumors 487
- Knudson “two-hit” hypothesis 434
- Kupffer cells 53, 128
- Kurloff cells 897
- laboratory animals
 bone marrow
 collection/processing 1042–5
 cytology preparations 1044–5
 staining 1045
 normal hematology 852–86
 primates 869–71, 872–83, 883–6
 rabbits 862, 863–6, 867–8
 rodents 852–4, 854–5, 856–61
 transgenic mouse studies 86
- lactoferrin 266, 271
- laminitis, equine 273
- lamivudine 397
- Langerhans cell(s) 374, 541
- Langerhans cell histiocytosis 540, 541, 543
- Langerhans cell tumors, regression 554
- large B cell lymphoma 504–7
 clinical features 507
 mediastinal 506
 pathological features 505–7
 T cell-rich 523–4

- large granular lymphocytic leukemia, T cell 528–9
- LaserCyte® analyzer 1064, 1065
- reticulocyte evaluation 1068, 1069
- LDS-751 staining solution 1042–4, 1080
- lead poisoning
- diagnosis 177–8
 - hematopoietic cell injury 109
 - porphyria 177–8
 - secondary dysmyelopoiesis in dogs 471
 - splenic hemosiderosis 380
- Leishmania* (leishmaniasis) 118, 119
- immune-mediated thrombocytopenia 594
 - macrophage proliferation 113
 - secondary dysmyelopoiesis in dogs 471
- Leishmania donovani* 327
- Leishmania infantum* 379
- lentiviruses 442
- monocytes 304
- leptocytes 148
- leptospirosis 213
- Leriche's syndrome 700
- leukemia 159
- acute 462–3, 1136
 - blast cells 493
 - blood smear morphology 461
 - bone marrow flow cytometry 1079–80
 - canine 333, 428, 462–5
 - B cell prolymphocytic 497–8
 - chronic lymphocytic 463–4
 - risk assessment 430
 - T cell large granular lymphocytic 528–9
 - CD markers 25
 - chronic 463–5, 1136
 - classification 451–4, 460, 492–3
 - clonality assays 461, 1139
 - diagnosis 460–1
 - equine 318
 - feline 341, 342–3, 429, 462–5 (*see also* feline leukemia virus (FeLV))
 - B cell prolymphocytic 497–8
 - risk 431
 - T cell large granular lymphocytic 528–9
 - gene therapy 555–6
 - immunophenotyping 461, 1135–6, 1139
 - large granular lymphocytic T cell 528–9
 - lineage determination 1136
 - lymph nodes 371
 - lymphocytic 1136
 - lymphocytosis 353
 - lymphoma differential diagnosis 1136
 - myeloid origin 1136
 - neutropenia 341
 - prognosis 463
 - prolymphocytic B cell 497–8
 - recurrent cytogenetic abnormalities 461–2
 - T cell
 - large granular lymphocytic 528–9
 - prolymphocytic 529*see also named acute and chronic leukemias*
- leukemia inhibitory factor (LIF) 16
- leukemia stem cells (LSCs) 460
- leukemogenesis 460
- leukemoid reactions, canine 323
- leukoagglutination method 1107–8
- leukocyte(s)
- avian 345–56
 - assessment techniques 356
 - function 349–50
 - production 349
 - bison 931, 932, 934
 - bovine 830–3
 - camelids 914, 915, 916
 - responses 311–12
 - canine 801, 802–6
 - responses 321–33
 - caprine 838–41
 - cervids 919, 920–2, 924, 925
 - clonality determination 1079
 - cytoplasmic vacuolation 335–6
 - depression 89
 - DNA ploidy determination 1079
 - elasmobranch 1013, 1014
 - elephant 943–4, 945, 946
 - equine 822, 823, 824–5
 - cell morphology 315, 316
 - response 314–19
 - feline 335–43, 813–15
 - responses 335–43
 - ferret 890, 891
 - fish 994, 995, 1002, 1013, 1014
 - flow cytometry 1076, 1079
 - fluorescence 1079
 - gerbil 901, 902–3
 - granules 307–8
 - guinea pig 894, 896, 897
 - hamster 905–6, 906–7
 - immunophenotyping 1079
 - innate immunity 359
 - laboratory animals
 - rabbits 864, 866, 867
 - rodents 856–8
 - laboratory primates 872–81, 883–5
 - anesthesia effects 869, 870
 - morphology
 - artifacts 335–6
 - changes 307–8, 347–9
 - evaluation 1025
 - nonpathologic responses 336
 - ovine 838–41
 - pathologic responses 336–7
 - platelets
 - adhesion 1079
 - interactions 573
 - porcine 844–5
 - psittacines 969–71, 972–3
 - raptors 982, 984–5
 - reindeer 936–7, 938–9, 939, 940
 - reptile 1006–8, 1010–11
 - ruminant responses 307–12
 - water buffalo 927–8, 929
 - corticosteroid response 929
 - waterfowl 978, 979
- leukocyte adhesion defects, leukocyte changes 858
- leukocyte adhesion deficiency (LAD) 275–6, 727
- artifacts 348–9
 - see also* bovine leukocyte adhesion deficiency (BLAD)
- leukocyte alkaline phosphatase 1146, 1147, 1150, 1151
- leukocyte organisms 309
- leukocyte reduction filters 741
- leukocyte–platelet aggregates 1129, 1130
- leukocytosis
- avian 350
 - B cell prolymphocytic leukemia 497
 - camelids 312
 - canine 322–3
 - chronic lymphocytic leukemia 463
 - elephant endotheliotropic herpesvirus 948
 - equine 317
 - estrogen-induced in dogs 100
 - heterophilic 350
 - inflammatory 322–3
 - physiologic 336
- Leukocytozoon*, avian leukocytes 348
- leukogram
- age-related changes 308–9
 - avian 349–50
 - camelid 311, 312
 - canine pattern 322–8
 - equine 314–15
 - changes 315–16
 - endotoxemia 319
 - response patterns 317–19
 - septicemia 319
 - serial 319
 - feline 336, 337
 - inflammatory 337
 - left shift 337, 347
 - pathologic effects 309
 - stress-induced 336
- leukemogenesis, retrovirus-induced 442
- leukopenia
- avian 350, 352
 - canine 806
 - parvovirus infection 324
 - cervid disease 925
 - drug-induced 89
 - equine 315
 - fish 1002
 - systemic lupus erythematosus 387
- leukotrienes 271–2, 286, 287
- levamisole 392
- light transmission aggregometry
- platelet aggregation 1124–5
 - platelet function 1124
- likelihood ratios 1032–3
- Lin[−] 16
- linearity checks 1029
- linkage analysis 1172
- linkage disequilibrium 1172
- lipid granulomas 114
- lipid mediators 294
- lipid membrane bilayer 647
- lipopolysaccharide *see* endotoxins
- lithium heparin, reptile blood samples 1004–5
- liver disease
- acquired coagulopathies 654–5, 657–8
 - birds 705–6
 - coagulation factor deficiency 696
 - plasma therapy 747
 - platelet hypofunction 627–8
- llama
- blood groups 720
 - bone marrow collection 1042
 - transfusion therapy 720
- LMP genes 776, 778
- long-term bone marrow culture (LTBMC) 1049
- long-term culture initiating cell (LTC-IC) assay 1049
- L-selectin 268, 269
- luciferin/luciferase 1126
- Lukes and Collins hematological malignancy classification 452, 453
- luna 1154
- lupus anticoagulant 656
- assay 1088–9
- lymph nodes 371–4
- anatomy 412
 - antigen sorting/processing 372
 - biopsy 415
 - cytology of aspirate 415
 - deep cortical nodules 372–3
 - dendritic cells 372
 - enlargement 413
 - germinal centers 371–2
 - hyperplasia 372
 - lymphadenopathy diagnosis 414, 415
 - lymphoma 458
 - mantle cell cuff 372
 - medullary cords/sinuses 373–4
 - paracortex 372–3
 - peripheral hyperplasia in FeLV 342
- lymphadenitis, bacterial 416
- lymphadenopathy
- benign 412–17
 - bone marrow 415
 - cervical 416–17
 - classification 413
 - definition 412
 - diagnosis 414–15
 - distribution 414

- evaluation 414–15
 feline immunodeficiency virus 395
 generalized 412
 idiopathic 416–17
 imaging 415
 infectious 415
 infiltrative 413
 inguinal 416–17
 laboratory evaluation 414–15
 mineral-associated 417
 pathogenesis 413
 physical examination 414
 reactive 413
 regional 412
 solitary 412
 lymphangiectasia 331
 lymphangioblasts 65
 lymphoblastic T cell lymphoma 527–8
 lymphoblasts 331–2, 341, 365
 psittacine 976
 lymphocyte(s) 61
 activation of autoreactive 218
 anti-inflammatory response 304
 avian
 predominance 350
 production 349
 responses 352–3
 bison, 932, 934 931
 bovine 831–2
 camelid 911–12
 canine 803, 809
 counts 321
 caprine 840–1
 cervids 919, 922, 926
 reindeer 936–7, 937– 938, 939–40
 chicken 963, 964
 clonality testing 1136–7
 congenital deficiency 331
 cytochemical staining 1147–8
 elasmobranchs 1013, 1014, 1014,
 1015–16
 elephant 944–5, 946, 946–7
 equine 823, 825
 feline 341–2, 815, 819
 ferret 890, 891
 fish 995, 996, 997, 1002
 granular 331, 332, 341 (*see also* natural
 killer (NK) cell(s))
 guinea pig 894, 896
 hamster 905–6, 906–7
 laboratory animals
 primates 872–80, 883, 884
 rabbits 864, 866, 867
 rodents 857–8, 860
 malignant 371, 1135
 marine mammal species variations 955
 morphology 372
 alterations 331–2
 ovine 840–1
 plasmacytoid 992
 porcine 844–5
 psittacine 970, 976
 raptors 983–4, 985
 ratites 990, 992
 reactive 331, 992
 recirculation 360, 361
 reindeer 936–7, 937– 938, 939–40
 reptile 1006, 1007–8, 1010
 subsets 358
 thymic cortical 368–9
 turkeys 963, 964, 966
 water buffalo 927, 929, 929
 waterfowl 978, 979
 see also B cell(s); natural killer (NK)
 cell(s); T cell(s)
 lymphocyte antigens (LA) 776
 lymphocyte function-associated antigen
 (LFA-1) 270
 lymphocyte transformation test 401
 lymphocytic leukemia, T cell large granular
 528–9
 lymphocytosis 112
 avian 352–3
 benign 112
 bovine leukemia virus 310–11
 canine 330–2
 causes 330–1
 chronic lymphocytic leukemia 463, 464
 equine 318
 feline 342
 mechanisms 330–1
 pyruvate kinase deficiency 185
 ruminants 310–11
 lymphoid aggregates 113
 lymphoid progenitor cells 11, 12
 lymphoid systems of body surfaces 374–5
 lymphoma
 anemia 248
 B cell 423, 491–2
 diffuse large-cell 504–7
 large 504–7, 523–4
 small lymphocytic 495–7
 bovine 432
 Burkitt's 507–9
 Burkitt-type 495, 507, 509
 canine 428, 455, 456, 457–8, 459
 Burkitt's 508–9
 enteropathy-type T cell 530
 extranodal NK/T cell 533
 lymphoblastic T cell 527
 mantle cell 500, 501
 prognosis 460
 risk assessment 429–30
 unclassifiable, high-grade plasmacytoid
 535
 centroblastic 505, 506
 chemotherapy 455, 456, 457–8, 459
 classification 451–4, 455–6
 clinical presentation 456–7
 clonality assays 1139
 cranial mediastinal 527–8
 diagnosis 455–6
 diffuse large B cell 504–7
 equine 431
 hepatosplenic gamma-delta T cell
 534
 large B cell 506
 lymphoplasmacytic 498
 features 455–60
 feline 428–9, 456–7, 458
 enteropathy-type T cell 530
 extranodal NK/T cell 533
 large B cell 506
 lymphoplasmacytic 498
 mantle cell 500, 501
 risk assessment 431
 T cell 243
 T cell-rich large B cell 523–4
 follicular 372, 502–4
 gastric 374
 gastrointestinal 456–7, 458–9
 intestinal T cell 530
 gene therapy 555–6
 Heinz bodies 248
 immunoblastic 505, 506
 immunophenotyping 456, 1139
 intestinal T cell 530
 large B cell 504–7
 T cell-rich 523–4
 leukemia differential diagnosis 1136
 lymph node hyperplasia differential
 diagnosis 372
 lymph nodes 371
 lymphoblastic T cell 527–8
 lymphocytosis 331
 lymphoplasmacytic 498
 mantle cell 500–2
 marginal zone 498–500, 507
 mediastinal large B cell 506
 nasopharyngeal 457
 non-Hodgkin's 436
 oxidative injury 241, 243
 plasmablastic 506
 prognosis 455, 456, 457–8, 459–60
 relapse 459
 remission assessment 458–9
 small lymphocytic 529
 B cell 495–7
 spleen involvement 381
 T cell 525–35
 enteropathy-type 530
 feline 243
 hepatosplenic gamma-delta 534
 intestinal 530
 lymphoblastic 527
 marginal zone lymphoma differential
 diagnosis 500
 oxidative injury 243
 T zone 532–3
 translocations 435
 treatment 455, 456
 unclassifiable, high-grade plasmacytoid
 535
 see also Hodgkin's lymphoma
 lymphopenia
 avian 352, 353
 canine 330–2
 causes 330, 331
 cervids 926
 equine 318
 feline 342
 feline immunodeficiency virus 395
 mechanisms 331
 ruminants 310–11
 stress response 311
 systemic lupus erythematosus 387
 water buffalo 930
 lymphoplasmacytic lymphoma 498
 lymphopoeisis 61–6
 psittacine 976
 spleen function 369
 lymphoproliferative disorders
 canine 333
 feline 342–3
 lysosomal enzymes, neutrophil 1118
 lysosomal granules 567
 lysosomal integral membrane protein
 (LIMP) 567
 lysosomal storage disorders
 macrophage proliferation 113, 305–6
 neutrophils 328
 lysosomal-associated membrane proteins
 (LAMPs) 264, 567
 lysozyme 266, 271, 839

 M cells 374, 375
 M phase *see* mitosis (M) phase
 Mac-1 (CD11b/CD18) 269
 macrocytosis 145–6, 155
 poodle 196, 197
 α_2 -macroglobulin 645
 macrophage(s) 12, 53, 298–9
 activation 301
 antigen processing 302
 antimicrobial mechanisms 301, 302
 benign proliferation 304
 cell surface receptors 300
 central 41
 chicken 964
 complement receptors 300
 cytokine expression 301, 302
 dead cell removal 303
 differentiation from dendritic cells and
 monocytes 54
 distribution 303
 fate 303
 Fc receptors 300
 fibrogenic cytokine production 115
 fibrosis induction 303
 function 301–3
 granulomas 113–14
 idiopathic systemic granulomatous
 inflammation 305

- macrophage(s)—*Continued*
immune response 301
infections 305
 control 301, 302
integrin receptors 300–1
iron metabolism 303
laboratory rodents 860
lysosomal storage disorders 113, 305–6
mannose receptors 301
metabolism 299
neovascularization regulation 303
primitive 4
proliferation 113
psittacine 975–6
scavenger receptors 301
secretory products 299–300
tissue-specific 53
Toll-like receptors 301, 302
tumor cell interactions 303
turkey 964
ultrastructure 299
viral infections 303–4
macrophage colony stimulating factor (M-CSF) 52
macrophage disorders 304–6
macrothrombocytopenia 806
 inherited 619–20, **621**
major acute-phase protein (MAP), porcine 846
major basic protein (MBP) 282, **284**
 airway epithelium toxicity 286
major histocompatibility complex (MHC) 361–2, 776–8
 amphibian 780
 bovine 779–80
 canine 779
 caprine 780
 cellular typing 777
 chicken 780, 960
 class I 541, 776
 class II 541, 542, 776
 feline progressive histiocytic proliferations 548, 549
 histiocytic sarcoma 544, 545
 class III 776
 equine 780
 feline 779
 fish 780
 guinea pig 779
 molecular typing 777–8
 ovine 780
 primate 778–9
 rabbit 779
 reptilian 780
 rodent 779
 serologic typing 776–7
 species variation 778–80
 swine 780
 turkeys 960
malignant catarrhal fever 692
malignant histiocytosis 381, 541
manatees *see* marine mammals
mannose receptors 301
mantle cell lymphoma 500–2
 clinical features 502
 pathologic features 501–2
 translocation 502
marginal zone cells 499–500
marginal zone lymphoma (MZL) 498–500
 clinical features 500
 clinical presentation 499
 diagnosis 499–500
 large B cell lymphoma differential diagnosis 507
 pathologic features 499–500
marine mammals
 anemia 951
 disease 954–5
 infection response 951, 954
 normal hematology 950–1, **952–4**, 954–6
 species variations 955–6
mast cell(s) 48
 activation 294–5
 allergic disease 294, 295
 anaphylaxis 294
 biologic functions 293
 cytochemical staining 1149
 degranulation 294
 eosinophil interactions 295
 Fc receptors for IgG1 294
 hypersensitivity reactions 293, 295
 IgE binding 293
 IgE-mediated degranulation 286
 laboratory evaluation 297
 laboratory rodents 861
 mediators 293–5
 morphology 297
 production 291
 products 295
 properties **292**
 staining 297
 structure 297
 tissue distribution 291
mast cell growth factor *see* stem cell factor (SCF)
mast cell tumors 483–9
 anatomic location 484, 485
 bone marrow aspiration 484
 buffy coat smear 484
 canine 430, 483–8
 chemotherapy 487, 488
 clinical signs 484
 clinical staging **485**
 cutaneous 488
 diagnosis 484
 equine 489
 feline 431, 488–9
 growth rate 486
 heparin production 1089
 histologic grade 485
 history 484
 intestinal 489
 Kit mutations 483–4, 486
 lymph node aspiration 484
 prognostic factors 485–6
 proliferation markers 486
 radiation therapy 487, 488
 splenic 488–9
 staging 484–5
 supportive care 487–8
 surgery 486, 489
 treatment 486–8
mastocytosis 297
 bone marrow 297
 ehrlichiosis 118
mean corpuscular hemoglobin (MCH) 910, **912–13**
 canine 801, **802**
 chickens 960
 feline 813
 fish 995, 1000, **1001**
 laboratory animals
 primates 870, **872–82**
 rabbits **863, 865, 867**
 marine mammal species variations 955
 psittacines 969
 raptors 983, 986
 turkeys 960
mean corpuscular hemoglobin concentration (MCHC)
 anemia 155
 bison 932, **933**
 camelids 910, **912–13**
 canine 801, **802**
 chickens 960
 feline 813
 fish 995, 1000, **1001**
 iron deficiency 167
 laboratory animals
 primates 870, **872–81**
 rabbits **863, 865**
 rodents 856
 marine mammal species variations 955
 psittacines 969, 971, **972–3**
 raptors 983, 986
 ratites 989
 turkeys 960
 waterfowl 979
mean corpuscular volume (MCV)
 anemia 155
 bison 932, **933**
 canine 801, **802**
 chickens 960, 965
 equine 824, **826**
 feline 813
 fish 995, 1000, **1001**
 hamster 904, **905–6**
 iron deficiency 167
 laboratory animals
 primates 870, **872–82**
 rabbits **863, 865, 867**
 rodents 856
 marine mammal species variations 955
 psittacines 969, 971, **972**
 raptors 983, 986
 ratites 987, 988, 989
 turkeys 960
 water buffalo 929
 waterfowl 978, 979
mean corpuscular volume (MCV) retic 1069
mean peroxidase activity index (MPXI) 1061
mean platelet component concentration (MPC) 582, 597, 1130
 equine 824
 hypercoagulability 674
mean platelet component distribution width (MPCDW) 674
mean platelet volume (MPV) 581, 597
 canine 806
 equine 824
 feline 816
 immune-mediated thrombocytopenia 589
meclofenamic acid, adverse effects in dogs 101
medial calcific sclerosis 691
mediastinal large B cell lymphoma 506
megakaryoblasts 808
 feline 818
megakaryocyte colony-forming cells (Meg-CFCs) 56
megakaryocyte-erythroid progenitor (MEP) 37, 56
megakaryocytes 56, 577
 bone marrow evaluation 582–3
 canine 808, 809
 cytochemical staining 1148–9
 development 11–12
 differentiation 58
 equine 828
 feline 818, 819
 fibrogenic cytokine production 115
 giant hyperlobulated 608
 hamster 908
 immune-mediated thrombocytopenia 589
 laboratory rodents 860
 maturation 58
 Pelger–Huët anomaly 278
 platelet production 606
 ploidy 60, 95, 1080
 primitive 4
 progenitors 577
 responsiveness to thrombopoietin 59
megakaryocytopoiesis/megakaryopoiesis 59, 576–7, 597
 evaluation 1045, 1046

- immune-mediated thrombocytopenia 590
 - thrombocytosis 607
- melanocytes 374
- melatonin 963
- membrane glycoprotein disorders 620–2
- membrane Na, K-ATPase, high activity in dogs 193–4
- membrane protein 4.1 139–40
- memory B cells 365–6
- memory T cells 365–6
- mercury, hematopoietic cell injury 109
- Merkel cells 374
- mesenchymal stem cells (MSCs) 16, 785
 - multipotent 447
- mesenchymal tumors 448–9
- messenger RNA (mRNA) 1166, 1173, 1175
- metamyelocytes 46
 - canine 808
 - feline 818
 - inflammation 323
 - psittacine 975
- metaphase 425
- metarubricytes 37–8, 136, 150
- metastatic mineralization 691
- methemoglobin 89, 239
 - RBCs 135
- methemoglobinemia 135
- methimazole, adverse reactions in cats 103
- methionine synthase deficiency 196–7
- method evaluation decision (MEDx) chart 1030
- methyl cyridina luciferin analog (MCLA) 1118
- methylene blue 135
 - oxidative injury 241–2
- methylmalonic-CoA mutase 196
- micro RNA (miRNA) 17, 1173
- microcytosis 146
 - copper deficiency 170
- microglial cells 53
- α_2 -microglobulin 516
- microlymphocytotoxicity assay 776–7
- microparticles (MPs) 647, 681, 682
- microsatellite markers 777
- microtubules 58, 561, 563, 577
 - assembly 58
- mineral-associated lymphadenopathy 417
- miniature pigs 849–50
- mitogen-activated protein kinase (MAPK) 294
- mitosis (M) phase 421, 422
 - progression 425–6
- molecular diagnosis 1165–9
 - application of techniques 1167–9
 - nucleic acid isolation 1166
 - RNA-based applications 1166
 - sample submission 1165–6
- molecular typing 777–8
- Monckeberg's arteriosclerosis 691
- monkey, bone marrow collection 1043
- monoclonal antibodies (MAbs) 20
 - immunophenotyping of lymphoma/leukemia 461
 - lymphoma treatment 459
- monoclonal gammopathy of uncertain significance (MGUS) 511, 512
- monoclonal paraproteins 1089
- monocytes 298
 - anti-inflammatory response 304
 - avian 353–4
 - bison 931, 932, **934**
 - bovine 832–3
 - canine 803, 804, 808, 809
 - caprine 841
 - cell surface receptors 300
 - cervids 922, **925**
 - reindeer 937, 937–938, **939–40**
 - chickens 963, 964
 - complement receptors 300
 - cytochemical staining 1146–7
 - cytokine regulation 51
 - differentiation
 - to dendritic cells 53
 - from dendritic cells and macrophages 54
 - disorders 303–4
 - distribution 303
 - elasmobranchs 1013, 1014, **1014**, 1015
 - elephant 944, 945, **946**, 946–7, 948
 - equine 824
 - expansion 52
 - fate 303
 - Fc receptors 300
 - feline 341, 815, 819
 - ferret **890**, 891
 - fish 995, 998, 1000, 1002
 - generation 52
 - gerbil **901**, 902
 - guinea pig 894, **896**, 897
 - hamster **905–6**, 907
 - integrin receptors 300–1
 - laboratory animals
 - primates **872–81**, 883, 884
 - rabbits **864**, **866**, 867, 868
 - rodents 857, 858, 860
 - lentiviruses 304
 - mannose receptors 301
 - maturation **964**
 - metabolism 299
 - ovine 840, 841
 - phenotypic heterogeneity **299**
 - porcine 845
 - production 50–1
 - psittacines 970, **972–3**, 975–6
 - raptors **983–4**, 985
 - ratite 992
 - reindeer 937, 937–938, **939–40**
 - reptile 1006, 1008, **1010**
 - scavenger receptors 301
 - transcriptional regulation 51
 - turkeys 963, 964
 - ultrastructure 299
 - viral infections 303–4
 - water buffalo 927–8, **929**
- monocytopenia 303
 - avian 354
 - canine 332–3
 - causes 333
 - elephants 947
 - equine 318
 - feline 341
 - mechanisms 333
 - ruminants 311
- monocytosis 304
 - avian 354
 - canine 332–3
 - causes 332–3
 - elephant 947
 - elephant endotheliotropic herpesvirus 948
 - feline 341
 - mechanisms 332–3
 - ratites 992
 - ruminants 311
- monogenic trait loci (MTLs) 1172
- monogenic traits 1172
- mononuclear phagocyte system (MPS) 126
- mouse
 - MHC 779
 - normal hematology in laboratory animals 852–61
 - RBC lifespan 138
 - transgenic 86
- mouse mammary tumor virus (MMTV) 445
- MS-222, fish anesthesia 994
- mucopolysaccharidosis 276–7, 328
 - feline 338, 339
- mucosa-associated lymphoid tissue (MALT) 371, 374
- mules, neonatal isoerythrolysis 722
- multimerin 566
- multipass transmembrane protein (III) 24, 25
- multiple myeloma 415, 511–16
 - clinical manifestations 512–13
 - diagnosis 513–14
 - disease evolution 512
 - epidemiology 511–12
 - etiology 512
 - feline 514
 - monoclonal paraproteins 1089
 - pathogenesis 512
 - prognosis 516
 - skeletal lesions 512, 513, 514
 - treatment 515–16
- multiple organ dysfunction syndrome (MODS) 273–4
- multipotent adult progenitor cells (MAPCs) 785
- murine leukemia virus (MuLVs) 445
- mutator phenotype 434, 437
- mycobacterial infections, elephants 947–8
- Mycobacterium avium* subsp. *paratuberculosis* (MAP) 302
- mycoplasma
 - camelids 911–13
 - hemotrophic 201–4
 - RBCs 1167, **1168**
- Mycoplasma felis* 379
- mycosis fungoides 531–2
- mycotoxins
 - aplastic anemia 110, 259–60
 - hematopoietic cell injury 110
- myeloblasts 46, 47
 - canine 807
 - feline 817
 - hamster 907
 - psittacine 975
- myelocytes 46, 282
 - canine 808
 - feline 817–18
 - hamster 907–8
 - inflammation 323
 - psittacine 975
- myelodysplastic syndromes 159, 467–73
 - bone marrow flow cytometry 1079–80
 - canine 469–71
 - classification **468**, 469, **469**
 - classification 467–9
 - equine 473
 - feline 343, 472–3
 - classification **468**, 469
 - nucleated RBCs 150
 - secondary 471
 - secondary dysmyelopoiesis differential diagnosis 472, 473
 - unclassifiable 471
- myelofibrosis 159
 - drug-induced 115
 - fibrogenic cytokines 115
 - inherited in pigmy goats 115
 - osteosclerosis association 115
 - periparturient 115
 - secondary 114–15
- myeloid leukosis, poultry 482
- myeloid progenitor cells 11
- myeloid:erythroid (M:E) ratio
 - bovine 834
 - camelids 916
 - canine 809
 - caprine 841
 - determination 1046
 - equine 828
 - feline 819
 - ferret 891
 - gerbil 903
 - guinea pig 897
 - hamster 907
 - laboratory animals
 - primates 885
 - rabbits 868
 - rodents 860

- myeloid:erythroid (M:E) ratio—*Continued*
 ovine 841
 porcine 845
 psittacine 976
 myelonecrosis 106, 107
 cats 107
 coagulation necrosis 107
 dogs 107
 drug-induced 107
 individual cell necrosis 107
 myeloperoxidase 266–7
 cytochemical staining 1149, **1150**
 deficiency in cyclic hematopoiesis of gray collies 277
 myeloproliferative disorders
 canine 333
 feline 342–3
 nucleated RBCs 150
 myelosuppression
 anti-neoplastic therapies 248
 eosinophilic inflammation 285
 myoglobin, elephant 943, **947**
- N-acetyl-neuraminic acid (NeuAc) 714, 715, 716
 N-acetyl-*para*-benzoquinoneimine (NAPQI) 241
 NADPH oxidase 270–1, 277
 eosinophil plasma membrane 283
 Nanog 17
 naphthalene, oxidative injury 242
 naproxen, adverse reactions in dogs 101
 National Cancer Institute (NCI)
 Comparative Oncology Trial 556
 natural killer (NK) cell(s) 61, 63, 331, 332, 364
 development 63
 progenitors 12
 natural killer (NK) cell neoplasms 535
 natural resistance-associated macrophage protein-1 (Nramp1) 303
 negative predictive value (NPV) 1032
 neonatal alloimmune thrombocytopenia 594, 728
 neonatal isoerythrolysis 236–7, 711
 canine 713
 equine 721–2
 transfusion 759, 760
 feline 717
 neonates, anemia 5
 neoplasia
 anemia 247–8
 anti-growth signals 435
 bone marrow 248
 bovine reference population 429
 canine
 reference population 428
 risk assessment 429–31
 cattle 432
 DIC 679, 680, **681**
 epidemiology 427–32
 epigenetic events 437
 equine
 reference population 429
 risk 431
 feline
 reference population 428–9
 risk assessment 431
 fibrinolysis 672
 gene therapy 550
 outcomes 555
 genetic instability 437
 genetics 433–8
 growth signals 435
 hallmarks 434–5
 hemorrhage 248
 hyperfibrinolysis 656
 immortalization 435
 immune-mediated thrombocytopenia 592
 immunophenotyping 1135–6
 initiation 437
 invasion 436–7
 Knudson “two-hit” hypothesis 434
 leukocyte changes 858
 macrophage interactions 303
 marine mammals 954
 platelet hyperfunction 628–9
 platelet hypofunction 627
 progression 437
 promotion 437
 RBC destruction 248
 retrovirus-induced oncogenes 442–3
 risk 433–4
 spleen 376, **377**, 380–1
 sporadic 434
 thrombocytopenia 600, **601**, 602
 thrombosis 672
see also metastases
 neoplastic cells, staining 1141–2
 neoplastic disease, immune-mediated
 hemolytic anemia trigger 219, 230
 neovascularization 65
 macrophage regulation 303
 nephrotic syndrome 672
 platelet hyperfunction 629
 NeuAc (N-acetyl-neuraminic acid) 714, 715, 716
 neutropenia
 canine 323–8
 canine parvovirus infection 324
 cervid disease 926
 chemotherapeutic agent-induced 100
 definition 99
 ehrlichiosis 310, 324
 equine 315, 318–19
 feline 340–1
 feline immunodeficiency virus 395
 immune-mediated 725, 727
 diagnosis 1107–8
 ruminants 309–10
 viral infections 310
 neutrophil(s) 47, 856
 acquired function defects 278–80
 actin detection 1119
 acute respiratory distress syndrome 273–4
 adaptive immune response 272
 adherence 268–70
 evaluation 1117–18
 flow cytometry 1119
 anaplasmosis 315, 316
 antigens 726
 clinical disorders 727
 apoptosis evaluation 1120–1
 asynchronous nuclear maturation 325
 bactericidal assays 401, 1118–19
 bactericidal mechanisms 270–1
 bison 931, 932, **934**
 bovine 830–1
 dysfunction in periparturient dairy cattle 278
 camelid 912–13, 916
 canine 802–3, 806
 counts 321
 immune-mediated destruction 325
 morphologic alterations 325–8
 caprine 838–9
 cellular movement 1116–17
 cervids 919, 920, **925**
 reindeer 936, 937, 938, **939–40**
 chemiluminescence evaluation 1118–19
 chemotaxis 270, 1116–17
 circulating pool 336
 collagen gel matrix 1117
 congenital function defects 275–8
 cytochemical staining 1142–3, **1144**, 1144–5
 cytokine secretion 272
 cytoplasmic alterations 326–8
 cytoplasmic vacuolation 326, 337, 339
 deficient production 340–1
 development 12
 diffuse cytoplasmic basophilia 337
 dysfunction
 neonates 278–9
 parasitic diseases 279
 periparturient dairy cattle 278
 viral infections 279
 EDTA-induced artifact 326
 equine 316, 824
 age-related changes 825, **826**
 hyper/hyosegmentation 314
 feline 337–41, 814
 ferret **890**, 891
 fish 998, 1002
 flow cytometry 1079, 1119–20
 function
 disorders 275–80
 evaluation 1114–21
 nutrition effects 279–80
 stress effects 279
 gradient centrifugation 1115
 granulation anomaly 339
 granules
 alterations 276–7
 contents 265, 266
 function 264–7
 release 265
 species differences 266–7
 structure 264
 types 263–4, 265
 hamster **905–6**, 906
 hemosiderin granules 327, 328
 hypersegmentation/hyosegmentation 314–15, 338
 immune-mediated destruction 325
 infectious agents 326–7, 328, 339–40
 inflammation amplification 271–2
 inflammatory conditions 273
 intracellular dysfunction 340
 ischemia/reperfusion injury 272–3
 isolation 1115–16
 laboratory animals
 primates **872–81**, 883, 884
 rabbits **864**, **866**, 867
 rodents 857
 leukocyte alkaline phosphatase activity 1151
 lysosomal enzymes 1118
 magnetic beads separation 1115–16
 marginated pool 336
 marine mammals 955, 956
 maturation 264
 microvascular thrombosis 274
 morphologic alterations 325–8, 337–40
 morphology changes 307–8
 mucopolysaccharidosis 328
 multiple organ dysfunction syndrome 273–4
 nuclear alterations 325–6
 nuclear hypersegmentation/hyosegmentation 325
 ovine 838–9
 oxidative metabolic burst activity 943–4, 1118–19, 1120
 oxidative metabolism defects 277
 particle uptake 1118
 phagocytosis 270, 1116–19
 flow cytometry 1119–20
 porcine 844, 845
 primary granules 326
 production kinetics 47
 reactive oxygen species 1118, 1120
 redistribution 341
 reindeer 936, 937, 938, **939–40**
 respiratory burst activity 1118–19
 scintigraphy 1051, 1052
 secretory vesicle membranes 266
 sedimentation techniques 1115
 sequestration 341
 storage 1114–15

- structure 263–4
 surface adhesion molecules 1119
 tissue injury 272–4
 toxic change 326, 337–8
 toxic granulation 337–8
 ultrastructure 263, 264
 under-agarose 1117
 water buffalo 927, 929, 929
- neutrophil extracellular traps (NETs) 271
 neutrophil granulation anomaly, Birman cat 276, 277
 neutrophil receptors, chemokine binding 270
 neutrophilia
 camelids 311, 312, 914
 canine 323–8
 elephant endotheliotropic herpesvirus 948
 feline 340
 inflammation 323
 physiologic 914
 ruminants 309–10
 water buffalo 930
 Nevada red water 212–13
 N-glycolyl-neuraminic acid (NeuGc) 714, 715, 716
 nitric oxide 134
 synthesis 646
 NKT cells 364
 no observed adverse effect level (NOAEL) 78, 83
 no observed effect level (NOEL) 78
 non-epitheliotropic lymphoma 532
 non-Hodgkin's lymphoma 436
 nonspecific esterase (NSE) 1141, 1142, 1147, 1148, 1150, 1152–3
 non-steroidal anti-inflammatory drugs (NSAIDs)
 platelet hypofunction 628
 systemic lupus erythematosus 392
 normoblastosis, phosphofructokinase deficiency 182
 nuclear factor-erythroid (NF-E2) 57
 nutrient artery 9
 capillaries 10
- oak leaves, oxidative injury 244
 Oct-4 17
 omega-exonuclease (OEN) 1146, 1154
 oncogenes 435
 retrovirus-induced 442–3
 oncogenic transformation 442
 oncolytic viruses 553
 oncoviruses, retroviral 443–5
 onions, oxidative injury 242, 244
 open canalicular system (OCS) 563–4
 optical platelet aggregation 1124–5
 Origin of Replication Complex (ORC) 425
 osteoblastic niche 12
 osteoblastogenesis 447
 osteoblasts 8, 9
 psittacine 976
 osteoclasts 8
 psittacine 976
 osteosarcoma 448, 556
 osteosclerosis 115
 pyruvate kinase deficiency 184
 ostrich *see* ratites
 Otamixaban 95
 ovalocytes 147, 148
 oxidants, RBCs 133–4
 protection 134–5
 oxidative injury
 adverse drug reactions 99–100
 anemias 239–44
 bovine 242–4
 causes 240–4
 equine 243
 feline 240–2
 drug-induced 99–100
 hemoglobin susceptibility 240
- pathophysiology 240
 RBCs 89, 133–4, 150–1
 sheep 244
 oxidative metabolic burst activity
 elephant heterophils 943–4
 neutrophils 1118–19, 1120
 oxygen affinity
 avian RBCs 962
 camelid RBCs 911
 oxygen carrying solution 758, 764–5
 oxygen extraction ratio (ERO₂) 758
 oxygen storage, marine mammal 955
 oxygen–hemoglobin dissociation curve, camelids 911
 Oxyglobin® 758, 764–5, 766
- P2 purinergic receptors 569–71
 p16/INK4A cyclin-dependent kinase inhibitor 555
 P100 tumor antigen 553
 packed cell volume (PCV)
 bison 931, 932, 933
 camelids 914, 916
 canine 801, 802
 cervids 923
 chickens 960, 965
 elephant 943, 947
 ferret 892
 fish 1000, 1001
 laboratory primates 870, 871
 psittacines 968, 969, 971, 972
 raptors 982
 RBC transfusion 741
 reptile 1005, 1009
 transfusion
 avian 763, 764
 equine 760
 large animals 757
 RBC 741
 threshold 738, 739, 758, 767
 turkeys 960
 water buffalo 929
 waterfowl 978, 979
 pagetoid reticulosis 532
 pancreatic necrosis, acute 672
 pancreatitis
 DIC 679, 681
 platelet hypofunction 627
 thrombosis 672
 pancytopenia, aplastic anemia 256
 Pappenheimer bodies 151
 para-aminophenol (PAP) 241
 paracetamol *see* acetaminophen (paracetamol)
 paraneoplastic leukocytoclastic vasculitis 694
 paraneoplastic syndrome
 eosinophilia 328
 mast cell neoplasia 1089
 parasitic diseases
 allergic disease 310
 basophils 296
 elasmobranch 1016
 elephants 948
 eosinophilia 310, 839–40
 equine 318
 helminthic 285–6, 291
 neutrophil dysfunction 279
 reptile RBCs 1006
 PARR (PCR for antigen receptor rearrangements) assay 1136, 1138
 parvovirus infection 119
 aplastic anemia 257–8
 leukopenia in dogs 324
 macrophage proliferation 113
 neutropenia in dogs 324
 pure red cell aplasia 253
 thrombocytopenia 601
 passive immunity, failure of transfer
 calves 720
 foals 758
- pathogen-associated molecular patterns (PAMPs) 361
 pathogenicity, host determinants 442
 pattern recognition receptors (PRRs) 361
 see also Toll-like receptors
 Pelger–Huët anomaly 277–8, 325–6, 824
 feline 338
 pemphigus foliaceus 747
 penicillin, adverse reactions in horses 104
 pentose phosphate pathway, RBCs 134–5
 percent platelet recovery 754
 percent platelet yield 736
 periarteriolary lymphoid sheaths 369, 370
 periodic acid–Schiff (PAS) stain 1148, 1150, 1152
 periosteal arterioles 10
 peripheral neuropathy, Waldenström's macroglobulinemia 517
 peripheral T cell lymphoma, not otherwise specified (PTCL-NOS) 534–5
 peroxidase (PEROX) activity, cytochemical staining 1142–3, 1144–5, 1146–9
 peroxidase (PEROX) cytogram 1059, 1060, 1064
 peroxidase (PEROX) stains 1149, 1150
 peroxiredoxins 134
 peroxisome proliferator activator receptor-γ (PPAR-γ) 447
 Peyer's patches 374, 375
 phagocytic inhibition test 1108
 phagocytic process, evaluation 1116–19
 phagocytosis
 eosinophils 286
 neutrophils 270, 1116–19
 flow cytometry 1119–20
 platelet destruction 580, 602
 RBC clearance 141
 phagosomes 265
 defective maturation 276
 phenazopyridine, oxidative injury 241
 phenobarbital, adverse reactions in dogs 102
 phenothiazine
 adverse reactions in horses 104
 oxidative injury 243
 phenylbutazone
 adverse effects in dogs 101
 aplastic anemia in horses 259
 phenytoin, adverse drug reactions in dogs 102–3
 Philadelphia chromosome 464
 phorbol myristate acetate (PMA) 1117, 1118
 phosphatidylethanolamine (PEth) 647
 phosphatidylserine (PSer) 573, 574, 577
 cell surface membranes 647
 DIC role 681
 phosphofructokinase 180, 181
 phosphofructokinase deficiency 181–3
 canine 181–3
 diagnosis 183
 inheritance 183
 life expectancy 183
 liver-type 181
 muscle-type 181
 platelet-type 181
 treatment 183
 phosphoinositide-3 kinase (PI3K) 16
 phospholipase A₂ (PLA₂) 294
 phospholipase C 211, 212, 213
 phosphorus, metastatic mineralization 691
 photosensitization dermatitis 693
 PI3 kinase pathway 572–3
 pigs
 blood groups 720, 721
 bone marrow 845
 coagulation 846
 fetal hematology 849
 hemotrophic mycoplasmas 203–4
 infectious thrombocytopenia 601
 leptospirosis 213
 leukocytes 844–5

- pigs—*Continued*
 MHC 780
 miniature 849–50
 neutrophils 844, 845
 normal hematology 843–50
 age influence 846, 847
 breed influence 846
 disease influence 848–9
 fetal 849
 gender influence 846
 lactation influence 846, 848
 miniature swine 849–50
 parturition influence 846, 848
 pregnancy influence 846, 848
 stress influence 848
 plasma proteins 846
 platelets 844, 845
 porphyria 175–6
 RBCs 843, 844
 reference intervals 843, 844
 transfusions 721
 PINCH1 adaptor protein 57
 piroplasms 204, 205, 206, 207
 PKLR gene 183
 plasma
 constituents 744–5
 hemostatic proteins 744
 plasma cell tumors 511–18
 canine 430
 plasma cells 331, 332, 365–6
 plasma components 744, 745–6
 administration 748
 plasma concentrates
 coagulation factor defects 696
 transfusion in inherited intrinsic platelet disorders 624
 plasma cryoprecipitate, vWF replacement therapy 617
 plasma derivatives 746
 administration 748–9
 plasma membrane calcium ATPases (PMCA) 565
 plasma products
 adverse reactions 749–50
 hyperimmune 758
 immune-mediated reactions 749–50
 sources 748
 storage 736
 transfusion 744–50
 administration guidelines 748–9
 indications 746–7
 see also fresh-frozen plasma (FFP); platelet-rich plasma
 plasma proteins
 bovine 834
 elasmobranch 1016
 laboratory rodents 859–60
 porcine 846
 reindeer 940
 plasma proteins, recombinant 746
 administration 748–9
 plasma transfusion 721
 failure of transfer of passive immunity 761
 large animals 758
 processing 760
 volumes 760
 plasmacytic tumors 516–18
 plasmacytoid lymphoma, unclassifiable
 high-grade 535
 plasmacytosis 113
 plasmapheresis 760
 plasminogen 650
 acquired abnormalities 1092
 assay 1092
 plasminogen activator inhibitor 1 (PAI-1)
 651
 assay 1092–3
 hypofibrinolysis 669–70
 plasminogen activators 650–1, 700–1
 assays 1092
Plasmodium 208–9
 plasticity concept in hematopoiesis 30
 platelet(s)
 abnormal distribution 580
 accelerated consumption 579
 activation 95, 274, 569, 570, 573–574
 blood vessel injury 597
 drug-induced 602
 flow cytometry 598, 1129, 1130
 markers 1078–9
 measurement 1128
 pathways 569–73
 thrombin 649
 activation-dependent surface changes 1129
 adhesion 597
 ADVIA 120/2120[®] analyzer 1057, 1058, 1059
 aggregation 95
 clinical disorders 1126
 collagen-induced 572
 destruction 580
 evaluation 1124–6
 thrombotic microangiopathies 579
 aggregometry 674
 agonists 1125–6
 alpha granules 566–7, 643
 apheresis 752, 754, 760
 assessment for transfusion 751–2
 automated hematology analyzers 581–2
 blood smear microscopic examination 582
 bovine 833
 buccal mucosal bleeding time 1123–4
 calcium pool 566, 570
 camelid 914
 canine 806
 caprine 841
 cell surface antigens 725
 cervids 919, 923
 chilled 752–3
 circulating lifespan 577
 clot retraction 597
 clumps 602–3
 collagen receptors 571–2
 concentration in blood 597
 cryopreserved 753
 cytochemical staining 1148–9
 cytoplasmic structural elements 561, 563–5
 cytoskeleton 565
 dense tubular system 564–5
 destruction 579–80, 599
 development 12
 disorders with complex mechanisms 600
 distribution disorders 600
 elephant 946
 equine 822, 823–5
 age-related changes 826
 feline 581, 815–16
 ferret 888, 891
 flow cytometry 1078–9
 formation 58
 function 569, 596–7
 assays 95, 674
 evaluation 1123–30
 flow cytometry 1128–30
 gerbil 902
 granules 565–7, 643, 648
 guinea pig 893, 894
 hamster 904, 906
 hemostasis 646
 altered 95
 hyperfunction 1128
 acquired 628–30
 hyperreactivity 669
 hypofunction 1127–8
 acquired 626–8
 hypothermia effects 580
 immune destruction 579–80
 indium-111 labeled 1051–2
 kinetics 576–83, 597
 laboratory animals
 primates 872–81, 885
 rabbits 867
 rodents 858, 859
 leukocytes
 adhesion 1079
 interactions 573
 loss 579, 598
 lyophilized 753
 lysosomal granules 567
 marine mammals 951, 955
 species variations 955
 mass 60
 membrane structure 561
 membranous elements 561, 563–5
 microdomain lipid rafts 561
 microparticles 1078–9
 microtubules 561, 563, 577
 mitochondria 565
 non-mammalian species 577–8
 numbers 577
 estimation from blood smears 607
 open canalicular system 563–4
 ovine 839, 841
 P2 purinergic receptors 569–71
 percent recovery 754
 percent yield 736
 phagocytosis 602
 pooling 600, 602
 porcine 844, 845
 procoagulation activity 573–4
 production 576–7, 597, 606
 decreased/defective 578–9
 disorders 600
 neoplasia 602
 quality control for counts 1026
 receptors 561, 562–3, 569–73
 cross-talk 569
 refractoriness 728–9
 reindeer 939, 939–40
 reticulated 598
 scintigraphy 1051–2
 secretion techniques 1126
 senescence 577
 structure 561–7
 substitutes 753
 thrombin generation 648
 thrombin receptors 572–3
 turnover 597
 von Willebrand factor 612, 613
 water buffalo 928
 whole blood-derived 752
 wound closure 597
 platelet activating factor (PAF) 287, 646
 platelet antigens 727–9
 alloimmunization 754
 clinical disorders 728–9
 identification 728
 inherited deficiency 729
 platelet component concentration
 distribution width (PCDW) 582, 825
 mean 674
 platelet concentrates 736, 752
 storage 736–7
 transfusion 754
 platelet count 92, 93
 altered hemostasis 95
 blood loss anemia 159
 disseminated intravascular coagulation 94
 normal 605, 606
 pseudothrombocytosis 607
 quality control 1026
 platelet disorders
 acquired 626–30
 hyperfunction 628–30
 hypofunction 626–8
 PFA-100 use 1128
 platelet aggregation 1126
 extrinsic 619

- function defect detection 1127
 inherited intrinsic 619–25
 diagnosis 624
 management 624–5
 mutations **621**
 transfusion therapy 696
 platelet distribution width (PDW) 581
 platelet factor 3 (PF3) test 1108
 platelet factor 4 (PF4) 59–60
 thrombocytopenia 1112
 Platelet Function Analyzer (PFA-100®) 615, 1126–8
 closure time 1127
 platelet function **1124**
 defect detection 1127
 test principle 1126–7
 platelet inhibitors 628
 platelet products
 storage 736–7, 752–3
 transfusion 753–4
 platelet surface-associated immunoglobulin (PSA Ig) 587, 591, 592, 593, 594, 1108–9
 flow cytometry 598
 platelet transfusion 751–4
 outcome 753–4
 prophylactic 753
 quality/quantity assessment 751–2
 reactions 754
 storage of platelet products 752–3
 therapeutic 753
 platelet-activating factor 274
 plateletcrit 581–2
 platelet-derived growth factor β (PDGF- β) 436
 platelet-endothelial cell adhesion molecule-1 (PECAM1) 57
 platelet-neutrophil aggregates 274
 plateletpheresis 752, 754, 760
 platelet-rich plasma 735–6, 752
 flow cytometry 1076, 1128–9
 platelet aggregation evaluation 1125
 storage 736–7
 transfusion 754
 inherited intrinsic platelet disorders 624
 poikilocytosis 144, 145, 146
 chemotherapeutic agent-induced 101
 iron deficiency 169
 point mutations 1173
 polyacrylamide gel electrophoresis 1158
 polychromasia 144–5
 phosphofructokinase deficiency 182
 polychromatophilic rubricytes 37, 38
 polycythemia treatment 165
 polycythemia vera 162–3
 essential thrombocythemia differential diagnosis 608, 609–10
 polymerase chain reaction (PCR) 1165
 DNA amplification 1167
 polymerase chain reaction, real-time (RT-PCR) 1166
 quantitative 1167
 poodle macrocytosis 196, 197
 porphyrias 172
 acquired toxic 177–8
 acute intermittent 176
 chemical 177
 classification 174
 clinical observation 173
 cutanea tarda 176
 diagnosis 173–4
 erythropoietic 174–6
 feline 176
 hepatic 174, 176–7
 hepatoerythropoietic 177
 laboratory detection 173–4, 174–5
 lead poisoning 177–8
 normal 176
 swine 175–6
 variegata 177
 porphyrin, synthesis 172–3
 porphyrinurias 172, 177–8
 clinical observation 173
 diagnosis 173–4
 laboratory detection 173–4
 portosystemic shunts, iron deficiency 169
 positive predictive value (PPV) 1032
 post-transfusion purpura 594, 728, 771–3
 potassium, RBC
 levels 132, 193, 194
 membrane 131–2
 poultry
 myeloid leukemia 482
 see also chickens; turkeys
 pre-B cell receptor 62
 preclinical studies *see* toxicological studies
 pregnancy
 cervids 923
 marine mammals 955
 pigs 846, **848**
 reindeer 940
 prekallikrein 640, 641
 contact factor pathway 704
 deficiency 666
 primates
 laboratory
 aging 885
 bone marrow **883**, 885–6
 coagulation **882**, 885
 Heinz bodies 870–1
 leukocytes **872–81**, 883–5
 normal hematology 869–71, **872–83**, 883–6
 platelets **872–81**, 885
 RBCs 870–1, **872–81**, 883
 reference intervals 869, **872–83**
 species differences 869
 MHC 778–9
 monkey bone marrow collection 1043
 primidone, adverse reactions in dogs 102
 prion diseases 379
 procoagulant expression disorders 623–4
 proficiency testing 1023, 1025
 progenitor assays 1048, 1049
 programmed cell death
 RBCs 88
 see also apoptosis
 progression elevated gene-3 (PEG-3) 552–3
 prolymphocytic leukemia, B cell 497–8
 promegakaryocytes 808
 feline 818
 promyelocytes 46
 canine 807–8
 proplatelets 58
 propylene glycol, oxidative injury 241
 propylthiourea, adverse reactions in cats 103
 prorubricytes 37, 38
 prostaglandin H2 572
 prostaglandins 271–2, 287
 protease activated receptors (PARs) 572–3, 645
 DIC 683
 inflammation 651, 652
 TF-FVIIa activation 651
 proteasomes 776
 protein 4.1 deficiency 191
 protein C 644, 645
 activity measurement in liver disease 658
 assay 1090–1
 deficiency 669
 pathway 644–5
 see also activated protein C (APC)
 protein C inhibitor 645
 protein S 644, 645
 assay 1091
 protein Z-dependent protease inhibitor 645
 protein-losing enteropathy 331
 protein-losing nephropathy 672
 proteins induced by vitamin K absence or antagonism (PIVKA) 655
 proteomics 1173
 prothrombin 643–4
 cleavage 648–9
 defects 665
 prothrombin fragment F 1+2 (F 1+2) 1093
 prothrombin time (PT) 92, 93, 597, 1085–6
 acquired coagulopathies 657
 avian 705
 coagulation factor assays 1088
 compound-related increases 93–4
 fish 998
 prolongation 1086
 shortening 1086
 thromboplastin effects 97
 prothrombinase complex 573, 574
 proto-oncogenes 435
 activation 443
 protoporphyrin IX 125
 protozoal infections 118, 119
 anemia 204–9
 RBCs 1167, **1168**
 thrombocytopenia 601
 P-selectin 269, 274, 567
 binding site 573
 expression 1079
 infectious thrombocytopenia 600
 platelet activation 95
 P-selectin glycoprotein ligand-1 (PSGL-1) 269
 pseudo Pelger–Huët anomaly 307, 325
 feline 338
 pseudohyperkalemia 605
 pseudothrombocytopenia 580–1, 602–3
 EDTA-dependent 729
 pseudothrombocytosis 607
 psittacines
 aging 971
 blood collection 971, 973
 bone marrow 973–6
 cell distribution 976
 cell morphology 974–6
 collection 973–4
 environmental influences 971
 hemoglobin 968, 969, 971, **972**
 leukocytes 969–71, **972**
 normal hematology 968–76
 physiological influences 971
 RBCs 968–9, 971, **972**, 974–5
 reference intervals 971, 973
 species variations 971, **972**
 thrombocytes 971
 ptaquiloside 110
 pulmonary adenomatosis 444–5
 pulmonary angiography, pulmonary thromboembolism 675
 pulmonary artery medial hypertrophy 692
 pulmonary embolism, immune-mediated hemolytic anemia 220
 pulmonary hypertension 691–2
 chronic hypoxic 691
 pulmonary scintigraphy 675–6
 pulmonary thromboembolism
 canine 670
 clinical signs 674–5
 diagnosis 674–6
 equine 672
 puppy strangles 416
 pure red cell aplasia (PRCA) 87–8, 159, 217, 251–4
 bone marrow pathology 220
 cats 253–4
 cell-mediated immune mechanisms 226–7
 clinical features
 cats 253
 dogs 252
 congenital 253
 definition 229, 253

- pure red cell aplasia (PRCA)—*Continued*
 diagnosis 220
 differential diagnosis
 cats 253
 dogs 252
 dogs 220, 251–3
 FeLV-induced 254
 immune response to rhEPO 253, 254
 immune-mediated
 cats 253–4
 dogs 251–3
 incidence 253
 laboratory features
 cats 253
 dogs 252
 lymphocytosis 112
 parvovirus infection 253
 prognosis
 cats 253–4
 dogs 252–3
 treatment
 cats 253–4
 dogs 252–3
 vaccination-associated 253
 purine box-binding transcription factor 1 (PU.1) 6, 40
 granulopoiesis 44, 45
 myeloid lineage differentiation 51
 pyridoxine deficiency 170
 pyruvate kinase 181
 pyruvate kinase deficiency 183–5
 canine 184–5

 quality assessment, external 1023
 quality assurance 79, 1022
 quality control 1021–6
 analytical quality specifications 1022–3
 manual slide evaluation 1025–6
 materials 1022, 1023
 methods 1022
 proficiency testing 1023, 1025
 rules 1023–5
 statistical rules 1023–4
 quality improvement 1022
 quality management 1021–2
 quality planning 1022

 rabbits
 anemia 766
 laboratory
 bone marrow 867–8
 coagulation 868
 leukocytes 864, 866, 867
 monocytes 868
 normal hematology 862, 863–6, 867–8
 platelets 867
 RBCs 862, 863, 867, 868
 MHC 779
 transfusion therapy 766–7
 radiation toxicity, aplastic anemia 87
 random error 1029–30
 Rapoport–Luebering shunt 180
 Rappaport hematological malignancy
 classification 452, 453

 raptors
 blood collection 982
 leukocytes 982, 984, 985
 normal hematology 981–2, 983–4, 985
 RBCs 982
 thrombocytes 985, 985

 rat
 MHC 779
 normal hematology in laboratory animals 852–61

 ratites
 blood collection 987–8
 granulocytes 991–2
 heterophils 987, 991, 992
 lymphocytes 990, 992
 monocytes 992
 normal hematology 987–93
 RBCs 989
 reference intervals 988–9
 thrombocytes 989–91
 reactive nitrogen species (RNS) 134
 reactive oxygen species (ROS) 134
 neutrophils 1118, 1120
 receiver-operating-characteristic (ROC)
 curves 1032, 1034
 recombination activating genes (Rag) 62
 recombination signal sequences (RSS) 62
 recombination-activating gene (RAG) 364
 red blood cell(s) (RBCs)
 ADVIA 120/2120[®] analyzer 1057, 1058, 1059
 agglutination 144, 145, 821, 824
 aging indirect markers 139–40
 amino acid transport 132
 antibody binding 141
 antioxidant capacity 141
 antioxidant status 138
 ATP production 132
 avian 961–2
 basophilic stippling 149, 155
 biochemistry 131–5
 bison 931, 932, 933
 blood group incompatibilities 231
 bovine 829–34
 lifespan 138
 calcium ions 132
 camelids 910–11, 912–13
 oxygen affinity 911
 shape 910, 911
 canine 799–802
 lifespan 138
 caprine 836, 837, 838
 lifespan 138
 carbohydrate metabolism 132
 cell surface molecules 124, 125
 cervids 918, 919, 923, 924
 chickens 961–2, 965
 count 959–60
 clearance mechanisms 138, 139–42
 complement 141
 composition 123
 count
 chickens 959–60
 fish 995, 1000, 1001
 manual slide evaluation 1025
 ratites 987, 988
 reptile 1005
 turkeys 959–60
 waterfowl 978, 979
 cytograms 155–6
 cytoskeletal proteins 124
 density profile 139
 destruction 142
 diphosphoglycerate pathway 132–3
 distribution 144
 donors for foals with neonatal isoerythrolysis 722
 elasmobranch 1013, 1014
 elephants 943, 947
 Emden–Meyerhof pathway 132, 179–81
 equine 821, 822, 823, 824
 age-related changes 825, 826
 lifespan 138
 erythropoietin effects 82
 feline 811–13
 lifespan 138
 ferret 888, 889
 sedimentation rate 892
 fish 994, 1000, 1001
 count 995, 1000, 1001
 elasmobranch 1013, 1014
 formation 996
 flow cytometry 1076, 1078
 gerbil 899, 900, 902
 glucose movement 132
 guinea pig 893, 894, 895
 sedimentation rate 897
 hamster 904, 905–6, 906
 sedimentation rate 908
 HbA1c aging marker 140
 Heinz body-containing 1067
 hemolysis 88–9, 126
 hereditary band 3 deficiency 189, 190
 hereditary enzyme abnormalities 179–85
 high potassium 132, 193, 194
 histograms 155–6
 hypochromic 169
 IgG binding 140–1
 immunoglobulin binding 1078
 inclusions 149–51
 indices 1078
 induced suicidal death 88, 132
 integral membrane proteins 124
 iron deficiency 169
 iron disorder indices 167
 laboratory animals
 primates 870–1, 872–81, 883
 rabbits 862, 863, 867, 868
 rodents 854, 856
 lifespan 136–42
 avian 763
 species variation 138
 study methods 138–9
 lipid rafts 124
 low potassium 132, 193
 marine mammal species variations 955
 membrane
 defects 187–94
 fluidity maintenance 124
 structure 123–4
 membrane protein 4.1 139–40
 membrane transport 131–2
 defects 193–4
 metabolic pathways 132–3
 methemoglobin 135
 morphology 144–51
 manual recognition 1026
 normal 144
 variation 144–51
 non-immunologic adsorption of protein 89
 nucleated 149–50, 155, 799
 nucleoside transporter 132
 opsonization 141
 osmotic lysis 1115
 ovine 836, 837, 838
 oxidants 133–4
 oxidative damage 89, 133–4, 150–1
 pathogens targeting 379
 pentose phosphate pathway 134–5
 phagocytosis 141, 142
 porcine 843, 844
 potassium levels 132, 193, 194
 primitive 3, 5, 6
 programmed cell death 88
 psittacines 968–9, 971, 972, 974–5
 raptors 982
 ratites 989
 count 987, 988
 reindeer 918, 936, 939–40, 940
 reptile 1005–6, 1009
 count 1005
 rheological compromise 140
 rouleaux 821
 formation 144, 145
 sedimentation rate
 ferret 892
 guinea pig 897
 hamster 908
 senescence evaluation 139
 senescence-based clearance 138
 senescent 139–42
 macrophages in removal 303
 shelf-life 733, 736
 sickling 144
 spiculated 148
 storage lesion 736
 stored 736, 739–40

- structure 123–4
- turkeys 965–6
- viability 736
- volume 155–7
- water buffalo 927, **928**
 - sedimentation rate 929
- waterfowl 977–8, **979**
- zinc protoporphyrin 168
- see also* pure red cell aplasia (PRCA); reticulocyte(s)
- red blood cell antigens 759
- red blood cell distribution width (RCDW) 155, 169
 - canine 801–2
 - inherited selective malabsorption of cobalamin 197
 - laboratory rodents 856
- red blood cell transfusion 738–42
 - administration 740–2
 - benefits 740
 - equine 759
 - filters 741
 - indications 738–40
 - infusion devices 741
 - massive 742
 - patient monitoring 742
 - rate 742
 - route 741
 - threshold 738–9
 - volume 741
 - warming of blood 740–1
- red blood cells, packed (pRBCs) 739, 758
- red maple toxicity 147, 157
 - camelids 911
 - horses 243
- red water disease 212–13
- Reed–Sternberg cells 520, 521, 522
- reference intervals 1034–8
 - avian 349
 - bias 1038
 - donor 1037–8
 - establishment 1035–7
 - homogeneity of populations 1038
 - partitioning 1038
 - relevance 1035
 - statistical methods 1036–7
 - subgroups 1038
 - transference 1037–8
 - transformed 1037, 1038
 - see also named species and animal groups*
- reference ranges 79
 - see also* reference intervals
- regression analysis 1037, 1038
- regulatory agencies 71–2
- regulatory guidelines, hematotoxicity studies 71–3
- reindeer
 - aging 940
 - gender 940
 - leukocytes 936–7, 938–9, 939, 940
 - normal hematology 936–7, 938, 939–40
 - platelets 939, **939–40**
 - RBCs 918, 936, **939–40**, 940
 - reference intervals 940
 - reproductive status 940
 - seasonal changes 940
- renal carcinoma and nodular dermatofibrosis 434
- renal disease
 - anemia 248–9
 - chronic renal failure 248, 258
 - multiple myeloma 512, 513, 516
 - protein-losing nephropathy 672
- reperfusion injury 700
- Reptilase® time 1087
- reptiles
 - blood collection 1004
 - blood sample processing 1004–5
 - bone marrow 1008–9
 - hematopoiesis 1008–9
 - hemoglobin 1005, **1009**
 - leukocytes 1006–8, **1010**
 - MHC 780
 - normal hematology 1004–9, **1009–10**
 - RBCs 1005–6, **1009**
 - count 1005
 - reference intervals 1005
 - reticulocytes 1005, **1009**
 - thrombocytes 1005, 1006
- respiratory burst 271
- respiratory system, MALT 374
- RET Scattergram 1063
- RETIC Scatter ABS cytogram 1061, 1062
- reticular cells 10
- reticulin 9
 - secondary myelofibrosis 114
- reticulocyte(s)
 - ADVIA 120/2120® analyzer 1061–2
 - anemia 138
 - automated methods of staining/counting 1068–9, 1070, 1071
 - blood loss anemia 157
 - bone marrow 137
 - canine 799, 801, 802
 - count 138
 - release 137
 - chickens 960
 - counting 137–8, 154, 1067–9, 1070, 1078
 - development 38
 - elephant 943
 - feline
 - aggregate **153**, 154–5
 - count 138
 - punctate **153**, 154–5
 - release 137
 - fish 996
 - flow cytometry 1078
 - identification 137–8
 - iron deficiency 1069, 1071
 - iron indices 167, 169
 - laboratory rodents 856
 - manual count 1026
 - maturation 38, 136–7
 - mRNA staining 1067–8
 - psittacines 968
 - raptors 982
 - ratite 989
 - release of aggregate 137
 - reporting 1069
 - reptile 1005, **1009**
 - ribosomal material 1068
 - size 1069
 - staining 1067–9
 - Sysmex XT-2000iV® 1063, 1064
 - turkeys 960
 - veterinary species 38, **39**
- reticulocyte maturation index 1078
- reticulocyte production index (RPI) 138, 154
- reticulocyte volume (MCVr) 1069
- reticulocytosis, iron deficiency 169
- reticuloendotheliosis virus (REV) 445
- retroviral gene therapy, X-linked recessive SCID 410
- Retroviridae 440–1
 - classification 441–2
- retroviruses 119
 - cis-activation 443
 - genes 441
 - life cycle 441
 - oncogene induction 442–3
 - prototypical 443–5
 - regulatory proteins 441
 - replication 443
 - structure 441
 - trans-activation 443
 - transduction 443
 - transforming 440–5
 - see also* feline immunodeficiency virus (FIV); feline leukemia virus (FeLV)
- retrovirus-induced disease 442
- reverse transcriptase 394
- reverse transcription 1166
- Rh antigen blood typing 1101
- Ribaroxaban 95
- rickettsial infection 118
 - anemia 199–201
 - immune-mediated thrombocytopenia 593
 - RBCs 1167, **1168**
 - thrombocytopenia 580, 600
 - vasculitis 693
- rituximab
 - immune-mediated thrombocytopenia 590
 - lymphoma treatment 459
- RNA
 - genomic 441
 - isolation for molecular diagnosis 1166
- Rocky Mountain spotted fever 693
- lymphocytosis 331
- rodenticides
 - anticoagulant 658–9
 - avian toxicity 705
- rodents
 - anemia 766
 - bone marrow
 - collection 1043
 - flow cytometry staining 1044
 - laboratory 852–61
 - bone marrow 860–1
 - coagulation 859–60
 - hematology techniques 852–3
 - leukocytes 856–8
 - platelets 858, 859
 - preanalytical factors 853–4
 - RBCs 854, 856
 - reference intervals 854, **854–5**
 - MHC 779
 - transfusion therapy 766–7
 - see also* mouse; rat
- rostral blood island, fish 996
- rubriblasts 37, 38
 - canine 807
 - feline 816
 - psittacine 974
- rubricytes 37, 38
 - canine 807
 - feline 817
 - psittacine 974
 - waterfowl 978, 980, 981
- ruminants
 - aplastic anemia 259–60
 - babesiosis 206
 - basopenia 310
 - basophilia 310
 - bone marrow, collection 1041–2
 - eosinopenia 310
 - eosinophilia 310
 - granulocytic anaplasmosis 200–1
 - hemotrophic mycoplasmas 204
 - leukocyte responses 307–12
 - leukogram changes
 - age-related 308–9
 - pathologic effects 309
 - lymphocytosis 310–11
 - lymphopenia 310–11
 - monocytopenia 311
 - monocytosis 311
 - neutropenia 309–10
 - neutrophilia 309–10
 - parturition 309
 - theileriosis 204–5
 - transfusion/transfusion reactions 761
 - see also named groups*
- RUNX DNA binding proteins 57
- Russel viper venom time (RVV-T), fish 998
- S phase *see* synthesis (S) phase
- safety
 - disparity between preclinical/clinical data 90
 - evaluation (*see* toxicological studies)

- saline replacement technique 1104–5
sarcocystis 208
schistocytes 148
scintigraphic imaging
 neutrophils 1051, 1052
 platelets 1051–2
Scott syndrome 623–4
scramblase 573, 574, 647
sea lions *see* marine mammals
sealants 697
seals *see* marine mammals
sedation, feline blood collection 732, 734
selectins 268–9
selective breeding, SCID in Arabian foals 408
selective IgA deficiency 402–3
selective IgM deficiency 403, 407
selective immunotherapy, systemic lupus erythematosus 392
selenium 135
 deficiency 243–4
 neutrophil function 279–80
sepsis
 DIC 679, 681, 682
 platelet hypofunction 627
 thromboembolism risk 673
 transfusion-associated 754, 773
SERCAs (sarco/endoplasmic reticulum calcium ATPases) 564–5
serine proteases 266
serologic typing 776–7
serum amyloid A (SAA) 1160
severe combined immunodeficiency (SCID) 406–10
 Arabian foals 406–8
 canine 409–10
 Fell pony syndrome 408–9
 horses 406–9
 Jack Russell terriers 410
 X-linked
 gene therapy 555
 recessive 409–10
sex chromosomes 1171
Sézary syndrome 532
sheep
 anaplasmosis 309
 babesiosis 206
 bacillary hemoglobinuria 212–13
 basophils 840
 blood groups 719–20
 typing 1103
 bone marrow 841
 collection 1042
 corynebacteriosis 213
 eosinophils 839–40
 granulocytic anaplasmosis 200–1
 hemoglobin 126, 836
 hemotropic mycoplasmas 204
 leptospirosis 213
 leukocytes 838–41
 counts in lambs 308
 lymphocytes 840–1
 MHC 780
 monocytes 840, 841
 mycotoxin toxicity 259–60
 neutrophils 838–9
 normal hematology 836–41
 oxidative injury 244
 parturition 309
 platelets 839, 841
 RBCs 836, 837, 838
 yellow lamb disease 211–12
shock, marine mammals 954
sialic acid-binding Ig-like lectin (Siglec-8) 284
sickle cells *see* drepanocytes
sickling, cervid RBCs 918, 919
side population (SP) cells 15
sideroblasts 170
siderocytes 151, 170
sideroleukocytes 340
signal transducer and activator of transcription (STAT) protein 32, 59, 362
 see also individual named STATs
signal transduction disorders 622–3
simian T cell lymphotropic virus (STLV) 445
single nucleotide polymorphisms (SNPs) 1171, 1173
 maps 1172
single pass type I transmembrane protein (I) 24, 25
single pass type II transmembrane protein (II) 24, 25
sinus endothelial cells 10
skunk musk, oxidative injury 242
small lymphocytic lymphoma (SLL) 529
 B cell 495–7
smooth muscle cells 689, 690
 atherosclerosis 690
snake envenomation, platelet hypofunction 628
snake venom 656
sodium ions, RBC membrane 131–2
somatic hypermutation 62
Sox-2 17
soybean oil, trichloroethylene-extracted 259
spectrin 124, 565
 autoantibodies against 218, 219
 deficiency 149, 190–1
 RBC membrane 187–8
spectrin anomaly with elliptocytosis 191
spherocytes 148–9
spherocytosis *see* hereditary spherocytosis
spleen 369–71
 accessory 378–9
 amyloidosis 371, 379
 atrophy 380
 blood flow 370
 chickens 960, 961
 cytology 377–8
 degenerative conditions 380
 developmental defects 378
 diagnostics 377–8
 disorders 376–81
 embryonic 5
 erythrotrophic pathogens 379
 fibroelastic capsule 378
 fibrohistiocytic nodules 380
 germinal centers 370, 960
 granulomas 380
 histiocytosis 380
 hypersplenism 380, 580
 hyposplenism 381
 immune disorders 379–80
 immune-mediated hemolytic anemia 379–80
 infarction 371, 378
 infections 378, 379
 inflammatory disorders 379–80
 lymphotropic pathogens 379
 mantle layer 369–70
 metastases 381
 neoplasms 380–1
 hemangioma 381
 hemangiosarcoma 248, 378, 379, 381
 neoplastic lesions 376, 377
 non-neoplastic lesions 376, 377
 penicillary vessels 370
 periarteriolar lymphoid sheaths 369, 370
 RBC clearance 142
 rupture 378
 sinusoidal system 369
 spontaneous disease 376–7
 torsion 371, 378
 toxic injury 380
 trauma 378–9
 turkeys 960, 961
 vascular system 369, 370, 378
 venous sinuses 370
splenic hemangioma 381
splenic hemangiosarcoma 248, 378, 379, 381
splenic remnants 378–9
splenomegaly 380
spumaviruses 442
Standard Operating Procedures (SOPs) 79, 1022
STAT3 59
STAT5 40, 59
Steel factor *see* stem cell factor (SCF)
stem cell(s) 14–19
 cancer 17, 19
 characteristics 14–15
 cytokines 17
 damage and leukocyte changes 858
 differentiation regulation 17, 18
 failure 17
 markers 15
 molecular mechanisms 16–17
 multipotent 15
 niche concept 16
 pluripotency regulation 16–17
 pluripotent 15, 783
 proliferative disorders 17, 19
 self renewal 14
 survival regulation 16–17
 tests 15
 totipotent 14–15
 unipotent 15
stem cell antigen-1 (Sca-1) 15
stem cell factor (SCF) 16, 17, 39, 794
 feline 794
 granulopoiesis regulation 44–5
 mast cells 291
 development 48
 recombinant canine 794
 uses 794
stem cell leukemia (*SCL*) gene 40
stem cell niches 12, 16, 17, 30, 31
stem cell-associated diseases 17, 19
stomatocytes 149
stomatocytosis
 hereditary 149, 191–3
 laboratory primates 871
storage lesion of RBCs 736
storage pool disorders 622
 PFA-100 use 1128
 platelet aggregation 1126
 see also cyclic hematopoiesis in gray collies
stored whole blood (SWB), transfusion 738
strangles, puppy 416
streptococcal lymphadenitis, contagious 416
Streptococcus equi, equine purpura hemorrhagica 694
streptokinase 701
stress
 camelids 914
 cervids 923
 elasmobranch 1016
 eosinopenia 329
 equine 317
 leukocyte changes 858
 leukogram changes 308
 lymphopenia 311
 neutrophil function 279
 reindeer 940
stress reticulocytes 38
stromal cell-derived factor-1 (SDF-1) 59
stromal cells
 bone marrow 8–9
 damage and leukocyte changes 858
stromal-derived factor 1 (SDF-1) 30, 31
Strongylus vulgaris 693
substance P 88
Sudan black B staining 1149, 1150
 cytochemical staining 1142–3, 1144–5, 1146–9
suicide gene therapy 553

- sulfonamides, adverse reactions in dogs 101–2
 sulfosalicylic acid (SSA) test, multiple myeloma 513
 superoxide
 accumulation in RBCs 244
 free radical 134, 240
 superoxide dismutase 134, 240
 copper deficiency 243–4
 RBC levels 138
 suppressors of cytokine signaling (SOCs) 32, 41
 swainsonine 306
 synacril black AN 1154
 syncytial viruses 442
 synthesis (S) phase 421, 422
 checkpoint 425
 progression 424–5
 synthetic Xa inhibitors 700
 Sysmex XT-2000iV® 1062–3
 reticulocyte evaluation 1068, 1069
 systematic error 1028–9
 systemic granulomatous inflammation, idiopathic 305
 systemic histiocytosis 540–1, 545
 immunophenotypic studies 546
 morphological features 546
 pathogenesis 546–7
 treatment 547
 systemic hypertension 691
 systemic inflammatory response syndrome (SIRS) 673
 systemic lupus erythematosus (SLE) 383–92
 acute inflammation 108
 antinuclear antibody testing 1109–11
 autoantibodies 385–6, 389
 B cell response 386
 canine 388
 canine model 387
 clinical presentation 387–8
 coagulation pathway 388
 diagnosis 388–9
 diagnostic criteria 389, 390
 drug-induced 384
 environmental factors 384, 385
 equine 388
 feline 388
 food-induced 384
 gender distribution 384
 genetic factors 384
 geographic factors 384
 hematological disorders 387–8
 immune complex deposition 386
 immune-mediated thrombocytopenia 592
 infectious agents 384
 pathogenesis 384–7
 prognosis 390–1
 risk factors 384
 sex hormones 384
 skin biopsy 389
 treatment 391–2
 T cell(s) 61, 359–64
 activation 360–2
 antigen presenting cell interactions 387
 APC interaction 541
 blast transformation 362
 CD4+ 360, 362
 feline immunodeficiency virus 394–5, 396, 398
 functions 362–3
 systemic lupus erythematosus 387
 CD8+ 360, 362
 feline immunodeficiency virus 396
 function 363–4
 subsets 364
 systemic lupus erythematosus 387
 chickens 960
 cytokine secretion 362
 definition 359
 development 63–4, 359–60
 dysregulation in immune-mediated hemolytic anemia 226–7
 extrathymic development 63
 functions 362–4
 growth factors 63
 immune system diseases 403–4
 immune-mediated thrombocytopenia 587
 intrathymic development 360
 lymph node migration 371
 memory 365–6
 natural suppressor 218
 negative selection 63–4
 NKT cells 364
 positive selection 63
 reactivity in autoimmune hemolytic anemia 219
 self-reactivity 385
 systemic lupus erythematosus 387
 thymus 369
 turkeys 960
 types 63
 X-linked recessive SCID 410
 T cell lymphoma 525–35
 angio-immunoblastic 533
 cutaneous 531
 enteropathy-type 530
 feline 243
 hepatosplenic gamma-delta 534
 intestinal 530
 lymphoblastic 527
 mediastinal 527–8
 marginal zone lymphoma differential diagnosis 500
 mature 528–35
 non-epitheliotropic 532
 oxidative injury 243
 peripheral, not otherwise specified 534–5
 precursor 526–8
 T zone 532–3
 T cell progenitors 5, 12
 T cell prolymphocytic leukemia (TPLL) 529
 T cell receptor (TCR) 359, 360
 T cell acute lymphoblastic leukemia 526–7
 $\gamma\delta$ T cells 364
 T helper cells
 enhanced activity 554
 type 0 precursor 363
 type 1 362–3
 B cell activation 365
 type 2 281, 362–3
 B cell activation 365
 exaggerated response 295
 type 17 363
 T regulatory (Treg) cells 218, 226, 363, 554
 T zone lymphoma 532–3
 TAP genes 776, 778
 Tarui-Layzer syndrome (muscle-type phosphofructokinase deficiency) 181–3
 taurine deficiency, platelet hyperfunction 629
 T-cell receptor (TCR)
 expression 63
 genes 1136, 1137
 telangiectasia 690
 terminal deoxynucleotidyl transferase (TdT) 62
 test validation 1027–33
 analytical performance 1027, 1031
 clinical performance 1031
 control material 1029
 detection limit 1030
 imprecision 1028
 inaccuracy 1028–9
 likelihood ratios 1032–3
 linearity checks 1029
 method comparison 1029–30
 overlap performance 1031
 predictive values 1032
 receiver-operating-characteristic curves 1032
 sensitivity/specificity 1031–2
 spiking recovery 1029
 Tet-on/Tet-off promoters 553
 tetrahydrofolate 197
 theileriosis 204–5
 eosinopenia 310
 lymphoid tissue 379
 neutropenia 310
 thieneopyridines 698–9
 thioredoxin 134
 thiourea 1162
 thrombin 644, 645, 646, 648–9
 amplification 648
 coagulation feedback regulation 649
 DIC
 perpetuation 683
 progression 681, 682
 fibrin formation 649
 fibrinogen cleavage 649, 650
 generating potential 674
 generation 639–45, 647–8
 inflammation 652
 plasma half-life 649
 platelet activation 649
 platelet agonist 1126
 production amplification 681
 propagation 648
 thrombomodulin-bound 646
 thrombin activatable fibrinolysis inhibitor (TAFI) 638, 651
 DIC 681, 683
 thrombin clotting time (TCT) 657, 1087
 fibrinogen deficiency 664
 thrombin receptors 572–3
 thrombin time (TT) 1087
 thrombin–antithrombin (TAT) complex 674, 1093
 thromboplasts 980, 981
 thrombocytes
 activation 991
 avian 704
 chickens 960, 962, 963, 965
 fish 995, 996, 997
 elasmobranchs 1013, 1014, 1016
 non-mammalian species 578
 psittacine 971, 975
 raptors 985, 985
 ratite 989–91
 reptile 1005, 1006
 turkeys 960, 962, 963, 965
 waterfowl 978, 979, 981
 thrombocytopenia 605–10
 definition 605
 essential 608–10
 pseudohyperkalemia 605
 thrombocytopenia 89–90
 alloimmune 594, 728
 anticoagulant rodenticide toxicity 598
 automated hematology analyzers 581–2
 blood smears 582
 bone marrow evaluation 582–3
 breed-associated 602
 buccal mucosal bleeding time 1124
 canine 806
 estrogen-induced 100
 immune-mediated 586–91, 729
 chemotherapeutic agent-induced 99
 clinical signs 581
 coagulation panel 582
 complete blood count 581, 597
 consumptive 583
 definition 98
 diagnosis 578
 diagnostic tests 582, 597–8
 DIC 684

- thrombocytopenia—*Continued*
 drug-induced 602
 immune-mediated 87, 602, 1112
 equine 104
 estrogen-induced in dogs 100
 feline
 immune-mediated 591
 infectious 601
 hemorrhage
 due to neoplasia 248
 risk 581
 heparin-induced in horses 104
 hypersplenism 580
 immune-mediated 586–94, 729
 platelet transfusion 753
 infectious 600–1
 inherited 619–25
 laboratory evaluation 581–3
 lymphadenopathy 414
 mechanisms 578–81, 598–603
 neonatal alloimmune 594, 728
 neoplasia 600, 601, 602
 non-immune-mediated 596–603
 pathogenesis 580
 platelet antigens 728
 platelet disorders 600
 plateletpheresis 752
 platelets
 consumption 598
 destruction 580, 598, 599
 systemic lupus erythematosus 387, 388
 transfusion therapy 696
 von Willebrand disease 617
see also disseminated intravascular
 coagulation (DIC); hemolytic uremic
 syndrome (HUS); thrombotic
 thrombocytopenic purpura
- thrombocytosis 605–10
 causes 606, 607–10
 drug-induced 607
 familial 610
 inherited 610
 mechanisms 606
 physiologic 607
 reactive 607–8
 essential thrombocythemia differential
 diagnosis 608, 609, 610
- thromboelastography 674, 1094–7
 acquired coagulopathies 657
 clinical application 1095–7
 coagulation assays 1094–7
 hemostasis 1094
 method 1094–5
 transfusion therapy 1096, 1097
- thromboembolic disease 670–3
 hypercoagulability laboratory tests 673–4
 immune-mediated hemolytic anemia
 220–1
- thromboembolism, definition 668
 thrombolytic therapy complications 700
- thrombomodulin 645
- thrombophilia, testing 1090–1
- thromboplastin
 absolute prothrombin time effects 97
 international sensitivity index (ISI) 97
 prothrombin time testing 1085
 tissue (*see* tissue factor (TF))
- thrombopoiesis 56–60, 597
 drug-induced suppression 95
 non-mammalian species 577–8
 psittacine 975
 thrombocytosis 605–7
 transcription factors 57
 waterfowl 981
- thrombopoietin (TPO) 6, 17, 32, 40, 58–9,
 793
 functions 577, 597, 606
 uses 793
- thrombosis 668
 canine 670
 clinical recognition 674–6
- equine 671–2
 feline 670, 671
 hypercoagulability laboratory tests 673–4
 hypercoagulable syndromes 672–3
 microvascular 274
 pathophysiology 668–70
 treatment 698
- thrombospondin 31, 566
- thrombotic disorders 668–76
 treatment 698–701
- thrombotic microangiopathies 598
- thrombotic thrombocytopenic purpura
 hemolytic uremic syndrome differential
 diagnosis 598
 platelet consumption 579, 598
- thromboxane A2 287, 572
 marine mammals 955
 metabolites 95
 platelet hypofunction 628
- thromboxane receptors 572
- thrombus
 detection 1052
 formation in contact coagulation
 pathway 640
 labeling techniques 1052
- Thy-1 541
- thymic stroma, T cell development 63
- thymocytes 63
- thymoma 331
- thymus 367–9
 chickens 960
 cortex 368–9
 embryonic 5
 epithelial cells 360
 migration 367–8
 heterophils 369
 hyperplasia 368
 lymphoid germinal centers 368
 T cell development 63
 turkeys 960
 X-linked recessive SCID 409
- thyroxine, erythropoiesis stimulation 163
- ticlopidine 699
- tissue factor (TF) 639, 641
 coagulation excessive activation 669
 DIC 680, 682
 pathway 641–2
 thrombin generation 647–8
 thromboelastography 1095
see also thromboplastin
- tissue factor (TF)-bearing cells 647
 thrombin generation 647, 648
- tissue factor pathway inhibitor (TFPI) 644
 deficiency 669
 DIC 681
- tissue factor–FVIIa complex 642, 643, 644,
 648
 inflammation 651
 response to injury 703
- tissue plasminogen activator/tissue-type
 plasminogen activator (tPA) 650–1,
 656, 700, 1092
- TNF-related apoptosis inducing ligand
 (TRAIL) 33
 erythropoiesis humoral inhibitor 40
- tolerance 385
 peripheral 554
- Toll-like receptors 301, 361
 eosinophils 284
 macrophages 301, 302
- toluidine blue 1146, 1154
- torocytes 145
- total allowable error (TE_{max}) 1023
- total body irradiation, G-CSF therapy 792
- total iron binding capacity (TIBC) 168
 measurement 1163
- total quality management 1021–2
- toxicokinetics 83
- toxicological studies 71–6
 adverse effects 82–3
 animal handling 73
- blood collection
 amount 74–5
 methods 74
 randomization 73
 timing 73–4
- bone marrow
 cytology 75–6
 histopathology 75
- classification of changes 80–1
 clinical signs 92–3
 compound-related cytopenias 85–6
 evaluation of changes 80–1
 exposure route 86
 fasted state 73
 flow cytometry 76
 good laboratory practice 79
 hematological analysis 75
 hematological parameters 75
 hematology changes 81–2
 correlation with other study data
 83
 hematology data interpretation 78–84
 preanalytical variables 73–5
 preclinical/clinical safety data disparity
 90
 reference ranges 79
 see also reference intervals
 regulatory guidelines 71–3
 report writing 83–4
 routine laboratory testing 92–3
 statistical analysis 79–80
 test species 86
 types 72
 vehicles 86
- toxins, hematopoietic cell injury 110
- transcription factors 16, 17
 dendritic cell regulation 51
 erythroid-specific 40
 erythropoiesis 40
 granulopoiesis regulation 44, 45
 hematopoietic 28, 29
 monocyte regulation 51
 pleiotropic 40
 thrombopoiesis 57
- transferrin 127, 1162
- transferrin receptor (TfR) 127, 128
- transforming growth factor β (TGF- β) 33
- transfusion reactions 711, 769–74
 allergic 771
 avian 765
 circulatory overload 773
 citrate toxicity 773
 DEA 712–13
 equine 760–1
 febrile 771
 feline 716–17
 hemolytic 769–71, 774
 immune complications 769–73
 infection transmission 773
 monitoring 760
 non-immune 773–4
 patient evaluation 774
 plasma products 749–50
 platelet transfusion 754
 prevention 774
 recognition 774
 ruminants 761
 sepsis 754, 773
- transfusion therapy
 administration 765, 767
 avian 706, 763–5
 compatibility 764
 indications 763–4
 blood groups 720–1
 blood loss at surgery 757
 blood typing 1101–3
 bovine 761
 camelids 761
 coagulation defects 696
 combined deficiency of vitamin
 K-dependent factors 667

- crossmatching 1101, 1103–5
 DIC 685, 686
 equine 721, 757–61
 administration 760
 adverse reactions 760–1
 collection techniques 759–60
 foals with neonatal isoerythrolysis 722
 exotic species 763–7
 factor X deficiency 665–6
 factor XI deficiency 666
 ferrets 765–6
 granulocytes 754–5
 hemorrhagic disorders 695–6
 immune-mediated hemolytic anemia 222–3
 inherited intrinsic platelet disorders 624–5
 large animals 757–61
 liver disease 658
 neonatal isoerythrolysis in foals 722
 oxygenation status 757–8
 plasma products 744–50
 platelet defects/disorders 696
 inherited intrinsic 624–5
 platelets 751–4
 prothrombin deficiency 665
 rabbits 766–7
 red blood cells 738–42
 rodents 766–7
 ruminants 761
 thrombocytopenia 696
 thromboelastography 1096, 1097
 von Willebrand disease 617
 vWF defects 696
 see also blood banking; plasma transfusion; red blood cell transfusion
 transfusion-associated sepsis 754, 773
 transfusion-related graft *versus* host disease 772–3
 transfusion-related immunomodulation (TRIM) 750
 transfusion-related lung injury (TRALI) 727, 750, 772
 transgenic mouse studies 86
 transient hypogammaglobulinemia of infancy in dogs 403
 transmembrane proteins 24
 types 24, 25
 transplantation 554–5
 MHC typing 777–8
 protective conditioning 778
 see also bone marrow transplantation; hematopoietic stem cells (HSCs), transplantation
 transportation stress 279
 trauma
 arterial rupture 691
 disseminated intravascular coagulation 680
 marine mammals 954
 traumatic coagulopathy 659
 treatment-related effects, transient 80
 trematodes, elasmobranch 1017
 trichloroethylene 110
 trophoblasts, intravascular fetal of hamster 908
 trypanosomiasis 207–8
 elephants 948
 neutropenia 310
 L-tryptophan, adverse reactions in horses 104
 tuberculosis, elephants 947–8
 β 1-tubulin gene mutation 620, 806
 tumor(s)
 adaptive evolution 438
 cancer stem cells 438
 genetic instability 437
 see also metastases; neoplasia
 tumor suppressor genes 435
 tumor vaccines 553
 tumor-associated antigens (TAAs) 552
 tumour necrosis factor α (TNF- α) 33
 multiple myeloma 512
 neutrophil release 272
 turkeys
 blood collection 958–9
 blood smears 959
 bone marrow 960
 defensins 963
 endothelium 961
 granulocytes 962–3
 granulopoiesis 960–1
 growth factors 961
 hematopoiesis 960–1
 leukocyte count 959, 960
 lymphocytes 963, 964, 966
 medullary sinuses 961
 monocytes 963, 964
 normal hematology 958–66
 RBCs 961–2, 965–6
 count 959–60
 reference intervals 965–6
 spleen 960, 961
 thrombocytes 962, 963, 965
 thymus 960
 tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) 17
 umbilical cord blood, hematopoietic stem cells 786
 unbound iron-binding capacity (UIBC) 1163
 under-agarose technique for chemotaxis 1117
 uremia, platelet dysfunction 627
 uremic gastropathy 691
 URO I 174, 176
 urobilinogen 142
 UROgenIII-Cosyn 175, 176
 urokinase 701
 urokinase plasminogen activator (uPA) 651, 1092
 uroporphyrins 176
 vaccines
 feline immunodeficiency virus 397
 immune-mediated hemolytic anemia trigger 220, 223–4
 pure red cell aplasia 253
 validation 1021
 diagnostic tests 1027–33
 transferred reference intervals 1037
 variable factor X deficiency 656
 variation, intra-/inter-individual 1023, 1035
 varicose veins 690
 vascular cell adhesion molecule 1 (VCAM-1) 31, 41
 vascular diseases 689–94
 arterial degeneration 690–1
 arterial hypertrophy 691–2
 congenital anomalies/malformations 690
 vasculitis 692–4
 vascular endothelial growth factor (VEGF) 435–6
 multiple myeloma 512
 vascular endothelial growth factor receptors (VEGFRs) 436
 vascular injury 689
 vascular niche 12
 vasculitis 692–4
 immune-mediated 693–4
 paraneoplastic 694
 vasculogenesis 65–6
 antigenic determinants 66
 VDJ rearrangement 61–2
 vectors
 detargeting 551
 novel 556
 structures 550–1
 viral 552
 Venezuelan encephalitis virus 601
 venipuncture technique, birds 704
 venous sinuses, bone marrow 10
 verminous arteritis 693
 very late antigen 4 (VLA-4) 30, 31, 41
 vicuna *see* camelids
 viral infections 119–20
 anemia 212, 213–14
 avian 352, 706
 bovine 379
 bovine leukemia virus 119–20, 310–11, 444
 bovine viral diarrhea virus 119, 279, 310, 627
 bovine viral diarrhea-mucosal disease 379
 fish 1002
 immunodeficiency 404
 lymphopenia 331
 macrophages 303–4
 monocytes 303–4
 neutropenia 310
 neutrophil dysfunction 279
 RBCs 1167, 1168
 systemic lupus erythematosus 384
 thrombocytopenia 600–1
 vasculitis 692–3
 see also named organisms and diseases
 viral vectors 552
 Virchow's triad 668–9
 virions 441
 vitamin B₁₂
 cobalamin deficiency treatment 197
 see also cobalamin
 vitamin D toxicity, metastatic mineralization 691
 vitamin E 135
 neutrophil function 279–80
 vitamin K 94
 acquired coagulopathies 655
 cycle 639, 641, 655
 epoxide 655
 oxidative injury 243
 prophylaxis in liver disease 658
 replacement therapy 659, 696–7, 706
 warfarin action 700
 vitamin K antagonists, oxidative injury 243
 vitamin K deficiency 94, 658–9
 avian 705
 coagulation factor deficiency 696
 plasma therapy 747
 treatment 696–7
 vitamin K epoxide reductase 655, 667
 vitamin K-dependent factors, combined deficiencies 666–7
 von Hippel–Lindau (VHL) tumor suppressor gene 436, 449
 von Willebrand disease (vWD) 612–17
 acquired 615
 affected species/breeds 614
 bleeding 616, 617
 buccal mucosal bleeding time 1124
 classification 613–14
 clinical management 615–17
 clinical signs 615–16
 diagnosis 616–17
 expression patterns 614–15
 gene mutations 614
 hereditary 614, 617
 inheritance 614–15
 mechanism 612, 613
 PFA-100[®] 1127–8
 plasma therapy 746–7
 platelet function evaluation 1127
 subtypes 613–14
 thrombocytopenia 617
 transfusion therapy 617
 von Willebrand factor (vWF) 566
 assays 615, 1089–90
 binding 561
 blood vessel injury 596–7

- von Willebrand factor (vWF)—*Continued*
 deficiency 617
 endothelial cell storage 646
 factor VIII binding 643
 platelet antigen binding 728
 point-of-care analyses 615
 replacement therapy 617
 thrombotic thrombocytopenic purpura 579
 transfusion therapy 617, 696
 treatment 617
 von Willebrand disease 612, 613
 von Willebrand factor (vWF) receptor 565
 VWF gene mutations 614
- Waldenström's macroglobulinemia 517
 Waldeyer's ring 374
 walleye dermal sarcoma virus 445
 walrus *see* marine mammals
 wapiti, RBCs 918, 919
 warfarin 658–9, 700
 water buffalo
 diurnal effects 930
 endotoxin response 930
 gender effects 930
 leukocytes 927–8, **929**
 corticosteroid response 929
 normal hematology 927–30
 plasma fibrinogen 928
 platelets 928
 RBCs 927, **928**
 sedimentation rate 929
 reference intervals 928–30
 waterfowl
 aging 978
 anemia 978
- blood collection 979–80
 bone marrow 980–1
 environmental influences 978–9
 leukocytes 978, **979**
 normal hematology 977–87
 physiological influences 978–9
 RBCs 977–8, **979**
 reference intervals 978–9
 species variations 978
 thrombocytes 978
 Weibel–Palade bodies 643, 646
 whales *see* marine mammals
 white blood cell count, total
 ADVIA 120/2120[®] analyzer 1059, 1060, 1061
 avian 346
 bison 931, **934**
 camelid 914
 canine 321, 806
 Cell-Dyn[®] 3500 1061
 feline 813–14
 hamster 907
 laboratory animals
 rabbits **864, 866, 867**
 rodents 856
 manual slide evaluation 1025
 psittacine 970–1, **972**
 raptors 982, **984**
 ratites 988, 989
 waterfowl 979
 white blood cell impedance count (WIC) 1062
 white blood cell optical count (WOC) 1062
 whole blood
 autoagglutination 228
 canine 734–6
- collection 732, 734
 feline 734, 736
 platelet aggregation **1124, 1125**
 platelet extraction 752
 separation into components 734–6
 storage 736
 transfusion 738
 large animals 757–8
 see also fresh whole blood (FWB)
 Wnt signaling pathway 16
 World Health Organization (WHO),
 hematologic malignancy
 classification 452–3, 454, 455, 456, 460
 B cell lymphomas 504, 507
 follicular lymphoma 504
 Hodgkin's lymphoma 520, 521
 myelodysplastic syndrome classification 468
 myeloid neoplasms 476–7
 T cell lymphoma 243
 wound closure, platelet function 597
- X chromosome 1171, 1172
 yellow lamb disease 211–12
- zinc
 elasmobranch exposure 1017
 oxidative injury 242
 poisoning in dogs 141, 242
 secondary dysmyelopoiesis 471
 zinc protoporphyrin 168
 zymogens 636
 zymosan activated serum (ZAS) 1117, 1118